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GENERAL INTRODUCTION
As a result of improved prevention and treatment, mortality due to coronary artery disease (CAD) 
has decreased substantially during the last decades.1, 2 For example, in the Netherlands in 1970 a to-
tal of 183 CAD deaths occurred per 100,000 of the population, as compared to 58 per 100,000 in 
2012, which corresponds with a relative reduction of 68%. 3 However, CAD remains the leading cause 
of death in Europe.4 Further improvements in the existing treatment standards (e.g. percutaneous 
coronary intervention (PCI)) of CAD only had a marginal effect on outcome. Therefore, it is time to 
break new grounds. We should improve prognosis in the individual patient, and strive for personalized 
medicine. There is a growing body of evidence that inflammation plays a central role in all stages of 
atherosclerotic disease from the preliminary lesion to late-stage plaque rupture.5-8 The concomitant 
presence of a vulnerable plaque in the vessel wall and the pro-inflammatory and pro-coagulable 
milieu as indicated by various biomarkers are necessary in making the patient prone to ”vulnerable” 
plaque rupture and turning stable coronary disease into an unstable phase. However after decades of 
cardiovascular research the mechanisms linking plaque composition and morphology, vascular inflam-
mation, coagulability and patient outcome are still not fully understood.  To understand this we also 
need to focus on different environmental and genetic factors. Environmental factors can be studied 
by for example assessing the effect of nutritional and life style choices within different groups of CAD 
patients.  Studying the genetic factors can be done by directly linking genetic variation to clinical traits, 
i.e. genome-wide association studies, but also by measuring levels of messenger RNA (transcriptome), 
proteins (proteome), and metabolites (metabolone) as a function of genetics. 9 Besides studying these 
factors more detailed information on the plaque composition of the vessel wall may provide important 
information.  One technique to do so is intravascular ultrasound-virtual histology (IVUS-VH), which 
allows visualization of the composition of the vessel wall, and the assessment of four different plaque 
compositions i.e. fibro-fatty, fibrous tissue, dense calcium and necrotic core.10, 11 Another upcoming 
technique that can be used is Near-infrared spectroscopy (NIRS), a novel catheter based imaging 
modality that determines composition of tissue, and has the potential to identify lipid-core containing 
coronary plaques (LCP) in patients, using the variation in reflection of the emitted near-infrared light 
to detect LCP.12, 13
The aim of this thesis is to improve characterisation and prognostication of patients undergoing PCI. 
To do so we first investigated if primary PCI is the best strategy for every patient in every clinical 
circumstance, and which categories of patients benefit most. We also assessed the effect of life style 
changes (quitting smoking) on outcome. To assess the best treatment for patients, preferably the re-
sult of randomized controlled trials (RCTs) are used. However, external validity of RCT results may 
be questioned since most clinical trials have strict in- and exclusion criteria, which tend to favour the 
enrolment of patients at low risk of potential side effects, and therefore may not reflect ‘the real world’ 
clinical practice. Therefore we also examined the effect of trial participation on outcome.
In the second part of this thesis we further tried to improve characterisation and prognostication 
of patients undergoing PCI. We designed the European Collaborative Project on Inflammation and 
Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound (ATHEROREMO-IVUS), an ex-
ploratory (non-pivotal) clinical study to investigate the associations between genetic profile, circulating 
biomarkers and coronary atherosclerosis phenotype and vulnerability as determined by IVUS virtual 
histology and/or NIRS. Finally, the prognostic implications of (the combination) of established and novel 
biomarkers and plaque phenotypes will be studied.
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EXCESS MORTALITY IN WOMEN COMPARED TO MEN AFTER PCI IN STEMI: AN ANALYSIS 
OF 11931 PATIENTS DURING 2000-2009
ABSTRACT
Background
Ambiguity exists whether gender affects outcome in patients undergoing percutaneous coronary 
intervention (PCI).
Methods
To evaluate the relationship between gender and outcome in a large cohort of PCI patients, 11931 
consecutive patients who underwent PCI for various indications during 2000 – 2009 were studied, 
using survival analyses and Cox regression models.
Results
Most patients (N=8588; 72%) were men. Women were older, and more often had a history of 
hypertension and diabetes mellitus. Men smoked more frequently, had a more extensive cardiovascular 
history (previous MI, PCI and CABG), a higher prevalence of renal impairment and multi-vessel disease. 
In STEMI patients, women had higher 31-day mortality rates than men (11.6% vs. 6.5% respectively, 
p<0.001). This difference remained after adjustment for confounders (aHR at 30-days 1.54 and 95% CI 
1.22 – 1.96). Likewise, higher mortality was observed at 1-year (15.1% vs. 9.3%) and 4-year follow-up 
((21.6% vs. 15.0%, aHR 1.30 and 95% CI 1.10-1.53). There were no differences in mortality between 
women and men in NSTE-ACS (aHR at 4-years 1.05 and 95% CI 0.85-1.28) or stable angina (HR at 
4-years 0.85 and 95% CI 0.68-1.08).
Conclusion
Women undergoing PCI for STEMI had higher mortality than men. The excess mortality in women 
appeared in the first month after PCI and could only partially be explained by a difference in baseline 
characteristics. No gender differences in outcome in patients undergoing PCI for NSTE-ACS and 
stable angina were observed. 
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INTRODUCTION
As a result of improved primary and secondary prevention and treatment strategies, mortality due to 
coronary artery disease (CAD) has decreased substantially during the last decades.1-2 For example, 
in the Netherlands in 1970 a total of 183 CAD deaths occurred per 100,000 of the population, as 
compared to 58 per 100,000 in 2012, which corresponds with a relative reduction of 68%. 3 Still, CAD 
is a major cause of mortality and morbidity in men and women in Western countries.4-5 Interestingly, 
the decrease of cardiovascular death has been lower in women than in men.6 Several studies have 
found that differences in age, primary and secondary prevention, clinical presentation, risk profile and 
treatment might account for this sex-based difference in mortality rate. 7-12 Furthermore, despite the 
well-known benefits of PCI for patients with stable coronary disease (symptom relief) as well as for 
patients presenting with acute myocardial infarction (improved survival), fewer women than men 
undergo invasive coronary revascularization.4 Satisfactory explanations for this phenomenon have not 
been provided. One of the reasons for the observed discrepancy might be the perception of treating 
physicians that women benefit less from invasive coronary procedures than men. Indeed, it has been 
found that women undergoing PCI have higher rates of adverse outcomes than men.13 Though, when 
differences in patient-and clinical characteristics are taken into account, ambiguity remains whether 
gender affects outcome.8, 14-21
In our institution, a high-volume tertiary referral center, we developed a database in which we 
systemically enter all baseline data, procedural data, and follow-up data of all PCI patients. Based on 
this database we studied the relationship between gender and clinical outcomes during follow-up.  
METHODS
Patient population
The Erasmus MC, located in Rotterdam the Netherlands, is a tertiary referral and teaching hospital 
in the Rotterdam region with approximately 1.9 million inhabitants. The catheterization laboratory of 
the Thorax center of the Erasmus MC is equipped to provide a 24/7 service for patients with chronic 
and acute CAD. 
Between January 2000 and December 2009 a total of 15,102 PCIs were conducted in 11,931 
consecutive patients of 18 years or older, which were the subject of our analysis. The patient and not 
the PCI procedure was the unit of our analysis. Therefore, the 2,470 patients who underwent multiple 
PCIs during the research period entered the study database at the moment of their first procedure. 
The PCIs that were conducted during follow-up were considered as outcome-events. The index PCI 
was adopted because of stable angina in 4,422 patients, non ST-segment elevation acute coronary 
syndrome (NSTE-ACS) in 3,280 patients, and ST-segment elevation myocardial infarction (STEMI) in 
4,229 patients. 
The nomenclature of stable angina - NSTE-ACS - STEMI has developed over time, and definitions have 
changed. 22-31 In this context, it is important to note that we used the classification that was performed 
at the time that the patient was treated. In general, stable angina was defined when a patient met two 
of the following three criteria: 1.substernal chest discomfort of characteristic quality and duration, 2. 
provoked by exertion or emotional stress, 3. relieved by rest and/or glyceryl trinitrate.26-27 NSTE-ACS 
was defined as patients with acute chest pain but without persistent ST-segment elevation.22-23, 28-29 
Patients presenting with ischemic symptoms and persistent (>20 min) ST-segment elevation in at least 
2 contiguous precordial leads or at least 2 adjacent limb leads by ECG were classified as STEMI.25, 30-31
Patient management
According to the standard policy in our department, all patients underwent stent implantation of (at 
least) the culprit lesion. The preferred stent varied during the study period. Between January 2000 
Excess mortality in women compared to men after PCI in STEMI | 21
and April 2002 bare metal stents (BMS) were implanted. Since April 2002 drug-eluting stents were 
implanted: until March 2003 sirolimus-eluting stents (SES), between March 2003 and March 2007 
paclitaxel-eluting stents (PES), and since March 2007 everolimus-eluting stents (EES). Within each 
period, the preferred stent was almost exclusively used in all patients. However, for specific clinical trials 
comparing stents, in a small number of patients another type of stent was used. 
Patient management was in accordance with the applicable guidelines of the European Society of 
Cardiology (ESC), which have changed over time. 22-33 Patients received an aspirin and (300 to 600 
mg) clopidogrel loading dose before PCI and STEMI patients received both drugs preferably in the 
ambulance. Clopidogrel (75mg/day) duration was at least one month for patients who received a BMS, 
at least 3 months for patients who received a SES and at least 6 months for patients with PES or EES. 
After the procedure, all patients were advised to remain on aspirin (>80mg/day) indefinitely. In the 
described period the preferred access site was the femoral artery. Periprocedural glycoprotein IIb/IIIa 
antagonists were used at the discretion of the interventional cardiologist.
Data collection
According to the standard data-management procedures in our department, data are systematically 
collected on demographics, cardiovascular history, clinical risk factors and treatment characteristics 
for all patients undergoing PCI. Data-elements are stored in an electronic database, which is filled out 
immediately after the completion of the PCI by the interventional cardiologist and by the technician 
who assisted during the procedure. The database, which is maintained by a dedicated IT-officer, is 
mainly designed for administrative purposes. A systematic evaluation of data-completion and data-
integrity is implemented for data that are used for research purposes, including the data that we 
describe in this manuscript.
Data management and Follow-up
Mortality data for all patients were obtained from municipal civil registries systematically on a yearly basis 
during the first five years after the initial PCI. Subsequently a health questionnaire was sent to all living 
patients with specific inquiries on rehospitalisation and major adverse cardiovascular events (MACE). 
For patients who had adverse events at other centers, medical records or discharge summaries from 
the other institutions were systematically reviewed. General practitioners, referring cardiologists, and 
patients were contacted in case additional information was required.
Endpoint definitions
The primary endpoints was all-cause mortality, which was evaluated at 31-days (‘early’) and at 1 year 
and 4 years (‘late’) after the index event. The secondary endpoints included (recurrent) myocardial 
infarction ((re)MI), repeat revascularization (repeat PCI (rePCI) or coronary artery bypass grafting 
(CABG)) and the composite endpoint of (re)MI, re-revascularization and all-cause mortality, which 
were evaluated at 31 day, 1 year and 4 year follow-up. If a patient reported (re)MI at follow-up, the 
referring hospital was contacted to verify the diagnosis. RePCI was defined as a repeat percutaneous 
coronary intervention of any lesion located in the epicardial vessels. CABG was defined as a surgical 
intervention of any lesion located in the epicardial vessels.
Statistical methods
Continuous variables are presented as mean ± standard deviation and categorical variables are 
expressed as numbers and percentages. Student’s t tests and Chi-square test (or Fisher’s exact tests) 
were applied to evaluate differences in baseline variables between women and men, as appropriate.
The incidence of events over time was studied with the use of the Kaplan-Meier method, whereas log-
rank tests were applied to evaluate differences between women and men. Patients lost to follow-up 
were considered at risk until the date of last contact, at which point they were censored.
Cox proportional hazard survival models were applied to evaluate the relationship between gender 
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and our primary and secondary endpoints. Baseline and procedural characteristics (i.e. age, medical 
history, procedural characteristics), as listed in Table 1 were considered as confounders. Subsequently, 
we performed a landmark analysis for the patients who survived the first 31 days, thereby excluding 
men and women who were most critical ill. We also performed a sensitivity analysis in the cohort of 
patients younger than 50 years of age.
Ethics
This is an observational study. For the purpose of this study patients were not subject to acts, neither 
was any mode of behavior imposed, otherwise than as part of their regular treatment. Therefore 
according to Dutch law, written informed consent for a patient to be enrolled in this study was not 
required. This study was conducted according to the privacy policy of the Erasmus MC, and to the 
Erasmus MC regulations for the appropriate use of data in patient oriented research, which are based 
on international regulations, including the declaration of Helsinki.
RESULTS
Baseline and procedural characteristics
Between January 1, 2000 and December 31, 2009, a total of 11,931 consecutive patients underwent a 
PCI in our institution. The majority of these patients were men 8,588 (72%). The indication for PCI was 
stable angina for 1,251 (37%) women versus 3,171 (37%) men, NSTE-ACS for 997(33%) women and 
2,283 (27%) men, and STEMI for 1,095 (33%) women and 3134 (37%) men. There were important 
differences in baseline and procedural characteristics according to gender and indication (Table 1). 
Women were older, and had more often hypertension and diabetes mellitus. Men smoked more 
often, had more often a cardiac history (previous MI, PCI and CABG) and renal impairment. As far as 
procedural characteristics were concerned, men had more often multi-vessel disease. No difference in 
the prevalence of left main disease was found. Women more often underwent treatment of the RCA, 
while men more often underwent treatment of the LCX. 
Mortality
Information on survival status at 1-year follow-up was complete for 96.5% of patients. The median 
follow-up period was 1596 days (IQR 154- 3030 days). During this period  a total of 1972 died.
As shown in figure 1A, we found higher mortality in women than in men (p=0.002). When focusing on 
gender differences within the different diagnostic subgroups (stable angina, NSTE-ACS, STEMI) only in 
STEMI patients this difference remained.
In patients treated for stable angina the cumulative incidence of all-cause mortality at 31-days follow-
up was similar in women compared to men, 0.8% vs. 1.8%, respectively (Kaplan Meier estimates). 
Similarly, no statistically significant differences were observed in all-cause mortality at 1-year (3.8% vs. 
3.5%) and 4-year follow-up (9.1% vs. 10.5%, HR 0.85 and 95% CI 0.68-1.08). Multivariate adjustment 
for potential confounders (i.e. age, medical history, procedural characteristics) of the relation between 
gender and the incidence of all-cause mortality did not change this outcome at 1 year, whereas this 
relation became borderline significant after 4 years (adjusted (a)HR 0.79 and 95% CI 0.63 – 1.00) 
(Figure 2A).
We found similar short- (3.0% vs. 2.4%) and long-term results (16.2% vs. 14.5%) of all cause mortality 
in women compared to men treated for NSTE-ACS, (aHR 1.05 and 95% CI 0.85-1.28) (Figure 2).
In STEMI patients undergoing primary (p)PCI  a significant gender difference was observed after 30-
days (11.6% women vs. 6.5% men, HR 1.82 (1.47-2.27), p<0.001), even after multivariate adjustment 
for potential confounders (aHR 1.56 and 95% CI 1.25-1.96). Likewise, differences in mortality were 
also observed at 1-year (15.1% vs. 9.3%) and 4-year follow-up (21.6% vs. 15.0%, aHR 1.28 and 95% CI 
1.09-1.51) (Figure 2A).
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Figure 1 Clinical outomes according to gender 
 A. all-cause mortality; B. recurrent myocardial infarction; C. repeated revascularization; 
 D. composite endpoint of all-cause mortality, (re)MI and re-revascularization.
Figure 3 Relation between gender, and the incidence of all-cause mortality and the composite  
 endpoint of all-cause mortality, (re)MI and re-revascularization in 31-days survivors.
 Adjusted for all confounders as listed in Table 1.
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Figure 2 Relation between gender, and outcome according to the various indications for PCI.
 A. the incidence of all-cause mortality; B. the incidence of recurrent myocardial infarction, 
 C. the incidence of repeated revascularization; D. the incidence of composite endpoint of 
 all-cause mortality, (re)MI and re-revascularization 
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except that women were older, had less often a history of previous MI and suffered less from multi-
vessel disease (table 2)
Differences in mortality rate over time
Figure 4 shows the absolute 31-day mortality risk in women and men according to year of treatment. 
In the year 2000 the absolute 31-days mortality rate was higher in men than women, thereafter the 
31-day mortality rate was consistently higher in women. Moreover there seems to be a trend towards 
a worse prognosis in women in the last 5 years. 
Patients younger than 50 years of age.
Of the female patients 388 (11,6%), and 1465 (17.1%)  of the male patients were younger than 
50 years of age, p<0.001. The cumulative incidence of all-cause mortality at 31-days follow-up was 
significantly higher in women as compared to men (5.1% vs. 3.5%, respectively, p<0.001). In STEMI 
patients this difference was 5.2% vs. 1.6%, p<0.001. No differences in 31-days mortality were found 
between women and men admitted with stable angina  (0.2% vs. 0.2%, p=0.33) and NSTE-ACS (2.2% 
vs. 0.9% p=0.31). 
Figure 4  Absolute 30-day mortality rate in men and women according to year of treatment
Non-fatal and composite endpoints
As shown in figure 1B no clinically relevant gender difference in the incidence of (re)mi at short-term 
and long-term follow-up was found, the cumulative incidence curves were superimposed for this 
endpoint, p=0.48. With the exception of the occurrence of 31-day (re)MI in NSTE-ACS, also after 
multivariate adjustment gender did not contribute to the occurrence of (re)MI (Figure 2B).
In contrast, the incidence of re-revascularization was higher in women than men, p=0.021 (Figure 1C). 
However, no difference in re- revascularization rate was observed between women and men after 
multivariate adjustment for potential confounders for all indications at all 3 follow-up times  (Figure 
2C)
As shown in figure 1D, we found no difference in incidence rate for the composite endpoint of 
all-cause death, (re)MI, re-revascularization between women and men,  p=0.94 (Figure 1D). After 
multivariable adjustment for potential confounders no difference was observed between women 
and men treated for stable angina pectoris (aHR at 4-years 0.93 and 95% CI 0.82-1.06) (Figure 2D). 
Similarly, no differences in the composite endpoint at short (7.7% vs. 7.3%) and long-term (34.2% vs. 
34.4%) follow-up (aHR at 4-years 1.05 and 95% CI 0.92-1.20) were observed in patients with NSTE-
ACS (Figure 2D).
We found a difference in the composite endpoint between women and men treated with PCI for 
STEMI 36% vs. 33% respectively, p=0.038 (aHR at 4-years 1.18 and 95% CI 1.05-1.39). In the STEMI 
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Table 2 Baseline characteristics according to gender and 31-day survival
 Death within 31 days in STEMI 
patients 
31 –day survivors in STEMI 
patients 
 Men 
n=151 
Women 
n=96 
P-
value 
Men 
n=2925 
Women 
n=966 
p-
Value 
Age (years ±SD) 66.5±12.3 70.7±15.2 0.007 59.1±11.9 64.4±13.2 <0.001 
Medical History       
  Hypertension n (%) 61 (29.8) 46 (36.2) 0.22 1060 (36.2) 493 (51.0) <0.001 
  Hypercholesterolemia n (%) 93 (45.4) 62 (48.8) 0.54 2174 (74.3) 705 (25.7) 0.46 
  Diabetes Mellitus n (%) 28 (13.7) 23 (18.1) 0.27 298 (10.2) 146 (15.1) <0.001 
  Family History n (%) 18 (8.8) 19 (15.0) 0.08 883 (30.2) 273 (28.3) 0.27 
  Current smokers n (%) 44 (21.5) 26 (20.5) 0.83 1252 (42.8) 370 (38.3) 0.014 
  Previous MI n (%) 49 (24) 18 (14.2) 0.03 298 (10.2) 146 (15.1) <0.001 
  Previous PCI n (%) 5 (2.4) 5 (3.9) 0.43 192 (6.6) 41 (4.2) 0.009 
  Previous CABG n (%) 12 (5.9) 2 (1.6) 0.06 75 (2.6) 14 (1.5) 0.044 
  Renal impairment n (%) 11 (5.4) 6 (4.7) 0.80 50 (1.7) 10 (1.0) 0.14 
Procedural characteristics       
  Cardiogenic shock n (%) 32 (25.2) 56 (27.3) 0.67 97 (3.3) 29 (3.0)  
Vessel disease   0.03   0.001 
    0-vessel disease (excluding 
LM) n (%) 
9 (4.4) 5 (3.9)  13 (0.4) 2 (0.2)  
    1-vessel disease (excluding 
LM) n (%) 
60 (29.3) 56 (44.1)  1629 (55.7) 607 (62.8)  
    2-vessel disease (excluding 
LM)  n (%) 
50 (24.4) 30 (23.6)  780 (26.6) 231 (23.9)  
    3-vessel disease (excluding 
LM)  n (%) 
86 (42.0) 36 (28.3)  505 (17.3) 126 (13.0)  
Left main disease 28 (13.7) 14 (11.0) 0.48 73 (2.5) 21 (2.2) 0.57 
 Multi-vessel disease n (%) 148 (72.2) 72 (56.7) 0.004 1310 (44.8) 360 (37.3) <0.001 
Treated vessel       
  Left main n (%) 33 (16.1) 14 (11.0) 0.20 38 (1.3) 14 (1.4) 0.72 
  RCA n (%) 52 (25.4) 29 (22.8) 0.60 1114 (38.1) 420 (43.5) 0.003 
  LCX n (%) 50 (24.4) 26 (20.5) 0.41 459 (15.7) 176 (18.2) 0.06 
  LAD n (%) 98 (47.8) 68 (53.5) 0.31 1425 (48.7) 395 (40.9) <0.001 
  Graft n (%) 3 (1.5) 1 (0.8) 0.58 26 (0.9) 6 (0.6) 0.43 
Glycoprotein IIb/IIIa antagonists 
n (%) 
26 (12.7) 11 (8.7) 0.29 588 (20.1) 134 (13.9)  <0.001 
 
patients who survived the first month similar 1-year (aHR at 1-year 0.96 and 95% CI 0.80-1.16) and 
long term (aHR at 4years 0.98 and 95% CI 0.84-1.14) composite endpoint rates were found for 
women and men (Figure 2D).
 Death within 31 days in STEMI 
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31 –day survivors in STEMI 
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 Men 
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Women 
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value 
Men 
n=2925 
Women 
n=966 
p-
Value 
Age (years ±SD) 66.5±12.3 70.7±15.2 0.007 59.1±11.9 64.4±13.2 <0.001 
Medical History       
  Hypertension n (%) 61 (29.8) 46 (36.2) 0.22 1060 (36.2) 493 (51.0) <0.001 
  Hypercholesterolemia n (%) 93 (45.4) 62 (48.8) 0.54 2174 (74.3) 705 (25.7) 0.46 
  Diabetes Mellitus n (%) 28 (13.7) 23 (18.1) 0.27 298 (10.2) 146 (15.1) <0.001 
  Family History n (%) 18 (8.8) 19 (15.0) 0.08 883 (30.2) 273 (28.3) 0.27 
  Current smokers n (%) 44 (21.5) 26 (20.5) 0.83 1252 (42.8) 370 (38.3) 0.014 
  Previous MI n (%) 49 (24) 18 (14.2) 0.03 298 (10.2) 146 (15.1) <0.001 
  Previous PCI n (%) 5 (2.4) 5 (3.9) 0.43 192 (6.6) 41 (4.2) 0.009 
  Previous CABG n (%) 12 (5.9) 2 (1.6) 0.06 75 (2.6) 14 (1.5) 0.044 
  Renal impairment n (%) 11 (5.4) 6 (4.7) 0.80 50 (1.7) 10 (1.0) 0.14 
Procedural characteristics       
  Cardiogenic shock n (%) 32 (25.2) 56 (27.3) 0.67 97 (3.3) 29 (3.0)  
Vessel disease   0.03   0.001 
    0-vessel disease (excluding 
LM) n (%) 
9 (4.4) 5 (3.9)  13 (0.4) 2 (0.2)  
    1-vessel disease (excluding 
LM) n (%) 
60 (29.3) 56 (44.1)  1629 (55.7) 607 (62.8)  
    2-vessel disease (excluding 
LM)  n (%) 
50 (24.4) 30 (23.6)  780 (26.6) 231 (23.9)  
    3-vessel disease (excluding 
LM)  n (%) 
86 (42.0) 36 (28.3)  505 (17.3) 126 (13.0)  
Left main disease 28 (13.7) 14 (11.0) 0.48 73 (2.5) 21 (2.2) 0.57 
 Multi-vessel disease n (%) 148 (72.2) 72 (56.7) 0.004 1310 (44.8) 360 (37.3) <0.001 
Treated vessel       
  Left main n (%) 33 (16.1) 14 (11.0) 0.20 38 (1.3) 14 (1.4) 0.72 
  RCA n (%) 52 (25.4) 29 (22.8) 0.60 1114 (38.1) 420 (43.5) 0.003 
  LCX n (%) 50 (24.4) 26 (20.5) 0.41 459 (15.7) 176 (18.2) 0.06 
  LAD n (%) 98 (47.8) 68 (53.5) 0.31 1425 (48.7) 395 (40.9) <0.001 
  Graft n (%) 3 (1.5) 1 (0.8) 0.58 26 (0.9) 6 (0.6) 0.43 
Glycoprotein IIb/IIIa antagonists 
n (%) 
26 (12.7) 11 (8.7) 0.29 588 (20.1) 134 (13.9)  <0.001 
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DISCUSSION
In this single center study with long-term follow-up, women undergoing PCI had a substantial different 
risk profile than men. A higher short and long-term mortality was observed in women compared to 
men in the STEMI population. This difference in mortality rate did not exist in patients who survived 
the first month and could only partially be explained by differences in baseline characteristics. No 
differences in clinical outcome between men and women undergoing PCI for stable angina pectoris 
and NSTE-ACS were observed.
There were distinct differences in baseline characteristics between women and men. Women were older 
and, with the exception of smoking, had a higher prevalence of cardiovascular risk factors at baseline. 
The gender differences in baseline characteristics have been related to the greater age dependency 
of CAD in women compared to men, women generally start developing CAD predominantly at 
postmenopausal age, which is 6 to 10 years later than men. 34-35 Still, considering that women had 
less often an extensive cardiac history and suffered more from single-vessel disease, men had more 
severe CAD. Whether this observation implies that the observed classical risk factors are less potent 
in women, is still subject of debate.
Our finding of a higher unadjusted mortality rate in women presenting with STEMI is in accordance 
with other reports. 8-9, 36-39 Several studies have demonstrated that this higher mortality rate is at-
tributable to the more frequent presence of co-morbidities in these women.8-9, 39 Contrary to these 
findings, gender  difference in mortality did not disappear in our cohort after adjustment for baseline 
characteristics. This finding is confirmed by the sub-analyses in patients younger than 50-years of age, 
in whom we also observed an unfavorable outcome for women as compared to men. An important 
observation is that this difference in mortality is dominated by the excess mortality of women in the 
first month after admission. This is in accordance with the finding of Jneid et al. who reported a higher 
mortality among women presenting with STEMI in the initial 24 hours of hospitalization.37 Moreover, 
gender differences are also observed regarding treatment delays, i.e. lower use of early medical treat-
ments and timely reperfusion in women. 37, 40-43 Unfortunately, information needed to calculate the 
time delay between symptom onset, first (para) medical contact and time to balloon inflation was not 
available for the majority of patients with STEMI. A factor contributing to a longer treatment delay 
might be the difference in clinical manifestation of CAD. Women not only present more often with 
atypical chest pain or complaints of abdominal pain, dyspnea, nausea, and unexplained fatigue instead of 
chest pain, the higher prevalence of co-morbidity may cause misdiagnosis.44-45 It is also suggested that 
this gender difference may be explained by a higher probability of surviving transport to the hospital, 
despite their poorer risk profile. Subsequently, this group of high risk AMI women are more likely to 
die in- hospital. 46-47 
With the exception of age,  we found no major gender differences in baseline characteristics of the pa-
tients who died within the first month, while the observed differences were to the detriment of men. 
However, when comparing baseline characteristics with the overall STEMI population, the patients 
who died within the first month had more often diabetes and renal impairment, less likely underwent 
prior revascularisation, were more likely to have left main disease, presented more often with cardio-
genic shock and were less likely treated with Glycoprotein IIb/IIIa platelet receptor antagonist. These 
characteristics indicated a subgroup of patient with a high-risk profile. Women with STEMI presented 
more often with single vessel disease, an observation that is in accordance with others. 9 
Moreover, women also are less likely to undergo guideline recommended treatment, undergo less 
invasive cardiac procedures, and when treated are less likely to be treated aggressively as compared 
to men.37, 40-43, 45 In our cohort women were less likely to receive Glycoprotein IIb/IIIa platelet receptor 
antagonist than men, despite the known benefit 48 and lack of gender difference in protection from 
major adverse outcomes by GP IIb/IIIa blockade.49 
No clinical relevant differences in short and long term clinical outcome between men and women 
undergoing PCI for stable angina pectoris and NSTE-ACS were observed. This is in accordance with 
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Mehilli et al. who also found identical 1-year outcomes in women and men undergoing PCI for symp-
tomatic CAD. 18
Limitations
The presented results are based on a single center experience, which may limit the external validity. 
Nevertheless, the Thorax center Rotterdam can be considered representative for larger tertiary refer-
ring and teaching (academic) hospitals in Western populations. For the follow-up on non-fatal end-
points we were dependent on the responses of patients on health questionnaires that were systemati-
cally sent to all living patients, with specific inquiries on rehospitalisation and MACE. Consequently, it 
cannot be excluded that we might have missed some non-fatal endpoints, particularly those that did 
not result in hospital admissions. We have no indication that underreporting (if any) was related to 
gender. This phenomenon might have resulted in effect estimates that are biased towards the null. Still, 
we are confident that similar effects were seen for all (‘hard’ and ‘softer’) endpoints.
Conclusion
Women undergoing PCI for STEMI treatment had higher mortality than men. The excess mortality in 
women appeared in the first month after PCI and could only partially be explained by a difference in 
baseline characteristics. No gender differences in outcome in patients undergoing PCI for NSTE-ACS 
and stable angina were observed. 
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LIFE YEARS GAINED BY SMOKING CESSATION AFTER PERCUTANEOUS CORONARY 
INTERVENTION
ABSTRACT
Previous studies have shown that smoking cessation after a cardiac event reduces the risk of subse-
quent mortality in patients. The aim of this study was to describe the effect of smoking cessation in 
terms of prolonged life-years gained. The study sample comprised 856 patients who underwent percu-
taneous coronary intervention (PCI) (balloon angioplasty) during 1980-1985. Patients were followed-
up for 30 years and smoking status at 1 year could be retrieved in 806 patients. The 27 patients who 
died within 1 year were excluded from analysis. The median follow-up was 19.5 years (IQR 6.0-23.0). 
Cumulative 30-year survival was 29% in the group of patients who quitted smoking and 14% in those 
who persisted smoking (p=0.005). After adjustment for baseline characteristics at the time of PCI, 
smoking cessation remained an independent predictor of lower mortality (aHR 0.55 and 95% CI 0.44-
0.69). The estimated life expectancy was 18.5 years in those who quit smoking and 16.4 years in the 
persistent smokers (p<0.0001). In conclusion, in patients with CHD who underwent PCI in the late 
1980s smoking cessation resulted in at least 2.1 life years gained.
INTRODUCTION
Smoking is a well-known risk factor for the development and progression of coronary heart disease 
(CHD)1-5 and its relation with increased morbidity and mortality from cardiovascular causes has long 
been established.6, 7 Previous studies have demonstrated that smoking cessation after coronary artery 
bypass grafting (CABG),8 percutaneous coronary intervention (PCI),9 and myocardial infarction (MI)10-
12 reduces the rate of subsequent mortality and further cardiovascular events.13 The aim of our study 
was to quantify the effect of smoking cessation in terms of prolonged life-years. We followed up the 
first 856 patients treated with PCI (balloon angioplasty) in the Thorax centre, Rotterdam during 1980-
1985 for 30 years. Since this 30-year period almost compromises the whole further life span of these 
patients, the mean age at admission was 56 years old, we were able to calculate without applying major 
model assumptions the life expectancy in quitters and persistent smokers.
38 | Chapter 1.2
METHODS
The Erasmus MC, located in Rotterdam the Netherlands, is a tertiary referral and teaching hospital 
in the Rotterdam region. In the eighties the Erasmus MC was the only hospital with PCI facilities in 
the Rotterdam region. Historically the first candidates for PCI (balloon angioplasty) were those with 
proximal, discrete, non-calcified single-vessel obstructions in the presence of recent angina, unaccept-
able to the patient and uncontrolled by medical therapy.14 However, due to greater confidence from 
increased experience and technological advances, more patients with larger numbers of diseased 
vessels, poorer left ventricular function and more accompanying risk factors were being treated in the 
following years.15
In this report we describe the first 856 consecutive patients of 18 years of age or older who under-
went PCI in the Thoraxcenter during September 1980 to December 1985 for various indications. 16 
Within 1 year after the PCI 27 patients died and 1 patient was lost to follow up. Among the 828 1-year 
survivors smoking status could not be retrieved in 22 patients. So, our final study population consisted 
of 806 1-year survivors with smoking status available. (Figure 1) 
All data on smoking status are based on self-reporting via phone calls and questionnaires. Patient 
smoking behaviour was determined before the PCI procedure, and 495 patients (61%) reported to be 
smokers. One year after the PCI smoking status was obtained again, and 287 patients (36%) smoked 
1 year after PCI. Based on this information patients were divided into 3 groups: non-smokers, quit-
ters and persistent smokers. Patients were considered non-smokers if they reported to never have 
smoked, or quitted smoking before the PCI and did not start smoking within the first year after PCI. 
Quitters were defined as those patients who smoked prior to PCI and indicated themselves as non-
smokers at 1-year follow-up. Patients were assigned to the persistent smoking category when they 
indicated themselves as smokers before PCI and 1 year after PCI. Two patients who started smoking 
within the first year after the PCI were considered as persistent smoker for this analysis. 
Figure 1 Flowchart patient selection
Life Years Gained by Smoking Cessation after Percutaneous Coronary Intervention | 39
Follow-up data for vital status were obtained from the municipal civil registry in February 2011.We 
were able to retrieve the vital status for 838 of the 856 patients (97.9%). Of the 18 patients who’s vital 
status could not be retrieved, 7 patients moved abroad. For these 18 patients we used the last know 
follow-up date, after which point they were considered lost to follow-up.
The endpoint of our analysis was all-cause mortality at maximum follow-up.
Continuous variables are presented as mean ± standard deviation and categorical variables are ex-
pressed as numbers and percentages. Student’s t tests, one-way ANOVA and Chi-square test (or 
Fisher’s exact tests) were applied, when appropriate, to evaluate differences in baseline variables be-
tween non-smokers, quitters and persistent smokers.
We intended to obtain complete information in all patients, but failed to do so for baseline information 
for a small number of patients. Using missing value analysis (MVA) we evaluated the extent of missing 
data and searched for patterns of missing data. MVA showed that 1.6% missing values were missing. 
For the patients with at least one of the variables of interest missing, we decided to impute the missing 
values by multiple imputation.17
The incidence of events over time was studied with the use of the Kaplan-Meier method, whereas log-
rank tests were applied to evaluate differences between the different groups (non-smokers, quitters 
of persistent smokers). Patients lost to follow-up were considered at risk until the date of last contact, 
at which point they were censored.
Subsequently, Cox proportional hazard models were used to analyse the association between smoking 
status and mortality during 30-year follow-up.  Baseline and procedural characteristics listed in Table 
1 were all considered as potential confounders.  We report crude and adjusted hazard ratio’s (HRs), 
with their 95% confidence interval (CIs).
Tables  
 
Table 1 Baseline characteristics according to smoking status 
 
Characteristics Non-
smokers 
(N=309) 
Persistent 
smokers 
(N=287) 
Quitters  
 
(N=210) 
P-value 
Persistent 
smokers 
vs. quitters 
P-value 
Non- smokers 
vs. quitters 
Age (years±SD) 59.0±8.5 53.8±8.9 54.9±8.9 0.17 <0.001 
Male 219 (71%) 251 (88%) 177 (84%) 0.31 <0.001 
Indication    0.06 0.041 
   Stable Angina Pectoris 174 (56%) 149 (52%) 100 (48%)   
   Unstable Angina Pectoris 112 (36%) 118 (41%) 81 (39%)   
   Acute Myocardial Infarction  23 (7.4%) 20 (7 %) 28 (13%)   
Hypercholesterolemia 87 (29%) 83 (29%) 57 (27%) 0.66 0.78 
Hypertension  132 (43%) 101 (36%) 84 (40%) 0.28 0.52 
Positive family history for 
Coronary Heart Disease 
131 (43.%) 111 (39%) 79 (38%) 0.84 0.28 
Diabetes Mellitus 39 (13%) 31 (11%) 19 (9.1%) 0.53 0.21 
Previous Myocardial infarction 113 (38%) 110 (40%) 94 (45%) 0.23 0.08 
Previous Coronary Artery 
Bypass Graft 
37 (12%) 18 (6.3%) 11 (5.3%) 0.62 0.010 
Multi-vessel disease 122 (40%) 94 (33%) 63 (30%) 0.54 0.026 
Clinical success procedure 241 (79%) 236 (83%) 166 (77%) 0.09 0.75 
 
 
 Table 1 Baseline characteristics according to smoking status
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Life expectancy after PCI was calculated from the area under the Kaplan-Meier curve.18 To calculate 
the exact life expectancy, the Kaplan Meier curves were extended beyond 30 years using the age- and 
sex-specific mortality data from the Dutch population in 2009, 19 assuming that the  251 patients with 
PCI who had survived 30 years had similar mortality as their age- and sex-matched peers.
All statistical tests were two-tailed and a p-value <0.05 was considered statistically significant. Statistical 
analyses were performed with SPSS for Windows version 17.0 (SPSS inc., Chicago, Illinois, USA).
RESULTS
The mean age of the patients was 56.2 years, and the majority of patients were men (80%). Key char-
acteristics of the non-smokers, quitters and persistent smokers are presented in Table 1. 
The patients that composed our study population were responsible for 14,977 patient years of follow-
up; the median follow-up duration was 19.5 years (IQR 6.0-23.0).
The cumulative 30-year survival rate was 29% in the group of patients who quit smoking and 14% 
in the persistent smokers (p=0.005). (Figure 2). Life expectancy in those who quit smoking was 18.5 
years (95% CI 17.3-19.6 years) and 16.4 years (95% CI 15.2-17.4 years) in the persistent smokers 
(p<0.0001).
 Quitters and non-smokers had significant lower mortality than persistent smokers (adjusted hazard 
ratio (aHR) 0.57 and 95% CI 0.46-0.71), and (aHR) 0.42 and 95% CI 0.34-0.52), respectively. Other 
significant predictors of long-term all-cause mortality were: multi-vessel disease (aHR 1.45 and 95% CI 
1.19-1.75), previous myocardial infarction (aHR 1.27 and 95% CI 1.06-1.53) and hypertension (aHR 
1.37 and 95% CI 1.14-1.64).
DISCUSSION
In this single centre study with long-term follow-up persistent smokers had significantly higher all-cause 
mortality than quitters. The life expectancy of quitters exceeded the life expectancy of persistent 
smokers by 2.1 years. Moreover, quitters had a similar all-cause mortality rate as patients who reported 
to be non-smokers. On average quitters were 4 years younger than non-smokers.
Our results are in accordance with previous studies. A systematic review studying the mortality risk 
reduction by smoking cessation in coronary heart patients found a substantial reduction in risk of all-
Figure 2                 Cumulative survival according to smoking status
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cause mortality and non-fatal myocardial re-infarctions.13 Van Domburg et al. have shown similar results, 
smoking cessation after CABG led to a reduction in mortality and a 3 year life gain.20
Convincing patients to stop smoking is a difficult task. Pharmacologic therapy including bupropion 
(Zyban) and varenicline, nicotine patches, inhalers, and behavioral interventions have been developed 
to improve the chances of smoking cessation.21-23  These interventions result in a modest increase in 
smoking abstinence at 12 months when compared with placebo. Unfortunately smoking relapse rates 
are rather high.23 Despite the introduction of national health campaigns in the 1980s in the Nether-
lands, 27% of the general population 24, and 15% of the CHD patients smoke. 25 With our results (the 
quantification of prolonged life-years), physicians have an additional tool to encourage and convince 
patients to stop smoking. 
The strength of the current study is the long-term follow-up of a cohort of patients undergoing PCI. 
At the same time, this population was treated with balloon angioplasty only, which is nowadays not the 
standard of care. Since the 1980s the patient population undergoing PCI has changed as procedures 
have been improved and refined and novel techniques were introduced, which made it possible to 
treat increasingly complex lesions and patients with a history of clinically significant cardiac disease, risk 
factors for coronary artery disease, coexisting conditions, or anatomical risk factors.26, 27 Furthermore, 
improvements in supportive medical care (i.e. pharmacological therapy) have been made. Overall, the 
improved care has led to better prognosis in all patients, including smokers. Our study showed that 
smoking cessation improved life expectancy. Although it remains to be seen to what extend smoking 
cessation will benefit current patients, there are no indications that the unfavorable effect of smoking 
can be made undone by using novel treatment modalities. In addition, it has been shown that stent 
placement as compared to balloon angioplasty benefits only on target vessel revascularization, not 
mortality. 28 More research is warranted.
For the classification of smoking status we were dependent on the patients to fill out a questionnaire, 
patients who continued to smoke may have falsely claimed cessation. Since tests to measure the car-
bonmonoxide476 concentration were not available in the 1980s we were unable to validate smoking 
status. However, self-reporting smoking behaviour appears to be accurate as demonstrated in the 
EuroAspire-I survey, and in a meta-analysis/review. 29, 30 Finally, we did not record smoking status after 
the one year follow-up; patients may have start or stopped smoking during the follow-up. Nonetheless, 
since patients had to sustain smoking cessation for one year, the misclassification is limited.
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PRIMARY PCI DURING OFF-HOURS IS NOT RELATED WITH INCREASED MORTALITY
ABSTRACT
Purpose
Previous studies have shown contradictory outcomes in ST-segment elevation myocardial infarction 
(STEMI) patients who underwent primary percutaneous coronary intervention (pPCI) during off-
hours versus regular “office” hours. We aimed to evaluate the relationship between pPCI timing (off-
hours versus regular hours) and mortality in patients with STEMI undergoing pPCI.
Methods
The study population comprised of 4352 consecutive STEMI patients treated with pPCI in a high 
volume centre with a 24/7 programme during 2000 - 2009. Descriptive statistics and multivariable 
survival analyses were applied to evaluate the relation between treatment during off-hours (Mon-
day- Friday, 06.00 PM- 08.00 AM and weekends) versus regular hours and the incidence of all-cause 
mortality at 30 day and 4 year follow-up.
Results
A total of 2760 patients (63.4%) were treated during off-hours and 1592 patients (36.6%) during 
regular hours. With the exception of smoking, diabetes mellitus, use of glycoprotein IIb/IIIa antagonists 
and calcium antagonists, no major differences in baseline characteristics were observed between both 
groups. Mortality at 30-days follow-up was similar in patients treated during off-hours and those 
treated during regular hours (7.7% vs. 7.7%; Hazard Ratio adjusted for potential confounders 1.03; 95% 
CI 0.82 - 1.28). Four-year mortality was similar as well (17.3% vs. 17.3%; adjusted Hazard Ratio 0.95; 
95% CI 0.81 - 1.11).
Conclusion
In STEMI patients who present during off-hours in a high volume centre with 24/7 service, pPCI pro-
vides similar survival as patients who were treated during regular hours.
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INTRODUCTION
Randomised clinical trials have convincingly demonstrated that patients with ST-segment elevation 
myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (pPCI) have 
better event-free survival and clinical outcomes than those treated with fibrinolysis. 1 In order to fully 
benefit from the instantaneous and long-term effects of pPCI, patients need to be treated as soon as 
possible after symptom onset. Guidelines recommend that pPCI be performed within 90 minutes after 
the first medical contact. 2-3 This recommendation is supported by several studies that reported a di-
rect relation between (increased) time delay to pPCI and (worse) clinical outcome. 4-6 Short onset-to-
treatment times are best guaranteed in hospitals with an established interventional cardiology program 
that offers full service 24 hours per day, 7 days per week (24/7 program). 2-3
Since the occurrence of STEMIs are more or less randomly distributed over time, in a 24/7 program, 
most patients will be treated during ‘off-hours’: evening and night shifts and weekends. Previous studies 
have shown contradictory outcomes in STEMI patients who underwent pPCI during off-hours versus 
regular “office” hours. However, most of these studies were conducted in centers using both fibrinoly-
sis and pPCI for treatment of patients with STEMI, and did not evaluate long term outcomes.7-18 In the 
year 2000 pPCI became the standard treatment for STEMI in our institution and a 24/7 program was 
established. Baseline, procedural, and follow-up data of all patients undergoing PCI in our institution are 
systematically collected. Consequently we were able to evaluate the relationship between pPCI timing 
(off-hours versus regular hours) and short- and long-term outcome in STEMI patients.
METHODS
Patient population
The Erasmus MC is a tertiary referral and teaching hospital in the broader region of Rotterdam (ap-
proximately 1.9 million inhabitants), located on the North bank of the Maas river. Between January 
2000 and June 2004 the Erasmus MC was the only hospital with pPCI facilities in the region. From July 
2004 onwards the Maasstad hospital (also located in Rotterdam, on the south bank of the Maas river) 
started a 24/7 programme locally and provided regional pPCI service on Mondays and Thursdays and 
the first weekend of every month to improve service. The Erasmus MC provided pPCI service on the 
remaining days.
All consecutive patients of 18 years of age or older, who presented within 12 hours of symptom onset 
with ST-segment elevation myocardial infarction (STEMI) and who subsequently underwent pPCI in 
our institution between January 2000 and December 2009 were included in the analysis. STEMI is de-
fined as patients presenting with ischaemic symptoms and persistent (>20 min) ST-segment elevation 
in at least 2 contiguous precordial leads or at least 2 adjacent limb leads by ECG. 3 In total, 4541 pPCIs 
in 4352 patients were performed. In patients who were admitted more than once for pPCI (n=189), 
only the initial procedure was used for this analysis.
Patient management
Patient management was in accordance with the applicable guidelines of the European Society of 
Cardiology (ESC). Patients received an aspirin and (300 to 600 mg) clopidogrel loading dose before 
pPCI and preferably in the ambulance. Clopidogrel (75mg/day) duration was at least one month for 
patients treated with bare metal stents (BMS), at least 3 months for patients treated with sirolimus 
eluting stents (SES) and at least 6 months to patients treated with paclitaxel eluting stents (PES) or 
everolimus eluting stents (EES). After the procedure, all patients were advised to remain on aspirin 
(>80mg/day) indefinitely. Periprocedural glycoprotein IIb/IIIa antagonists were left at the discretion of 
the treating interventional cardiologist.
Since the year 2000, the interventional cardiology department has the policy to us 1 particular stent 
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as default in a given time interval. The default stent between January 2000 and April 2002 was a BMS, 
between April 2002 and March 2003 a SES, between March 2003 and March 2007 a PES, and the EES 
since March 2007. Of note, during the study period a small number of STEMI patients was treated with 
another stent due to participation in a clinical trial comparing stents.
Data collection
According to the approved standard data-management procedures in our department, data are col-
lected on demographics, cardiovascular history, clinical risk factors and treatment characteristics for 
all patients undergoing PCI and are stored in an electronic database. Data-elements are filled out im-
mediately after the completion of the PCI by the interventional cardiologist and the technician who 
assisted during the procedure. The database, which is maintained by a dedicated IT-officer, is mainly 
designed for administrative purposes. A systematic evaluation of data-completion and data-integrity is 
implemented for data that are used for research purposes.
Data management and Follow-up
Mortality data related to the entire cohort was obtained from interrogation of municipal civil regis-
tries between April and September 2011. A health questionnaire was subsequently sent to all living 
patients with specific inquiries on rehospitalisation and major adverse cardiovascular events (MACE). 
For patients who had adverse events at other centres, medical records or discharge summaries from 
the other institutions were systematically reviewed. General practitioners, referring cardiologists, and 
patients were contacted in case further information was required.
Endpoint definitions
The primary endpoints were early mortality, which was defined as all-cause mortality within thirty days 
after the index event, and late mortality, which includes all-cause mortality at 1-year and 4-year follow-
up). The secondary endpoints included repeat PCI (rePCI), coronary artery bypass grafting (CABG) 
or recurrent MI (reMI) and the composite endpoint of reMI, revascularization (rePCI or CABG) and 
all-cause mortality at 30 day, 1-year and 4-year follow-up. ReMI at follow-up was diagnosed MI was 
diagnosed by recurrent typical clinical symptoms, the development of ST-segment 
elevation or left bundle branch block on electrocardiography with a CK-MB rise of three 
times the upper limit of normal and/or positive troponin levels in the laboratory values.  rePCI was 
defined as a repeat percutaneous intervention of any lesion located in the epicardial vessels. CABG 
was defined as a surgical intervention of any lesion located in the epicardial vessels.
Statistical methods
Off-hours were defined as weeknights (Monday through Friday from 06.00 PM to 08.00 AM) and 
weekends (from Friday 06:00 PM to Monday 08:00 AM).
Continuous variables are presented as mean ± standard deviation and categorical variables are ex-
pressed as numbers and percentages. Student’s t tests, Chi-square tests and Fisher’s exact tests were 
applied to evaluate differences in baseline variables between patients treated during off-hours and 
regular hours, as appropriate.
We intended to obtain complete information in all patients, but failed to do so for the medication at 
discharge. Using missing value analysis (MVA) we evaluated the extent of missing data and searched 
for patterns of missing data. MVA showed that there were 6.2% missing values on average for medica-
tion at discharge. For the patients with at least one of the variables of interest missing, we decided to 
impute the missing values by multiple imputation.19
The incidence of events over time was studied with the use of the Kaplan-Meier method, whereas 
log-rank tests were applied to evaluate differences between the treatment groups (treatment during 
off-hours versus regular hours). Patients lost to follow-up were considered at risk until the date of last 
contact at which point they were censored.
Cox proportional hazard (PH) regression models were applied to evaluate the relationship between 
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 1 
 Off-hours 
n=2760 
Regular hours 
N=1592 
P-value 
Age (years ±SD) 60.9±12.8 61.5±12.5 0.14 
Male (%,n) 73.5, 2029 75.2, 1197 0.23 
Medical History 
 Hypertension (%,n) 40.1, 1107 38.6, 614 0.32 
 Hypercholesterolemia 72.4, 1998 71.4, 1137 0.49 
 Diabetes Mellitus (%, n) 13.0, 358 10.4, 165 0.011 
 Family History (%, n) 28.6, 790 27.6, 439 0.46 
 Current smokers (%, n) 41.8, 1154 36.0, 573 <0.001 
 Previous MI (%, n) 12.1, 334 13.1, 209 0.32 
 Previous PCI (%, n) 9.2, 147 7.9, 217 0.12 
 Previous CABG (%, n) 2.4, 66 3.2, 51 0.11 
 Renal impairment (%, n) 2.1, 57 1.8, 29 0.58 
Procedural characteristics    
 Cardiogenic shock (%, n) 4.9, 135 4.8, 76 0.86 
 Vessel disease    0.63 
 1-vessel disease (%, n) 54.8, 1513 55.2, 878  
 2-vessel disease (%, n) 26.9, 742 27.6, 440  
 3-vessel disease (%, n) 18.3, 505 17.2, 274  
 Multi-vessel disease (%, n) 45.2, 1247 44.8, 714 0.83 
Treated vessel   0.35 
 Left main (%, n) 3.5, 97 4.5, 71  
 RCA (%, n) 34.0, 938 35.3, 562  
 LCX (%, n) 14.3, 396 13.4, 213  
 LAD (%, n) 46.6, 1285 44.9, 715  
 Graft (%, n) 0.6, 17 0.9, 15  
Glycoprotein IIb/IIIa antagonists 
(%, n) 
16.5, 456 21.4, 340 <0.001 
Discharge medication    
Aspirin (%, n) 90.1, 2599 90.2, 1338 0.91 
Calcium antagonist (%, n) 14.5 378 19.8, 294 <0.001 
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treatment during off-hours versus regular hours and the incidence of all-cause death at 30 days, 1 year 
and 4 years. The baseline clinical and procedural characteristics that are listed in Table 1 were consid-
ered as potential confounders for the 1 year and 4 years mortality analysis. As the number of events 
was limited at 30 days, we were only able to adjust for the following clinically relevant factors: age, sex, 
multi-vessel disease, shock, previous MI, renal impairment, and diabetes mellitus.
Final results are presented as adjusted hazard ratios (aHR) with 95% confidence interval (CI). All sta-
tistical tests were two-tailed and a p-value <0.05 was considered significant. Statistical analyses were 
performed with SPSS for Windows version 17.0 (SPSS inc., Chicago, Illinois, USA).
RESULTS
Key characteristicsBetween January 1, 2000 and December 31, 2009, a total of 4352 consecutive 
patients presenting with STEMI underwent pPCI in our institution. A total of 2760 patients (63.4%) 
were treated during off-hours and 1592 patients (36.6%) during regular hours. Key characteristics of 
the two cohorts are presented in Table 1. With the exception of diabetes mellitus (13.0% vs. 10.4%, 
p=0.011), current smoking (41.8% vs. 36.0%, p<0.001), use of glycoprotein IIb/IIIa antagonists (16.5% 
vs. 21.4%, p<0.001) no statistically significant differences in baseline and procedural characteristics 
were observed between both groups. Noteworthy, the percentage of patients presenting with car-
diogenic shock was similar in both groups (4.9% and 4.8%, respectively, p=0.86). There were also no 
statistically significant differences in discharge medication, except for the use of calcium antagonists 
(14.5% vs. 19.8%, p<0.001).
Mortality
Information on survival status at 1-year follow-up was complete for 96.5% of patients. The median 
follow-up period was 1246 days (IQR 651 - 2228 days).
The cumulative incidence of all-cause mortality at 30-days follow-up was similar in the patients treated 
during off-hours and those treated during regular hours 7.7% vs. 7.7% respectively (Kaplan Meier es-
timates). Similarly, no statistically significant differences were observed in all-cause mortality at 1-year 
(10.9% vs. 12.5%) and 4-year follow-up (17.3% vs. 17.3%). In fact, the cumulative incidence curves were 
superimposed throughout the entire 4 year follow-up period (figure 1A). Multivariable adjustment for 
potential confounders of the relation between treatment timing and the incidence of all-cause mortal-
ity did not change this message (aHR at 4-years 0.96 and 95% CI 0.81 - 1.12).
Non-fatal and composite endpoints
We did not found any clinically relevant difference in the incidence of non-fatal endpoints between 
patients treated during off-hours vs. regular hours. Results were similar at short-term and long-term 
follow-up (table 2, figure 1B-D). At 4-years follow-up, the crude cumulative incidences of reMI were 
5.5% and 4.6%, the incidences of CABG were 1.6% and 3.0%, and the incidences of rePCI were 12.9% 
and 13.4%, respectively. Again, cumulative incidence curves were superimposed for all these endpoints. 
Treatment timing had no contribution in multivariable Cox PH models that related patient characteris-
tics with non-fatal clinical outcomes. Adjusted HRs of treatment timing were non-significant and close 
Table 1 Baseline and procedural characteristics according to pPCI timing
 2 
Beta-blockers (%, n) 51.6, 1342 54.0, 801 0.14 
RAAS-inhibitors (%, n) 41.7, 1085 39.9, 592 0.25 
Statins (%, n) 71,6, 1861 71.2, 1056 0.79 
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to 1 for all endpoints at all three follow-up moments that we studied.  
The cumulative incidence of the composite endpoint of all-cause death, reMI, PCI or CABG at 4-years 
follow-up was 29.5% in patients treated during off-hours and 29.5% in those treated during regular 
hours (table 2, figure 1E). The aHR was 1.05 and the 95% CI ranged from 0.93 to 1.18, indicating that 
there was no association between treatment timing and the incidence of this composite endpoint.
Findings in subgroups
Figure 2 shows the relation between treatment timing and 30-day all-cause mortality in a number 
of clinically relevant subgroups. All in all, in the subgroups that we considered, we found no major 
deviations from the overall result. Except in the strata according to the history of MI, 95% confidence 
intervals of treatment effect were largely overlapping, and none of the formal heterogeneity tests were 
statistically significant.
Figure 1 Clinical outomes according to regular hours versus off hours 
 A: all-cause mortality, B: reMI, C: rePCI, D: CABG, E: composite endpoint of all-cause  
 mortality, reMI, rePCI and CABG.
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Figure 2 Treatment during off hours in different subgroups
DISCUSSION
In this long-term follow-up study of STEMI patients who were treated during 2000-2009 in a high 
volume centre with 24/7 service, clinical outcomes were similar in patients undergoing pPCI during 
off-hours and those undergoing pPCI during regular hours. This similarity in outcome was already ob-
served at 30 days and was maintained until 4 years after the initial procedure. Consistent results were 
seen in clinically relevant subgroups, including the elderly and patients with multi-vessel disease.
The quality of care delivered to STEMI patients may differ during day and night because of variations 
in door to balloon time, performance of physicians, catheterization laboratory, and coronary care 
staff. Compared to regular office hours the hospital staffing is generally reduced during nights and on 
weekends compared with weekdays. The short-term outcome (after adjustment for any differences in 
case-mix) may be regarded as a proxy measure of the quality of care during the procedure, whereas 
the long-term outcome to a greater extent depends on the development of the disease, the use of 
long-term medication and (probably) the use of coronary revascularisations. Interestingly, we found 
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few differences in baseline characteristics between patients treated during off-hours and regular hours. 
Also medical treatment at discharge was similar. Apparently, in the region of Rotterdam, STEMI patients 
constitute a quite homogeneous population, regardless the timing of presentation. Consequently, the 
point estimates of the effect of treatment timing didn’t change after adjustment for patient character-
istics. The estimates of the effect for all the endpoints indicated that treatment during off-hours is as 
safe and effective as treatment during regular hours.
Previous studies have shown contradictory results in outcome in STEMI patients who underwent pPCI 
during off-hours versus regular hours. Whereas some studies showed that presentation and treatment 
during off-hours only had limited impact on in-hospital mortality 7, 9, 12-13, 15-16, 18, other studies revealed 
higher in-hospital mortality in pPCI patients during off-hours than regular hours. 8, 10-11, 14 A straight-
forward comparison of these clinical studies is complicated by differences in patient characteristics 
and (medical) co-treatment, as well as by the applied definitions. For example, Henriques et al., who 
reported higher mortality after off-hour treatment, focussed on the circadian patterns of symptom on-
set, including routine duty hours (0800-1800) versus off-hours irrespective of day of the week.8 In the 
study by Kostis et al.10 the significant difference in 30-day mortality to the disadvantage of the patients 
treated during off-hours disappeared after adjustment for the use of invasive cardiac procedures, which 
appeared less often in patients admitted on weekends. Furthermore, in some of the previous studies 
patients were not only treated with pPCI, but also with fibrinolysis, which may have lead to different 
results. 9-11, 15, 18 Since 2000 in our centre pPCI is the default strategy for all STEMI patients on a 24/7 
basis, precluding potential bias due to fibrinolysis. At the other hand, most patients that are treated in 
our center are referred for pPCI by hospitals in the larger region of Rotterdam that do not provide a 
24/7 pPCI service. Although, apparently, the referral pattern is not dependent on the day of the week 
and the time of the day (as we found no differences in patient characteristics in relation to treatment 
timing), the patient selection by referral hospitals might partly explain the consistent outcomes.
Study limitations
Other predictors of outcome after pPCI that have been reported include time delay from symptom-
onset to the first balloon inflation 4-6 and physician volume. 20-21 Since the database that we used for our 
study was not specifically designed to address these issues, several relevant quality parameters have 
not been recorded prospectively. Still, we retrospectively recorded the time between hospital admis-
sion and the start of the pPCI procedure (data were available for 70% of patients), and we found no 
differences between patients treated during off-hours versus those treated during regular hours (data 
not shown).  The presented results are based on a single centre experience, which limits the ex-
ternal validity. Nevertheless, the Thoraxcenter Rotterdam can be considered representative for larger 
tertiary referring and teaching (academic) hospitals in Western populations.
For the follow-up on non-fatal endpoints we were dependent on the responses of patients on health 
questionnaires that were systematically sent to all living patients, with specific inquiries on rehospitali-
sation and MACE. Thus, we might have missed some non-fatal endpoints, particularly those that did 
not result in hospital admissions. We have no indication that underreporting (if any) was related to 
the timing of the initial treatment. This phenomenon might have resulted in effect estimates that are 
biased towards the null. Still, we are confident that similar effects were seen for all (‘hard’ and ‘softer’) 
endpoints.
Conclusion
STEMI patients who were treated in a high-volume center with a 24/7 program have similar short- 
and long-term outcomes if they are treated during off-hours or regular hours. Our findings, which are 
based on systematic monitoring of treatment outcome results, do not give rise to change our practice. 
Instead, these results may encourage other centers to expand their service.
56 | Chapter 1.3
Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy 
for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 
361(9351): 13-20.
Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr., Jacobs AK, Kern MJ, King SB, 3rd, Morrison DA, O’Neill 
WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, 
Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Ameri-
can College of Cardiology/American Heart Association Task Force on Practice G, Interven-
tion AASWCtUtGfPC. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary 
intervention: a report of the American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 
Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47(1):e1-121.
Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Hu-
ber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M, Guidelines 
ESCCfP. Management of acute myocardial infarction in patients presenting with persistent 
ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute 
Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29(23):2909-
2945.
Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ, Gore JM, Weaver 
WD, Rogers WJ, Tiefenbrunn AJ. Relationship of symptom-onset-to-balloon time and door-to-
balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. 
JAMA 2000; 283(22):2941-2947.
De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortal-
ity in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circu-
lation 2004; 109(10):1223-1225.
De Luca G, Suryapranata H, Zijlstra F, van ‘t Hof AW, Hoorntje JC, Gosselink AT, Dambrink JH, 
de Boer MJ, Group ZMIS. Symptom-onset-to-balloon time and mortality in patients with acute 
myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2003; 42(6):991-997.
Berger A, Meier JM, Wasserfallen JB, Graf D, Renders F, Dascotte Y, Prudent V, Eeckhout E. Out 
of hours percutaneous coronary interventions in acute coronary syndromes: long-term out-
come. Heart 2006; 92(8):1157-1158.
Henriques JP, Haasdijk AP, Zijlstra F, Zwolle Myocardial Infarction Study G. Outcome of primary 
angioplasty for acute myocardial infarction during routine duty hours versus during off-hours. 
J Am Coll Cardiol 2003; 41(12):2138-2142.
Jneid H, Fonarow GC, Cannon CP, Palacios IF, Kilic T, Moukarbel GV, Maree AO, LaBresh KA, 
Liang L, Newby LK, Fletcher G, Wexler L, Peterson E, Get With the Guidelines Steering C, 
Investigators. Impact of time of presentation on the care and outcomes of acute myocardial 
infarction. Circulation 2008; 117(19):2502-2509.
Kostis WJ, Demissie K, Marcella SW, Shao YH, Wilson AC, Moreyra AE, Myocardial Infarction 
Data Acquisition System Study G. Weekend versus weekday admission and mortality from 
myocardial infarction. N Engl J Med 2007; 356(11):1099-1109.
Magid DJ, Wang Y, Herrin J, McNamara RL, Bradley EH, Curtis JP, Pollack CV, Jr., French WJ, 
Blaney ME, Krumholz HM. Relationship between time of day, day of week, timeliness of rep-
erfusion, and in-hospital mortality for patients with acute ST-segment elevation myocardial 
infarction. JAMA 2005; 294(7):803-812.
Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Aquilina M, Baldazzi F, Silenzi S, Taglieri 
N, Grosseto D, Bacchi-Reggiani ML, Guastaroba P, Grilli R, Branzi A. Clinical comparison of 
“normal-hours” vs “off-hours” percutaneous coronary interventions for ST-elevation myocar-
dial infarction. Am Heart J 2007; 154(2):366-372.
REFERENCES 
01.
02. 
03.
04.
05.
06.
07.
08. 
09. 
10.
11.
12.
Primary PCI during off-hours is not related with increased mortality | 57
Sadeghi HM, Grines CL, Chandra HR, Mehran R, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin 
JJ, Stuckey TD, Lansky AJ, O’Neill WW, Stone GW. Magnitude and impact of treatment delays 
on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial 
infarction (the cadillac trial). Am J Cardiol 2004; 94(5):637-640, A639.
Saleem MA, Kannam H, Aronow WS, Weiss MB, Kalapatapu K, Pucillo AL, Monsen CE. The 
effects of off-normal hours, age, and gender for coronary angioplasty on hospital mortality in 
patients undergoing coronary angioplasty for acute myocardial infarction. Am J Cardiol 2004; 
93(6):763-764.
Zahn R, Schiele R, Seidl K, Schuster S, Hauptmann KE, Voigtlander T, Gottwik M, Berg G, Kunz T, 
Glunz HG, Limbourg P, Senges J. Daytime and nighttime differences in patterns of performance 
of primary angioplasty in the treatment of patients with acute myocardial infarction. Maximal 
Individual Therapy in Acute Myocardial Infarction (MITRA) Study Group. Am Heart J 1999; 
138(6 Pt 1): 1111-1117.
Casella G, Ottani F, Ortolani P, Guastaroba P, Santarelli A, Balducelli M, Menozzi A, Magnavacchi 
P, Sangiorgi GM, Manari A, De Palma R, Marzocchi A. Off-hour primary percutaneous coronary 
angioplasty does not affect outcome of patients with ST-Segment elevation acute myocardial 
infarction treated within a regional network for reperfusion: The REAL (Registro Regionale 
Angioplastiche dell’Emilia-Romagna) registry. JACC Cardiovasc Interv 2011; 4(3):270-278.
Glaser R, Naidu SS, Selzer F, Jacobs AK, Laskey WK, Srinivas VS, Slater JN, Wilensky RL. Fac-
tors associated with poorer prognosis for patients undergoing primary percutaneous coro-
nary intervention during off-hours: biology or systems failure? JACC Cardiovasc Interv 2008; 
1(6):681-688.
Bell CM, Redelmeier DA. Mortality among patients admitted to hospitals on weekends as 
com-pared with weekdays. N Engl J Med 2001; 345(9):663-668.
Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR. 
Multiple imputation for missing data in epidemiological and clinical research: potential and 
pitfalls. BMJ 2009; 338:b2393.
Magid DJ, Calonge BN, Rumsfeld JS, Canto JG, Frederick PD, Every NR, Barron HV, National 
Registry of Myocardial I, Investigators. Relation between hospital primary angioplasty volume 
and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic 
therapy. JAMA 2000; 284(24):3131-3138.
Canto JG, Every NR, Magid DJ, Rogers WJ, Malmgren JA, Frederick PD, French WJ, Tiefenbrunn 
AJ, Misra VK, Kiefe CI, Barron HV. The volume of primary angioplasty procedures and survival 
after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. N 
Engl J Med 2000; 342(21):1573-1580.
13.
14.
15.
16.
17.
18.
19. 
20.
21.

1.4
HIGH-RISK STEMI PATIENTS DERIVE GREATEST ABSOLUTE BENEFIT 
FROM PRIMARY PERCUTANEOUS CORONARY INTERVENTION: 
RESULTS FROM THE PRIMARY CORONARY ANGIOPLASTY TRIALIST 
VERSUS THROMBOLYSIS (PCAT)-2 COLLABORATION
Sanneke P.M. de Boer
Elizabeth H. Barnes
Cynthia M. Westerhout 
R. John Simes
Christopher B. Granger
Adnan Kastrati
Petr Widimsky
Menko Jan de Boer
Felix Zijlstra
Eric Boersma
60 | Chapter 1.4
High-risk STEMI patients derive greatest absolute benefit from primary percutaneous coronary intervention | 61
HIGH-RISK STEMI PATIENTS DERIVE GREATEST ABSOLUTE BENEFIT FROM PRIMARY PER-
CUTANEOUS CORONARY INTERVENTION: RESULTS FROM THE PRIMARY CORONARY AN-
GIOPLASTY TRIALIST VERSUS THROMBOLYSIS (PCAT)-2 COLLABORATION
ABSTRACT
Background
Meta-analyses of randomised trials show that primary percutaneous coronary intervention (PPCI) re-
sults in lower mortality than fibrinolytic therapy in myocardial infarction (MI) patients. We investigated 
which categories of MI patients would benefit most from the strategy of PPCI, and thus have lowest 
numbers needed to treat (NNTs) to prevent a death.
Methods
Individual patient data were obtained from 22 (n=6763) randomised trials evaluating efficacy and 
safety of PPCI vs. fibrinolysis. A risk score was developed and validated to estimate the probability of 
30-day death in individuals. Patients were then divided in quartiles according to risk. Subsequent analy-
ses were performed to evaluate if the treatment effect was modified by estimated risk.
Results
Overall, 446 (6.6%) patients died within 30 days after randomisation. The mortality risk score con-
tained clinical characteristics, including the time from symptom onset to randomisation. The c-index 
was 0.76, and the Hosmer-Lemeshow test was non-significant, reflecting adequate discrimination and 
calibration. Patients randomised to PPCI had lower mortality than patients randomised to fibrinolysis 
(5.3% vs. 7.9%; adjusted OR 0.63 95%CI (0.42-0.84); p<0.001). The interaction between risk score and 
allocated treatment interaction term had no significant contribution (p=0.52) to the model, indicating 
that the relative mortality reduction by PPCI was similar at all levels of estimated risk. In contrast, the 
absolute risk reduction was strongly related to estimated risk at baseline: the NNT to prevent a death 
by PPCI versus fibrinolysis was 516 in the lowest quartile of estimated risk compared to only 17 in 
the highest quartile.
Conclusion
PPCI is consistently associated with a strong relative reduction in 30 day mortality, irrespective of 
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patient baseline risk, and should therefore be considered as the first choice reperfusion strategy when-
ever feasible. If access to PCI is longer than 2 hours, fibrinolysis remains a legitimate option in low risk 
patients, because of the small absolute risk reduction by PPCI in this particular cohort.
INTRODUCTION
Based on the results of several randomised clinical trials (RCTs) and meta-analyses, it is broadly ac-
cepted that the strategy of primary percutaneous coronary intervention (PPCI) compared to fibrin-
olytic therapy results in better outcomes in patients presenting with acute myocardial infarction (MI).1,2 
In general, PPCI results in fewer deaths, repeat MIs and strokes than fibrinolysis.3 Recent analyses 
demonstrated that relative risk reductions are not influenced by the time from onset of symptoms to 
presentation,4 nor by the patient’s age.5 Still, these observations do not necessarily imply that PPCI is 
the best strategy for every patient in every clinical circumstance. Primary PCI results are dependent on 
operator and site experience and volume,1 and are reported to be better during on- than off-hours.6 
Although it is true that beneficial results have been observed in clinical trial settings where PPCI was 
available within ‘distances’ of 2h from the MI scene,4 it still might be challenging to perform treatment 
within that time-window in a wide variety of clinical practice settings. Finally, large relative risk reduc-
tions do not necessarily translate into large absolute risk reductions. In fact, the magnitude of absolute 
risk reductions - and thus the number of patients who need to be treated to prevent an adverse event, 
the so-called ‘number needed to treat’ (NNT) - is highly dependent on the patient’s baseline risk.
This study was performed to address the issue of which (categories of) MI patients would benefit 
most from the strategy of PPCI, and thus have lowest NNTs. Based on 6763 individual patients who 
participated in 22 randomised clinical trials of PPCI versus fibrinolysis, a model of 30-day mortality 
was developed and validated to estimate risk in these patients. We examined whether the relative and 
absolute mortality reductions by PPCI were modified by the estimated baseline mortality risk.
METHODS
Details on the applied methodology of the pooled analysis have been published elsewhere.4 For the 
purpose of this study, we will briefly describe the trial selection and data collection process, the end-
point definitions, and the applied methods of data analysis.
Trial selection
All clinical trials were considered that enrolled at least 50 MI patients who were randomly assigned to 
treatment with fibrinolysis or PPCI. Trials published between January 1990 and December 2002 were 
identified by OVID MEDLINE and ISI Web of Science using a variety of keywords. Each trial identified 
in this search was evaluated for patient population, study treatment, protocol, and endpoints. The pri-
mary investigators of these studies were contacted for verification and access to the individual patient 
data. In this way, 25 eligible trials were identified, which enrolled a total of 7743 patients. Individual 
patient data were unavailable in two smaller trials (140 patients), and in the CAPTIM trial (n=840). 
Consequently, individual patient data were obtained from 22 trials (n=6763), which were pooled for 
analyses. Data were assessed for completeness, and internal consistency with published reports. Any 
discrepancies between analysis of the data provided and previously published results were queried and 
resolved with the primary investigator.
Endpoint definition
The endpoint of the current analysis was all-cause mortality at 30 days after randomisation, which was 
available for all trials.
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Data analysis
Differences in baseline characteristics between patients who reached the primary endpoint and those 
who remained endpoint free were analysed by unpaired Student’s t tests and chi-square tests, as ap-
propriate.
We developed and validated a model to estimate the probability of 30-day death in individual patients. 
The model was developed on a random selection of 80% of patients (n=5421), and validated on the 
remaining 20%. First, univariable logistic regression analyses were applied to study the relation between 
a broad range of potential risk factors (table 1) and the incidence of 30-day death. All variables that had 
a p-value <0.5 in univariable analysis, based on Wald’s chi-square test, entered the multivariable stage. 
The final multivariable model was then constructed using backward elimination of the least significant 
variables, until all variables had a p-value ≤0.15. During the iteration process study was included as 
covariate in all models irrespective of its corresponding p-value. Subsequently, a mortality risk score 
was determined that included all relevant risk factors, which were weighted according to the natural 
logarithm of the corresponding odds ratio. For this purpose, the continuous variables age, systolic 
blood pressure and heart rate were categorized as follows: age <50, 50-60, 60-70, and ≥70 years; sys-
tolic blood pressure <115, 115-129, 130-149, and ≥150 mmHg; heart rate <65, 65-74, 75-84, and ≥85 
beats per minute. The performance of multivariable models was studied with respect to discrimination 
(c-index) and calibration (Hosmer-Lemeshow [H-L] goodness-of-fit test).
To examine the influence of baseline risk on treatment effect, a multivariable model was fitted to the 
entire dataset (n=6763), which included the mortality risk score, allocated treatment (PPCI versus 
fibrinolysis) and the interaction term between the risk score and allocated treatment. We report rela-
tive treatment associations as adjusted odds ratios (OR) and corresponding 95% confidence intervals 
(CI), and absolute treatment effects by NNTs that are based on the final model.
A total of 1793 (27%) patients had missing data on at least one of the variables that might indicate 
patient risk. This subset had a higher 30-day mortality than the patients with complete data (8.6% ver-
sus 5.9%). Excluding patients with missing data therefore could lead to biased risk estimates.7 To partly 
correct for this, all multivariable analyses were performed on a dataset that included imputed predic-
tive variables. The imputation technique used for continuous as well as dichotomous variables was 
mean substitution. Dichotomous variables were coded as 1 (determinant present) or 0 (determinant 
absent). Thus, after data imputation, the value of the variable can be interpreted as the probability of 
the determinant being present. As a comparison we repeated all multivariable analyses on the patients 
with complete data on all determinants, and consistent results were observed.
All statistical tests were two-sided, and a p-value <0.05 was considered statistically significant. Analyses 
were performed using the SPSS® System version 15.0.
RESULTS
Patients
This pooled analysis included 6763 patients from 22 trials in which patients were randomised to 
fibrinolysis (n=3452) or PPCI (n=3451). Overall, 446 (6.6%) patients reached the primary endpoint 
of all-cause mortality within 30 days of randomisation. There were clinically relevant differences in 
sex, age, history of MI, diabetes, infarct location, time to randomisation and hemodynamic status at 
presentation, between patients who died within 30 days and those who survived (table 1). Thirty-day 
mortality was significantly higher among women, patients with advanced age, those with anterior MI, 
prior MI, diabetes mellitus, low systolic blood pressure and high pulse rate. The median time between 
randomisation and the injection (fibrinolysis patients) and between randomisation and the first balloon 
inflation (PPCI patients) was respectively 19 minutes (interquartile range (IQR) 10 to 30 minutes) and 
76 minutes (IQR 62 to 95 minutes)
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Characteristic 30 day death %,  
(n events/n total) 
* 
P-value 
* 
Crude OR (95% 
CI)¶ 
Adjusted OR  
(95% CI) in 
multivariable 
analysis¶ 
P-value  
in multi-variable 
analysis¶ 
      Sex   P<0.001    
 Female 10.3% (167/1455)  1 1  
 Male 5.2% (249/4790)  0.52 (0.42-0.65) 0.77 (0.60-
0.98) 
0.04  
Age, years  P<0.001 1.08 (1.07-1.09)   
 <50 1.5% (18/1213)  1 1  
 50-60 3.0% (53/1704)  2.0 (1.3-3.6) 2.0 (1.1-3.6) 0.016 
 60-70 5.9% (115/1823)  4.0 (2.4-6.9) 3.8 (2.2-6.6) <0.001 
 !70 14.2% (260/1577)  10 (6.0-17) 9.5 (5.6-16) <0.001 
Infarct location  P<0.001    
 Non-
anterior 
5,0% (180/3624)  1 1  
 Anterior 8.5% (264/3121)  1.8 (1.42-2.2) 1.6 (1.3-2.1) <0.001 
Prior MI  P<0.001    
 No 5.9% (325/5480)  1 1  
 Yes 9.4% (80/855)  1.6 (1.2-2.1) 1.3 (1.1-2.0) 0.016 
Diabetes  P<0.001    
 No 5.9% (318/5050)  1 1  
 Yes 8.3% (83/864)  1.6 (1.2-2.1) 1.35 (1.0-1.8) 0.05 
SBP per 
10mmHg 
  0.87 (0.84-0.91)   
SBP, mmHg  P<0.001    
 !150 4.9% (75/1539)  1 1  
 130-149 6.3% (186/2940)  1.5 (1.1-2.0) 1.2 (0.80-1.7) 0.40 
 115-129 5.3% (53/992)  1.1 (0.76-1.7) 1.7 (1.1-2.6) 0.020 
 <115 10.2%(132/1292)  2.5 (1.8-3.4) 3.5 (2.5-5.0) <0.001 
Heart rate per 
10 beats/min 
  1.21 (1.15-1.27)   
Heart rate, 
beats/min 
 P<0.001    
 <65 3.9% (60/1529)   1 1  
 65-74 12.8% (57/1103)  1.2 (0.82-1.9) 1.4 (0.89-2.1) 0.16 
 75-84 6.9% (175/2550)   1.7 (1.2-2.3) 1.4 (0.9-2.2) 0.10 
 !85 9.7% (154/1581)   2.5 (1.8-3.5) 2.7 (1.8-3.8) <0.001 
Time to 
randomization 
 P<0.001    
 <2 hours 5.2% (144/2603)  1 1  
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Figure 1 The mortality risk score and the relation between the mortality risk score and 30-day 
 mortality.
Table 1 Relation between baseline characteristics and 30-day all-cause mortality
       
 !2 hours 7.5% (302/3714)  1.5 (1.2-1.9) 1.3 (1.0-1.7) 0.02 
Prior CABG  P=0.20    
    Yes 8.9% (10/112)  1.46 (0.67-3.19) - - 
    No 6% (316/5277)  1 - - 
Prior PCI  P=0.10    
    Yes 3,5% (9/254)  0.57 (0.29-1.19) - - 
    No 6.1% (311/5129)  1 - - 
 
* Numbers were based on total dataset 
¶ Numbers were based on random 80%selection of 80%of the total dataset 
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Risk factors of 30-day mortality
In the randomly selected development set (n=5421), 30-day mortality was 6.7% (n=363). In univari-
able analysis, we identified ten potentially relevant determinants of deaths, eight of which remained 
(p<0.15) in the multivariable model (table 1). Age, hemodynamic status, and infarct location were the 
most dominant risk factors. Patients above the age of 70 years had an almost 10 times higher odds of 
30-day death than patients below the age of 50. Patients with a systolic blood pressure lower than 115 
mmHg had a 3.5 times higher odds of death than those with a value of 150 mmHg and above. Patients 
with a heart rate of 85 beats/min or higher had a 3.6 times higher odds of death than patients with a 
heart rate below 65 beats/min. The mortality risk score that is based on the natural logarithm of the 
ORs of the variables that compose the final multivariable model is presented in figure 1. This figure also 
shows the relationship between the mortality risk score (range and quartiles) and 30-day mortality. 
Model performance
In the development dataset, the c-index for the multivariable 30-day mortality model was 0.75, reflect-
ing adequate discriminatory power. The H-L test was non-significant (p=0.90), which implies that there 
were only minor differences between the predicted and actually observed mortality risk (i.e. the model 
showed adequate calibration; figure 2A). The mortality risk score also showed satisfactory discrimina-
Figure 2 Observed risk versus expected risk for the multivariable model and the simple 
 mortality risk score
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Clinical effects of PPCI compared with fibrinolysis
To further evaluate the relation between baseline risk, allocated treatment and 30-day mortality, we 
determined the risk score for each patient, which was then used as a single variable in the modeling 
process. Allocated treatment had a significant (p<0.001) contribution to the model. Patients who were 
randomised to PPCI had lower mortality than those randomised to fibrinolysis (5.3% versus 7.9% 
events; adjusted OR 0.61 and 95% CI 0.49 to 0.77; p<0.001). The interaction between risk score and 
allocated treatment had no contribution to the model (p=0.52), indicating that the relative mortality 
reduction by PPCI (versus fibrinolysis) was not modified by the baseline mortality risk.
This finding is confirmed by an analysis of the treatment effect in subgroups of patients according to 
the quartiles of the distribution of the mortality risk score (figure 3). In contrast, the absolute mortality 
reduction by PPCI was strongly and positively associated with the baseline mortality risk. The NNT 
to prevent one death by PPCI compared with fibrinolysis in patients with a risk score in the lowest 
risk quartile was 516, whereas the NNT was as low as 17 in patients belonging to the highest risk 
quartile.
 
The relation between the risk score and 30-day mortality in patients randomised to PPCI and fibrin-
olysis (left panel), as well as the absolute mortality reduction by PPCI (right panel) is presented in 
figure 4 for the risk score based on the multivariable model (Figure 4 A and B) and for the mortality 
risk score (figure 4 C and D). 
As an example, a 71-year old man without co-morbidities, who presents within 2h with a first MI (an-
terior), with a systolic blood pressure of 115 mmHg and a heart rate of 70 beats/min has a mortality 
risk score of 10.0 points, which corresponds with an estimated 30-day mortality risk of 13.4% after 
fibrinolysis and 9.0% after PPCI, and thus an absolute 4.4% mortality reduction in favor of PPCI.
Figure 3 Relation between allocated treatment (PPCI versus fibrinolysis) and NNT, and the inci-
 dence of death, according to the quartiles of the distribution of the mortality risk score
tion (c-index 0.76) and calibration (H-L p=0.75; figure 2B).
Thirty-day mortality in the randomly selected 1342 patients who were used to validate the mortality 
risk score was 6.2% (n=83). There was no difference in the mean score between the patients compris-
ing the development (2.2 ± 1.1) and validation (2.2 ± 1.1) datasets, indicating a successful random 
(4:1 ratio) assignment of patients to one of these datasets. When applied to the validation set, the full 
multivariable model showed satisfactory discrimination (c-index 0.78) and calibration (H-L p=0.64; 
figure 1C) figures, and so did the mortality risk score (c-index 0.78; H-L p=0.82; figure 1D).
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DISCUSSION
In this analysis of the pooled data of 22 randomised trials, we demonstrated that the relative mortality 
reduction by PPCI compared with fibrinolysis was not modified by the patient’s estimated mortality 
risk. A consistent 37% relative risk reduction by PPCI was seen across the entire spectrum of estimated 
risk. In contrast - and as a consequence of the consistent relative risk reduction - absolute mortality 
reduction was strongly associated with the patient’s baseline mortality risk. Patients with high mortality 
risk scores benefited most from PPCI: their NNTs were lowest.
We based the stratification of patients according to their predicted mortality risk on a simple model 
that we developed and validated in our dataset. The determinants of adverse outcome that compose 
the risk model are consistent with the analysis of the PCAT data,8 as well as with mortality risk models 
that were developed in other datasets of patients receiving fibrinolysis or PPCI. For example, Lee et 
al., who studied the GUSTO-1 dataset of 41021 patients who were treated with streptokinase and/
or alteplase, described advanced age, low SBP, high heart rate, previous MI, and an anterior location 
of the current MI as the most relevant determinants of 30-day death. 9 Similar findings were reported 
by the GRACE and TIMI investigators, who studied the prognosis of acute coronary syndrome and 
ST-elevation MI patients, respectively. 10-12 
In view of this consistency with the literature, and in view of its adequate discrimination and calibration 
performance, our mortality risk model might be used for risk stratification purposes. We acknowledge 
Figure 4 A and C (left panel) Absolute 30-day mortality risk in patients randomised to  
    PPCI versus fibrinolysis (bold) in relation to risk score
Figure 4 B and D (right panel) Absolute 30-day mortality reduction by PPCI in relation to 
    risk score
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that the model did not demonstrate excellent discrimination, mainly due to the limited number of 
baseline characteristics that were collected. The performance of the model might have been better if 
a broader variation in baseline data were available, including data on baseline ST-deviation, biomarker 
estimates of infarct size and renal function. 13,14 Still, it is unlikely that an improvement in the model 
discrimination will influence the main result of this analysis: the relative mortality reduction by PPCI was 
not modified by the (estimated) patient baseline risk.
One of the challenges for contemporary medicine is to rationally implement available therapies in 
clinical practice, in the appropriate patients at the appropriate time. Before certain therapy will be 
initiated, a physician must consider the probability that the patient will improve or deteriorate without 
such therapy, the chances of improvement if the therapy is initiated, the risks of adverse events, and, 
last but not least, the therapy-related costs. Our findings provide insight into opportunities to improve 
evidence-based treatment decisions for MI patients in cost-conscious environments. Since the NNT to 
prevent one death by PPCI compared with fibrinolysis was strongly related to the baseline mortality 
risk, it seems logical to first estimate that risk - preferably by using a validated risk score - and then 
decide on treatment. In our view, fibrinolysis remains a legitimate option for the categories of patients 
with estimated NNTs that exceed 100, particularly in regions where hospitals with PCI facilities are 
rare, or where the costs related to PPCI are considered too high to treat the entire MI population, as 
fibrinolysis compared with conservative treatment has proven to reduce mortality by 25-30% when 
initiated within 3 hours of symptom onset. If treated later, but within 12h, still a 15% mortality reduc-
tion might be realised. 15, 16. According to the AHA/ACC guidelines STEMI patients presenting to a facil-
ity without the capability for expert, prompt intervention with PPCI within 90 minutes of first medical 
contact should undergo fibrinolysis unless contraindicated. Similarly the ESC guidelines indicate fibrin-
olytic therapy in the absence of contraindications and if primary PCI cannot be performed within the 
recommended time. Both guidelines valued these recommendations as class 1-A 1, 2. Our analyses do 
not give rise to change these recommendations. 
Patients who participate in clinical trials must satisfy several inclusion criteria and must not meet ex-
clusion criteria, and thus form selected cohorts. In general, patients enrolled in clinical trials tend to 
be those with the fewest co-morbidities and the lowest risk of potential side effects. We realise that 
patients who participate in the randomised trials that we considered might therefore not be repre-
sentative of all patients. Also approximately 80% of all patients in our meta-analysis had a PCI related 
delay of less than 2 hours, the results of this meta-analysis can therefore not rule on a clinical setting 
with a delay of more than 2 hours. In the context of our meta-analysis we cannot overcome this issue 
of external validity. Still, we would like to emphasize that our results are internally valid, since based on 
random allocation of treatment. 
 
Conclusion
PPCI is consistently associated with a strong relative reduction in 30-day mortality, irrespective of 
patient baseline risk, and should therefore be considered as the first choice reperfusion strategy when-
ever feasible. If access to PCI is longer than 2 hours, fibrinolysis remains a legitimate option, especially 
for patients with a low risk score due to the small absolute risk difference between both treatment 
modalities in this patient group. Therefore in regions where hospitals with PCI facilities are rare, respec-
tively, where geography does not allow primary PCI in all MI patients, this risk score might be used to 
select those higher-risk patients who benefit most from PPCI.
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MORTALITY AND MORBIDITY REDUCTION BY PRIMARY PERCUTANEOUS CORONARY 
INTERVENTION IS INDEPENDENT OF THE PATIENT’S AGE
ABSTRACT
Objective
The aim of this study was to obtain a valid estimate of the clinical effects of primary percutaneous 
coronary intervention (PPCI) in relation to age
Background
Treatment with PPCI is most beneficial in high-risk myocardial infarction (MI) patients. Paradoxically, 
elderly patients, who are at increased risk of adverse outcome, are often withhold PPCI.
Methods
Individual patient data were obtained from 22 randomized trials (6763 patients) evaluating the clinical 
effects of PPCI vs. fibrinolysis (FL). Differences in 30-day death, repeat myocardial infarction (reMI) and 
stroke between patients randomized to FL and PPCI were determined in 5 age-strata: ≤50, >50-60, 
>60-70, >70-80, and >80 years. Treatment effects are reported as odds ratios (ORs) and 95% confi-
dence intervals (CI). Multivariable logistic regression analyses, which included age*treatment interac-
tion, were applied to examine evidence of heterogeneity in age-specific ORs.
Results
Thirty-day death increased with increasing age, and ranged from 1.1% (FL) and 1.8% (PPCI) in patients 
≤50 years to 26.4% and 18.3% in patients >80 years. The point estimate of treatment effect (overall 
adjusted OR 0.65 and 95% CI 0.52-0.79) was compatible with a mortality reduction favoring PPCI in all 
age-strata (except in patients ≤50 years), and 95% CIs were largely overlapping. There was no evidence 
of heterogeneity in ORs between age categories. Similar results were observed for reMI and stroke.
Conclusion
In this analysis of randomized trials, the reduction in clinical endpoints by PPCI was not influenced by 
age. Hence, age per se should not be considered an exclusion criterion for the application of PPCI.
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INTRODUCTION
Despite the dominant role of age in the prognosis of coronary artery disease (CAD), elderly patients 
are often excluded from participation in clinical trials evaluating efficacy and safety of cardiac treat-
ment.1 The main reason why is that clinical trialists tend to favor the enrolment of patients at low risk 
of potential side effects, and large proportions of elderly patients meet one or more of the associated 
exclusion criteria.
Because of the limited availability of clinical trial data, and the increasing variability in treatment response 
in relation to age, estimates of treatment effect in elderly CAD patients appear to be uncertain for a 
broad variety of clinical situations. Particularly, uncertainty exists about the balance between beneficial 
and harmful treatment effects, which hampers the application of evidence-based treatment in clinical 
practice. For example, the application of reperfusion therapy in patients presenting with ST-elevation 
myocardial infarction (MI) is strongly related with age: elderly patients less often receive reperfusion 
therapy than their younger counterparts.2-4 Most likely the choice for conservative treatment in the 
elderly is based on negative perceptions of the chances to reduce mortality risk due to limitation of 
the infarct size (treatment benefit) relative to the chances to cause harm. Particularly, the risk of severe 
disability, or even death, due to severe hemorrhagic complications is feared in elderly patients receiv-
ing fibrinolytic (FL) therapy. Still, the underutilization of reperfusion therapy in older MI patients is also 
reported with respect to primary percutaneous coronary intervention (PPCI).5 Apparently, in clinical 
practice, there is a mismatch between (suspected) patient risk and applied treatment. This treatment-
risk paradox has been observed in other settings in clinical cardiology as well.6,7
The clinical outcome after PPCI as compared to FL in elderly patients has been evaluated in the 
randomized trial of De Boer, et al. (patients aged 75+), and in the randomized SENIOR PAMI trial (pa-
tients aged 70+).8,9 Although De Boer et al. demonstrated a favorable clinical outcome after PPCI - a 
statistically significant reduction was observed in the 30-day incidence of death, reMI and stroke - the 
sample sizes of both trials were too small to draw definite conclusions. We recently pooled individual 
patient data from 22 clinical trials of PPCI versus FL in patients with acute MI. This meta-analytic dataset 
provides a unique and powerful opportunity to study the clinical outcome of PPCI in relation with 
age.
METHODS
Details on the applied methodology of the pooled analysis have been published previously.10 In this 
section, we briefly describe the trial selection and data collection process, endpoint definition, and data 
analysis for the current study.
Trial selection
All randomized trials that enrolled at least 50 patients presenting with MI assigned to treatment with 
FL or PPCI were considered. Trials published between January 1990 and December 2002 were identi-
fied by OVID MEDLINE and ISI Web science using a broad range of keywords. Each trial identified in 
this search was evaluated for patient population, study treatment, protocol, and endpoints. The primary 
investigators of these studies were contacted for verification and access to the individual patient data. 
In this way, 25 eligible trials were identified, which enrolled a total of 7743 patients. Individual patient 
data were unavailable in two smaller trials (140 patients),11,12 whereas the investigators of the larger 
CAPTIM trial (n=840) elected not to release their data.13 Consequently, individual patient data from 
22 trials (n=6763) were pooled for the primary analysis. Table 1 presents the main design features of 
the included trials. Data were assessed for completeness, internal consistency with published reports. 
Any discrepancies between analysis of the data provided and previously published results were que-
ried and resolved with the primary investigator.
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Definitions of clinical endpoints
The primary endpoint of this pooled analysis was all-cause mortality at 30 days after randomization. 
Secondary endpoints included repeat myocardial infarction (reMI) and stroke, as well as the composite 
endpoints all-cause mortality or reMI, and all-cause mortality, reMI or stroke. Endpoints were counted 
until 30 days after randomization.
Statistical analysis
Summary statistics for all continuous variables are presented as medians with the corresponding in-
terquartile range (IQR), and discrete variables are presented as counts and percentages. Patients were 
categorized according to their age into 5 categories: ≤50, >50-60, >60-70, >70-80, and >80 years. 
Differences in baseline characteristics in relation to age were evaluated by Kruskal-Wallis tests, or 
Mantel-Haenszel chi-square tests for trend, as appropriate.
All analyses of the relation between randomized treatment and the incidence of clinical endpoints 
were performed according to the intention-to-treat principle. Age-specific outcome data were pooled 
using the Cochrane-Mantel-Haenszel method, and odds ratios (OR) and 95% confidence intervals 
(CI) for clinical endpoints are reported. Breslow-Day tests were applied to examine statistical evidence 
of heterogeneity among the age-specific ORs. The association between treatment and the clinical 
endpoints in relation to age were also evaluated by logistic regression (LR). First, crude ORs for study 
endpoints were determined based on the single fixed effect LR model, stratified by age-category. 
Subsequently, non-stratified models were fitted with age (as a continuous variable), treatment and 
the age* treatment interaction term. To adjust for trial effects and for variations in the standards of 
practice across participating institutions, these models were then extended taking study membership 
into account. The final multivariable adjustment included study membership, sex, body weight, diabetes 
mellitus, previous MI, prior revascularization, anterior MI at presentation, heart rate, systolic blood pres-
sure, time to treatment.
Time to treatment was categorized into time from symptom onset to randomization (‘presentation 
delay’) and time from randomization to treatment (‘treatment delay’). Per definition, the interval be-
tween randomization and the actual commencement of treatment is a post-randomization variable, 
which is influenced by allocated treatment. Hence, analyses in relation to treatment delay that are 
based on observations in individual patients can result in biased estimates of treatment effect. More-
over, patients are randomized to either FL or PPCI, so on a patient-level time to treatment can only 
be obtained for one strategy. Analyses based on observations on hospital level may help to overcome 
this. Thus, the median time between randomization and the start of treatment (i.e., first injection of the 
fibrinolytic agent or the first balloon inflation) was calculated for each of the 153 participating hospitals. 
The hospital-specific difference between these median times was then determined, which is hereafter 
referred to as ‘PCI-related delay’, and assigned each patient within that hospital. Consequently, PCI-
related delay should be interpreted as the additional time that is needed to start the PCI procedure 
after treatment with a fibrinolytic agent could have been started.
All tests are two-sided with a significance level of 0.05. All statistical analyses were performed using the 
SAS® System version 8.2 (SAS® Institute Inc., Cary, NC).
RESULTS
Patients
This pooled analysis included 6763 patients from 22 trials in which patients were randomized to FL 
(n=3383) or PPCI (n=3380). There were important differences in clinical baseline characteristics in 
relation to age (table 2). Elderly patients had an unfavorable risk profile, as they more often had dia-
betes mellitus, a history of MI, and a longer presentation delay. For example, 46% of patients in the 
≤50-age category were randomized within 2h after the onset of symptoms, in contrast to only 26% in 
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Figure 1 Incidence of death, MI, Stroke/Treatment According to Age
Relation between allocated treatment (PPCI versus FL), and the incidence of death,   
myocardial infarction, and stroke at 30 days according to age category
Data represent adjusted odds ratios and 95% confidence intervals
Figure 2 (left panel) Absolute 30-day mortality risk in patients randomised to PPCI
   versus FL in relation to age
Figure 2 (right panel) Absolute 30-day mortality reduction by PPCI in relation to age
Data are based on results of multivariable regression analysis, with adjustment for the following 
variables: study membership, sex, body weight, diabetes mellitus, previous MI, prior revasculariza-
tion, anterior MI at presentation, heart rate, systolic blood pressure, and time to treatment.
Right panel presents point estimates (middle line) together with the 95% confidence band.
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those older than 80 years. Interestingly, PCI-related delay tended to decrease with age. We observed 
a statistically significant relation between admission systolic blood pressure, heart rate and age, but the 
difference in median values of these hemodynamic parameters between younger and elderly patients 
seemed clinically irrelevant.
Clinical endpoints
Overall, 446 (6.6%) patients died within 30 days of randomization. Mortality was significantly lower in 
patients randomized to PPCI (n=178; 5.3%) than in patients randomized to FL (n=268; 7.9%). Irrespec-
tive of treatment, elderly patients had higher mortality risk than younger patients (table 3). Primary PCI 
was associated with a lower incidence of death than FL therapy in all age-categories, except in patients 
≤50 years (table 3, figure 1). The Breslow-Day test for homogeneity of ORs across age-categories was 
non-significant (p=0.24), and interaction between age and treatment was not statistically significant 
(p=0.73). Hence, there was no evidence that the observed mortality reduction by PPCI was hetero-
geneous with respect to age. After multivariable adjustment, PPCI was associated with a 36% propor-
tional reduction in the odds of death compared to FL therapy, irrespective of age (adjusted OR 0.65 
and 95% CI 0.52-0.79).
 
Repeat myocardial infarction occurred in 225 (6.7%) patients who were randomized to FL and in 80 
(2.4%) of those randomized to PPCI. A lower incidence of reMI in patients randomized to PPCI was 
consistently seen in all age-categories (table 3, figure 1), and there was no evidence of heterogeneity in 
ORs (p=0.67). PPCI was associated with a 63% proportional reduction in the odds of reMI (adjusted 
OR 0.37 and 95% CI 0.28-0.48), and a 49% reduction in the composite endpoint of all-cause mortality 
or reMI (adjusted OR 0.51 and 95% CI 0.43-0.60), irrespective of age.
Similar results were observed with respect to stroke, which occurred in 83 (2.6%) of the patients 
randomized to FL and in 48 (1.5%) of those randomized to PPCI. Although the incidence of stroke 
was increased after PPCI in patients younger than 50 years (Figure 1, right panel), the confidence 
interval of treatment effect was wide, and there was no evidence of heterogeneity in ORs in relation 
to age (p=0.40). Primary PCI was systematically associated with a lower incidence of the composite 
endpoint of all-cause mortality, reMI or stroke in all age-categories, and again there was no evidence 
of heterogeneity in ORs (p=0.35).
Absolute treatment effects
Figure 2 shows 30-day mortality in patients randomized to PPCI and FL (left panel), as well as the 
absolute mortality reduction by PPCI (right panel) in relation to age as a continuous variable. Appar-
ently, the absolute risk reduction was strongly and positively associated with age. For example, at age 
60, PPCI was associated with 1.4 fewer deaths per 100 patients treated compared with FL, whereas 
the risk reduction amounted to 5.1 per 100 patients at age 80.
Octogenarians
Octogenarians (>80 years old) comprise a clinically relevant cohort and represented 6% of patients. In 
this cohort, the patients who were randomized to PPCI had a lower incidence of mortality (26.4% ver-
sus 18.3% events; p=0.049), reMI (7.0% versus 3.9%; p=0.18) and stroke (7.9% versus 5.8%; p=0.45) 
than their counterparts who were randomized to FL. Statistical significance was not reached for each 
of these endpoints, most likely due to small numbers.
DISCUSSION
In this pooled analysis, which was based on randomized trials that involved 6,763 MI patients, age did 
not modify the mortality reduction by PPCI compared with FL therapy. Since age is a key determinant 
of mortality in MI patients, the consequence of the consistent relative risk reduction across all age 
groups is an increasing absolute risk reduction with increasing age, and a decreasing number of patients 
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that need to undergo PPCI (in stead of FL therapy) to prevent one death - the ‘number needed to 
treat’ (NNT). Noteworthy, PPCI was associated with significantly reduced mortality in patients aged 
80 years or over. The estimated NNT in these patients was only 20. In view of our results, age per se 
should not be considered an exclusion criterion for the application of PPCI.
One of the most severe complications of FL therapy is the risk of stroke, particularly intracranial 
hemorrhage (ICH). This complication occurs in approximately 1% of patients receiving FL therapy, 
with a case-fatality of around 50%, whereas half of the ICH victims who survive will remain irreversibly 
disabled.14 Since age is one of the strongest determinants of ICH risk after pharmacology-based rep-
erfusion therapy,15 physicians tend to be quite conservative in treating the elderly. Indeed, in our data, 
among octogenarians who received FL, stroke risk was as high as 8%. We demonstrated that PPCI was 
associated with a reduced incidence of stroke. Importantly, the risk reduction was particularly strong in 
elderly patients (although there was no evidence of heterogeneity in relative stroke reduction in rela-
tion to age). This observation provides another argument to not systematically exclude elderly patients 
from treatment with PPCI.
We did not observe significant heterogeneity in treatment effect with respect to the specified out-
come events. Indeed, the confidence intervals around the point estimates of treatment effect in the 
five age-categories were largely overlapping. Still, any heterogeneity cannot be excluded with com-
plete certainty. Despite the considerable amount of included patients, the applied statistical tests of 
heterogeneity lacked power to reveal small, though clinically relevant differences. The true existence 
of such differences is unlikely as far as death is concerned, since point estimates were quite consistent 
across age-groups. However, we acknowledge that age might be a modifier of the influence of PPCI 
on the incidence of reMI (risk reduction slightly decreases with age) and stroke (risk reduction slightly 
increases with age). In fact, additional randomized trials are needed to obtain more precise estimates 
of treatment effects in strata according to age, but, in view of the unambiguous results of the trials that 
have been conducted, it is unlikely that such new trials will ever be conducted.
We realize that elderly patients who are eligible to participate in a randomized trial might not be rep-
resentative for real-world patients. As the elderly don’t fit the in-and exclusion criteria as the younger 
patients, they are more likely to be excluded from participation in trials. Indeed, not only suffer elderly 
often from comorbidities that formally exclude participation in most trials, such as dementia, gastro-
intestinal bleeds, or malignancy, but also are clinicians often reluctant to include the fragile elderly 
patient who otherwise doesn’t met exclusion criteria. Thus, the elderly who are included in trials form 
a selected group, more so than younger patients. Consequently, the observed favorable effects in 
the elderly might probably not fully be extrapolated to the general population. In the context of our 
pooled analysis we cannot overcome this issue.
The main strength of this study is that it is based on randomized trials. Thus, although one might chal-
lenge the external validity, the observed results are at least internally valid (i.e. the results are valid for 
the type of patients that have entered the included trials). In this respect, the main limitation of our 
analyses is the fact that the CAPTIM trial data were not included. CAPTIM strongly suggested that 
the strategy of (prehospital) fibrinolysis, followed by a ‘rescue’ PCI in case of persistent ischemia, might 
result in a mortality reduction compared with the PPCI strategy in patients presenting within 2h after 
onset of symptoms. Although these results were not confirmed in the PCAT-2 main analysis (in fact, a 
statistically significant mortality reduction was observed in favor of PPCI in patients presenting within 
2h),10 the inclusion of the CAPTIM data would have lead to more precise estimates of treatment ef-
fect in patients presenting early. This particularly affected younger patients, since they tend to present 
earlier than the elderly.
Conclusion
In this pooled analysis of randomized clinical trials, there was no evidence that the reduction in clinical 
endpoints by PPCI was influenced by age. Hence, age per se should not be considered an exclusion 
criterion for the application of PPCI.
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EVALUATING THE ‘ALL-COMERS’ DESIGN: A COMPARISON OF PARTICIPANTS IN TWO
‘ALL-COMERS’ PCI TRIALS WITH NON-PARTICIPANTS
 ABSTRACT
Aims
We aimed to asses the generalizability of two ‘all-comers’ randomised clinical trials (AC-RCTs) in pa-
tients undergoing percutaneous coronary intervention (PCI). 
Methods and Results
Recently two large AC-RCT’s comparing drug-eluting stents were performed in our institution (LEAD-
ERS and RESOLUTE-III). During the inclusion period of these trials 1242 consecutive PCI patients were 
treated of whom 579 (48%) were actually included. The most important reasons for non-participation 
were: inability to provide informed consent (33,5%), refused to participate (19%) or patient met one 
of the other exclusion criteria (26.9%). Trial participants more frequently had stable angina (42.5% 
versus 34.4%) and less frequently acute myocardial infarction as indication for PCI (31.4% versus 
42.4%) than non-participants. Hypertension (52.8% versus 49.1%) and hypercholesterolemia (56.3% 
versus 49.1%) were seen more frequently in trial participants; heart failure was less common (2.1% 
versus 4.4%). A significant difference in 30-day mortality was observed between AC-RCT participants 
and non-participants (0.7% versus 4.5% events; adjusted hazard ratio [aHR] 0.18 and 95% confidence 
interval [CI] 0.06-0.52). One-year mortality was also lower (3.1% vs. 6.9% events; aHR 0.51 and 95% 
CI 0.29-0.91, but 1-year mortality in 48 hours survivors was similar (3.1% vs. 4.2% events; aHR 0.74 
and 95 CI% 0.41-1.34).
Conclusion
Applying the all-comers design did not result in inclusion of all consecutive patients, as only half of the 
target population was enrolled. It should be noted, however, that this design included more patients 
than observed in classical RCTs. AC-RCT participants and non-participants were different in terms of 
baseline characteristics and outcome.
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INTRODUCTION
Randomized controlled trials (RCTs) are the gold standard to evaluate the efficacy and safety of thera-
peutic options.1 Randomization results in valid estimates of treatment effect, as it minimizes bias due to 
differential selection and confounding. w Still, external validity of RCT results is often questioned, since 
clinical trial conditions are highly controlled (strict in- and exclusion criteria are usually applied, which 
tend to favour the enrolment of patients at low risk of potential side effects) and may not reflect what 
is sometimes called ‘the real world’ clinical practice. As a result, sizeable and clinically relevant groups 
of patients are underrepresented in most RCTs. Elderly patients, women, and patients with cardiac or 
non-cardiac co morbid conditions are often underrepresented in RCTs that are conducted in the field 
of cardiology, and thus the generalizability of their results to the broader population can be questioned. 
3, 4 
In order to improve the generalizability of RCT results, the ‘real world’ or ‘all-comers’ (AC) design is 
becoming increasingly popular in cardiology. Randomised clinical trials with an ‘all-comers’ design (AC-
RCTs) apply wide inclusion criteria and no (or very few) exclusion criteria, which may result in a more 
representative sample of the target population. It should be noted, however, that even in an all-comer 
trial it is not to be expected that each and every consecutive patient will be enrolled. For example, 
the key principle that patients participate in an RCT on a voluntarily basis only, might still result in non-
random patient selection. 
Recently, our department participated in two major AC-RCTs (LEADERS and RESOLUTE-III) in pa-
tients undergoing percutaneous coronary intervention (PCI). In this paper we studied if and to what 
extend we succeeded in enrolling a truly representative sample of the PCI patients that form the 
routine practice in our department, by evaluating baseline characteristics and outcome.
METHODS
Patients and material
The LEADERS trial was designed to compare the clinical safety and efficacy of the BioMatrix Flex 
(Biolimus A9-Eluting) stent system with the Cypher SELECT (Sirolimus-Eluting) stent system. 5 The 
RESOLUTE-III trial was designed to compare the clinical results of the Medtronic Endeavor-Resolute 
(Zotarolimus-Eluting) stent system with the Abbott XIENCE V (Everolimus-Eluting) stent system. 6 
Both trials had a prospective, multi-centre, randomized, controlled, non-inferiority design. The broad 
inclusion criterion in both trials was: patients undergoing routine PCI for any indication. Almost no 
exclusion criteria were applied, except that patients were not accepted if they already participated in 
another clinical trial, if they were pregnant, had a known intolerance for aspirin, clopidogrel, ticlopidin, 
heparin or components of the stents, if surgery was planned within 6 months, had a too large diameter 
of the study vessel (LEADERS > 3.5 mm, RESOLUTE-III > 4.0 mm) or if no informed consent was 
provided. Between Nov 27, 2006 and May 18, 2007 LEADERS enrolled a total of 1707 patients in 10 
hospitals throughout Europe, and during 22 May, 2008 to 28 October, 2008 RESOLUTE-III enrolled 
2292 patients in 19 European hospitals. 
According to the standard data-management procedures in our department, data are collected on 
demographics, cardiovascular history, clinical risk factors and treatment characteristics for all patients 
undergoing PCI, which are stored in an electronic database. Data-elements are filled out immediately 
after the completion of the PCI by the interventional cardiologist and the technician who assisted dur-
ing the procedure. The database, which is maintained by a dedicated IT-officer, is mainly designed for 
administrative purposes. A systematic evaluation of data-completion and data-integrity is implemented 
for data that are used for research purposes. 
According to this database, during the inclusion period of both AC-RCTs, 1242 consecutive patients 
underwent PCI in our centre. 579 (47%) participated in the LEADERS or RESOLUTE-III AC-RCT, 
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whereas, 663 (53%) did not. In the latter patients, the reasons for non-participation were collected by 
the research staff prior to the intervention.
Follow-up and endpoint definition
We aimed to learn differences in clinical characteristics between patients who participated in an AC-
RCT and those who did not, as well as differences in their clinical course during extended follow-up. 
In that respect, it seems logical to study (differences in) the occurrence of major adverse cardiac 
events (MACE: re-occurrence of MI (reMI), target lesion revascularisation (TLR), and all-cause mor-
tality) between both patient groups. It should be realised, however, that the drug-eluting stents that 
were studied in the LEADERS and the RESOLUTE-3 trial, were designed to reduce the incidence of 
MACE. Consequently, differences (if these appear) in MACE incidence between AC-RCT participants 
and non-participants are not only to be explained by differences in their baseline characteristics, but, 
most likely, by the applied (study) stent as well. Therefore, we decided to study all-cause mortality as 
the single clinical endpoint, as mortality is not influenced by the stent type. Data on vital status was 
obtained from the municipal civil registries. We report mortality at 30-day and at 1-year follow-up.
Data-analysis
We intended to obtain complete baseline information in all patients, but failed to do so in 17 AC-RCT 
non-participants, which presented with cardiogenic shock and died within 24h after hospital admis-
sion. For these patients with at least one of the variables of interest missing, we decided to impute the 
missing values. The imputation technique used for continuous as well as dichotomous variables was 
mean substitution. Dichotomous variables were coded as 1 (determinant present) or 0 (determinant 
absent). Thus, after data imputation, the value of the variable can be interpreted as the probability of 
the determinant being present. Continuous data are presented as mean ± standard deviation (SD) and 
categorical variables are expressed as numbers and percentages. Differences in baseline characteristics 
between participants and non-participants in an ‘all-comer’ trial were analyzed by student’s t-tests and 
chi-square tests, as appropriate. 
Univariable and multivariable logistic regression (LR) analyses were applied to reveal clinical character-
istics that were related to participation in an AC-RCT. AC-RCT participation was considered the de-
pendent variable, and the variables that are listed in table 1 were considered as potential determinants. 
The final LR model was constructed via backward deletion and all variables with a p-value <0.15 were 
maintained. Thus, we accepted a type I error of 15% for all variables that composed the final model, 
in order not to miss clinically relevant explanatory factors. The performance of the final model was 
studied with respect to discrimination (C-index) and calibration (Hosmer-Lemeshow goodness of fit 
test for predicted versus observed probabilities).
We applied multivariable logistic regression analysis to develop a propensity score for the likelihood of 
participating in an AC-RCT. The variables listed in table 1 were included in the model. 
The method of Kaplan Meier was used to describe the incidence of all-cause death during follow-up. 
A logrank test was applied to study differences in survival between AC-RCT participants and non-
participants.
Subsequently, Cox proportional hazard (PH) models were used to analyze the relation between 
AC-RCT participation and mortality at 30 days and 1 year. We adjusted for a range of potential con-
founders. Since the number of outcome events was limited, we applied a model reduction strategy, 
which was similar as described above. We forced age and sex in the model, since these are common 
predictors for mortality.  We repeated the analysis and added the propensity score to the model. 
Subsequently, we repeated the analysis for the patients who survived the first 48h, thereby excluding 
patient who were unable to give informed consent (IC) due to their critical illness. Finally, Cox PH 
models were applied to study determinants of mortality in trial non-participants only, combining clini-
cal characteristics and patient-specific reasons for non participation.
We report crude and adjusted odds ratios (ORs) and hazard ratios (HRs) along with their 95% con-
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Text tables 
 
Table 1 Baseline characteristics 
 
 
Non-participant 
n=663 * 
Study participant 
n=579 P-value 
Mean age, yr (±SD) 64.9 ± 12.2 63.7 ± 10.9 0.02 
Male sex, n (%) 470 (70.9) 430(70.4) 0.18 
Indication   <0.001 
   Stable Angina, n (%) 228 (34.4) 246 (42.5)  
   Unstable Angina, n (%) 154 (23.2) 151(26.1)  
   Acute MI, n (%) 281 (42.4) 182 (31.4)  
              Cardiogenic shock, n (% of AMI) 17 (6.0) 0 (0)  
Cardiovascular history    
   Coronary revascularization, n (%) 176 (26.5) 172 (29.7) 0.22 
   MI, n (%) 187 (28.2) 171 (29.5) 0.62 
   Heart failure, n (%) 29 (4.4) 12 (2.1) 0.024 
   Peripheral artery disease, n (%) 45 (6.8) 36 (6.2) 0.52 
Clinical risk factors    
   Hypertension, n (%) 325 (49.1) 306 (52.8) 0.022 
   Hypercholesterolemia, n (%) 327 (49.3) 326 (56.3) 0.001 
   Diabetes Mellitus, n (%) 125 (18.9) 104 (18.0) 0.68 
   Renal dysfunction, n (%) 71 (10.7) 54 (9.3) 0.42 
   Body mass index, kg/m2 (±SD) 27.2 ± 4.0 27.1 ± 4.1 0.12 
   Smoking status, n   0.80 
   -Current, n (%) 192 (29.6) 163 (28.2)  
   -quit <=1 year, n (%) 29 (4.5) 25 (4.3)  
   -quit > 1 year, n (%) 97 (14.9) 98 (16.9)  
   -Never, n (%) 331 (51.0) 293 (50.6)  
   Family History, n (%) 232 (35.0) 261 (45.1) <0.001 
* In the non-participants group there are missing values for a few variables, these missing values were 
imputed for the multivariable analyses. 
 
 
 
Table 1 Baseline characteristics
fidence intervals (CIs). For all tests, a two-sided P-value of less than 0.05 was considered significant. All 
statistical analyses were performed using SPSS 17.0 for Windows (SPSS, Inc., Chicago, IL).
 For the main analysis AC-RCT participants were compared with all non-participants (i.e. the patients 
who did not participate in any of the AC-RCTs) with respect to baseline characteristics and outcome. 
As the non-participants form a heterogeneous group, we performed sensitivity analyses including dif-
ferent subgroups of non-participants, to study the robustness of our main findings. We compared the 
AC-RCT participants with the non-participants, excluding patients who participated in another study. 
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Furthermore, we compared the AC-RCT participants with the non-participants, excluding the patients 
who met at least one of the (AC-RCT) exclusion criteria. Since the results of these analyses were 
highly consistent with the main analysis, we decided to only report the latter. 
RESULTS
Baseline characteristics
A total of 579 patients participated in either of the two AC-RCTs during the study period, whereas 
663 patients were not enrolled in one of the two AC-RCTs, figure 1.
The most frequent reasons for non participation in an all-comers trial included; inability to provide IC 
(33, 5%), patient refused to participate (19%) or patient met one of the other exclusion criteria (26, 
9%). Of all patients who could not provide IC, 82.9% were admitted with an AMI. The most important 
reasons to refuse were; their home situation (e.g. a critically ill spouse), severe co-morbidity (cancer, or 
other severe illness), or study requirements (follow-up visits, repeat angiography, etc.) The reason for 
non participation was not recorded in 11, 9%.
Baseline characteristics differed considerably between study participants and non-participants with 
respect to age, the indication for PCI, heart failure, hypertension, hypercholesterolemia, and family 
history (table 1). Participants in an AC-RCT were younger and had more often stable angina pectoris 
or unstable angina pectoris as indication for PCI, but suffered less often acute myocardial infarction 
than the non-participants. Hypertension, hypercholesterolemia and positive family history were seen 
more often in study participants, whereas heart failure was observed more often in non-participants. 
None of the study participants were admitted with cardiogenic shock, whereas 17 patients in the non 
Determinants of all-comer trial
participation
We identified seven clinical characteristics that were (P-value
,0.15) predictors of trial participation; age (aOR: 0.99 and 95%
CI: 0.98–1.00), sex [aOR: 1.17 (0.90–1.52)], indication for PCI
[acute myocardial infarction (MI) (aOR: 0.71 and 95% CI: 0.51–
0.99) reference is stable angina pectoris], hypertension (aOR:
1.20 and 95% CI: 0.95–1.52), positive family history for CHD
(aOR: 1.37 and 95% CI: 1.08–1.74), heart failure (aOR: 0.42 and
95% CI: 0.21–0.84), and treatment during off-hours (weekends
and between 18.00 and 08.00 during weekdays) (aOR: 0.77 and
95% CI: 0.55–1.07) (Table 3). The C-index for the LR model
that contained these predictors was 0.60, and the Hosmer–Leme-
show test was non-significant (P  0.94), reflecting poor discrimi-
nation, and adequate calibration.
Mortality
As shown in Figure 2, study participation was associated with a
lower mortality rate than non-participation. Log rank test gave a
significant overall difference (P  0.002) in mortality among the
two categories (study participants vs. non-participants). In patients
surviving the first 48 h, this difference was non-sig ificant (P 
0.31).
After 30 days a significant difference in 30-day mortality was
observed between AC-RCT participants and non-participants
[n  4 (0.7%) vs. n  30 (4.5%, KM estimates); aHR: 0.18 and
95% CI: 0.06–0.52]. Thirty-day mortality in AMI patients was 1.6
vs. 7.5%, respectively (P  0.006). One-year mortality was also
lower in trial participants [n  18 (3.1%) vs. n  46 (6.9%, KM esti-
mates); P  0.001; aHR: 0.51 and 95% CI: 0.29–0.91]. In those who
survived the first 48 h (n  1224), no significant differences in 30
day [0.7 vs. 1.7% (KM estimates), aHR: 0.40 and 95% CI: 0.13–
1.34] and 1-year mortality were found and [3.1 vs. 4.2% (KM esti-
mates), aHR: 0.74 and 95% CI: 0.41–1.34, respectively]. None of
the study participants died within 48 h, whereas 18 patients in
the non-participant group died. Applying the model reduction
strategy we indentified predictors of 30-day mortality (Table 4):
age, sex, study participation, indication for PCI; AMI and unstable
angina pectoris, heart failure, and treatment during off-hours.
Figure 1 Selection of AC-RCT participants.
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Table 2 Procedural Characteristics  
 
 Non-participant 
n=663 
Study participant 
n=579 P-value 
Offhours, n (%) 214 (32.3) 133 (23.0) <0.001 
Intervention   <0.001 
   Balloon only, n (%) 56 (8.4) 21 (3.6)  
   Direct stenting, n (%) 276 (41.6) 272 (47.0)  
   Stenting after balloon, n (%) 314 (47.4) 282 (48.7)  
   Failed procedure, n (%) 17 (2.6) 4 (0.7)  
Treated vessel   0.06 
   RCA, n (%) 214 (32.3) 178 (30.7)  
   LAD, n (%) 279 (42.1) 235 (40.6)  
   LCx, n (%) 121 (18.3) 138 (23.8)  
   LM, n (%) 23 (3.5) 10 (1.7)  
   LIMA, n (%) 0 (0) 1 (0.2)  
   Graft, n (%) 26 (3.9) 17 (2.9)  
CTO, n (%) 50 (7.5) 35 (6.0) 0.30 
Bifurcation lesion, n (%) 33 (5.0) 54 (9.3) 0.003 
Clinical success, n (%) 551 (83.1) 523 (90.3) <0.001 
Complications    
   Dissection, n (%) 14 (2.2) 14 (2.5) 0.78 
   Side branch occlusion, n (%) 2 (0.3) 3 (0.5) 0.57 
   Perforation, n (%) 4 (0.6) 1 (0.2) 0.22 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Procedural Characteristics Table 3 Multivariable analysis: predictors for participation in an all-comers trial 
 
Characteristic Crude Adjusted for confounders 
OR, 95 CI OR, 95 CI 
Age (per year) 0.99 (0.98-1.00) 0.99 (0.98-1.00) 
Sex (male) 1.19 (0.92-1.52) 1.17 (0.90-1.52) 
Indication for PCI  
   Acute MI 0.60 (0.46-0.78) 0.71 (0.51-0.99) 
   Unstable Angina Pectoris 0.91 (0.68-1.21) 0.94 (0.70-1.26) 
   Stable Angina Pectoris 1 1 
Hypertension (yes) 1.20 (0.96-1.50) 1.20 (0.95-1.52) 
Positive Family History for CHD (yes) 1.50 (1.19-1.88) 1.37 (1.08-1.74) 
Heart failure (yes) 0.46 (0.23-0.92) 0.42 (0.21-0.84) 
Treatment during Off-hours (yes) 0.63 (0.49-0.81) 0.77 (0.55-1.07) 
 
 
 
 
Table 4 predictors for 30-day mortality  
 
Characteristic Adjusted for confounders 
HR, 95 CI 
Adjusted for confounders and 
propensity score* 
HR, 95 CI 
Age (per year) 1.05 (1.01-1.08) 1.02 (0.94-1.09) 
Sex (male) 2.22 (0.95-5.18) 2.14 (0.92-5.00) 
Study participation 0.18 (0.06-0.52) 0.18 (0.06-0.51) 
Indication for PCI   
   Acute MI 17.12 (3.85-76.07) 18.01 (4.04-80.34) 
   Unstable Angina Pectoris 5.56 (1.17-26.54) 5.57 (1.17-26.59) 
   Stable Angina Pectoris 1 1 
Heart failure 2.74 (0.76-9.89) 2.51 (0.69-9.13) 
Treatment during Off-hours (yes) 0.53 (0.24-1.14) 0.52 (0.24-1.13) 
* The propensity score model included all confounders listed in table 1 
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participants groups were admitted with cardiogenic shock. As far as procedural characteristics are con-
cerned, trial participants were significantly less often treated during off-hours and were treated more 
often with balloon angioplasty only, and had significantly more bifurcation lesions and clinical success 
than non-participants (table 2).  
Determinants of AC trial participation
We identified 7 clinical characteristics that were (p-value <0.15) predictors of trial participation; age 
(adjusted [a]OR 0.99 and 95%CI 0.98-1.00), sex ([a] OR 1.17 (0.90-1.52),  indication for PCI (acute MI 
([a]OR 0.71 and 95%CI 0.51-0.99) reference is stable angina pectoris), hypertension ([a]OR 1.20 and 
95%CI 0,95-1.52) , positive family history for CHD ([a]OR 1.37 and 95%CI 1.08-1.74), heart failure ([a]
OR 0.42 and 95%CI 0.21-0.84), and treatment during off-hours (weekends and between 18.00-08.00 
during weekdays) ([a]OR 0,77 and 95%CI 0.55-1.07) (table 3). The C-index for the LR model that 
contained these predictors was 0.60, and the Hosmer-Lemeshow test was non-significant (p=0.94), 
reflecting poor discrimination and adequate calibration.
Table 3 Multivariable analysis: predictors for participation in an all-comers trial 
 
Characteristic Crude Adjusted for confounders 
OR, 95 CI OR, 95 CI 
Age (per year) 0.99 (0.98-1.00) 0.99 (0.98-1.00) 
Sex (male) 1.19 (0.92-1.52) 1.17 (0.90-1.52) 
Indication for PCI  
   Acute MI 0.60 (0.46-0.78) 0.71 (0.51-0.99) 
   Unstable Angina Pectoris 0.91 (0.68-1.21) 0.94 (0.70-1.26) 
   Stable Angina Pectoris 1 1 
Hypertension (yes) 1.20 (0.96-1.50) 1.20 (0.95-1.52) 
Positive Family History for CHD (yes) 1.50 (1.19-1.88) 1.37 (1.08-1.74) 
Heart failure (yes) 0.46 (0.23-0.92) 0.42 (0.21-0.84) 
Treat ent during Off-hours (yes) 0.63 (0.49-0.81) 0.77 (0.55-1.07) 
 
 
 
 
Table 4 predictors for 30-day mortality  
 
Characteristic Adjusted for confounders 
HR, 95 CI 
Adjusted for confounders and 
propensity score* 
HR, 95 CI 
Age (per year) 1.05 (1.01-1.08) 1.02 (0.94-1.09) 
Sex (male) 2.22 (0.95-5.18) 2.14 (0.92-5.00) 
Study participation 0.18 (0.06-0.52) 0.18 (0.06-0.51) 
Indication for PCI   
   Acute MI 17.12 (3.85-76.07) 18.01 (4.04-80.34) 
   Unstable Angina Pectoris 5.56 (1.17-26.54) 5.57 (1.17-26.59) 
   Stable Angina Pectoris 1 1 
Heart failure 2.74 (0.76-9.89) 2.51 (0.69-9.13) 
Treatment during Off-hours (yes) 0.53 (0.24-1.14) 0.52 (0.24-1.13) 
* The propensity score model included all confounders listed in table 1 
 
 
Figure 2 Cumulative incidence for 1-year mortality
Table 4 predictors for 30-day mortality 
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Mortality
As shown in figure 2, study participation was associated with a lower mortality rate than non-partic-
ipation. Log rank test gave a significant overall difference (p=0.002) in mortality among the two cat-
egories (study participants vs. non-participants). In patients surviving the first 48 hours, this difference 
was non-significant (p=0.31).
After 30-days a significant difference in 30-day mortality was observed between AC-RCT participants 
and non-participants (n=4 (0.7%) versus n=30 (4.5% (KM estimates)); [a] HR 0.18 and 95% CI 0.06-
0.52)). 30-day mortality in AMI patients was 1.6% vs. 7.5% respectively (p=0.006). One-year mortality 
was also lower in trial participants (n=18 (3.1%) versus n=46 (6, 9% (KM estimates)); p=0.001; aHR 
0.51 and 95% CI 0.29-0.91)). In those who survived the first 48 hours (n=1224), no significant differ-
ences in 30-day (0.7% vs. 1, 7% (KM estimates), aHR 0.40 and 95 CI% 0.13-1.34) and 1-year mortality 
were found and (3.1% vs. 4.2% (KM estimates), aHR 0.74 and 95 CI% 0.41-1.34 respectively). None 
of the study participants died within 48 hours, whereas 18 patients in the non participants group died. 
Applying the model reduction strategy we indentified predictors of 30-day mortality (table 4): age, 
sex, study participation, indication for PCI; AMI and unstable angina pectoris, heart failure, and treat-
ment during off hours. After we adjusted for the propensity of AC-RCT participation (by adding the 
propensity score to the model), the relation between AC-RCT participation and 30-day mortality 
remained unchanged.
The additionally multivariable model fitted only to the non-participants indentified four predictors for 
30-day mortality: age, sex,  indication for PCI, unable to give informed consent, and treatment during 
off hours (table 5).The C-index for this model was 0.80 and the Hosmer-Lemeshow test was non-
significant (p=0.56), reflecting both adequate discrimination and calibration. Of the 30 patients who 
died within 30 days in the non participants group, 12 patients (40%) were admitted with cardiogenic 
shock.
DISCUSSION
The all-comers design in RCTs is becoming increasingly popular as it is supposed to reflect the real 
world in a better way than the standard RCTs with strict inclusion and exclusion criteria, resulting in 
limited generalizability. Although it is not to be expected that all consecutive patients will be included in 
an AC-RCT, it is important to note that we were only able to enrol 47% of the target population. This 
raises the question if we enrolled a more representative population than in a classical RCT. Importantly, 
Table 5 Multivariable model fitted to the non-participants (n=663) indentified four predictors for 30-
day mortality 
 
Characteristic Adjusted for confounders 
HR, 95 CI 
Age (per year) 1.05 (1.02-1.09) 
Sex (male) 2.13 (0.86-5.26 
Indication for PCI  
   Acute MI 8.46 (1.69-42,38) 
   Unstable Angina Pectoris 4.85 (0.98-24.11) 
   Stable Angina Pectoris 1 
Unable to provide IC 2.89 (1.14-7.33) 
Treatment during Off-hours (yes) 0.39 (0.16-0.95) 
 
 
 
 
 
Table 5 Multivariable model fitted to the non-participants (n=663) indentified four predictors 
for 30-day mortality
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differences in baseline characteristics and mortality were observed between participants and non-
participants. It should be noted, however, that the observed differences in 30-day and 1-year mortality 
between participants and non-participants in the two ‘all-comers’ trials became smaller in those who 
survived the first 48 hours. These results reveal that the all-comers design does not fully represent 
daily ‘real world’ clinical practice. Furthermore, our data indicate that an all-comers design is suitable 
for studying long term treatment effects, but probably less so for studying acute treatment effects in 
the broad spectrum of patients undergoing PCI.
The inability of an all-comers design to represent the vast majority of real-life patients is most likely 
related to the increased likelihood of excluding higher risk patients from these trials, although study 
criteria would have formally allowed their inclusion without restriction. This phenomenon particularly 
affects the estimates of early prognosis, whereas the reasons behind are multifactorial. Physicians tend 
to avoid including patients with a perceived high risk of adverse effects; high-risk patients themselves 
are less likely to volunteer to participate in a clinical study; and finally regulatory authorities may restrict 
the inclusion of higher risk subjects (note that the medical ethical committee of our centre prohibited 
proxy consent).
Although we indentified a number of clinical characteristics for trial participation it is important to 
note that the low C-index indicated that there are still unidentified predictors for trial participation. 
Nevertheless it is important to focus on patients who were unable to provide IC. More than 4 out of 
5 patients who were unable to provide IC suffered from acute myocardial infarction. This large propor-
tion is most likely due to their poor physical condition, which prevented the interventional cardiologist 
from asking IC. Not including the most critically ill patients makes the all-comers design less suitable 
for studying acute treatment effects in PCI patients. As second best option in these critically ill patients 
IC might be provided by their relatives. Our Medical Ethical Committee, however, did not approve 
proxy consent. 
In addition to the above mentioned study related issues for non-participation, also patient related 
issues may cause selection bias. 7, 8 Patients with acute myocardial infarction, and acute heart failure 
participated less often in a study, probably due to their physical condition. In contrast, patients with 
hypertension, hypercholesterolemia, and positive family history for CHD participated more often, 
which might be due to the fact that these patients with known risk factors are more aware of their 
physical condition. Their motivation might be the increased contact (phone/ out patient clinic) with the 
treating cardiologist which may provide a feeling of greater security, hope for a better intervention, the 
contribution to science, helping others. 9, 10 
We observed a higher mortality in the AC-RCT non-participants as compared to the participants. 
Interestingly, this difference appeared in the first 48 hours and did not exceed in the period thereafter. 
In fact, similar survival was observed in AC-RCT participants and non-participants after they have sur-
vived the first 48 hours. Still, we appreciate that a difference in survival might have been missed, due to 
the relatively low statistical power (note the relatively low number of deaths after 48 hours).
In patients who did not participate in a study an important predictor for mortality was the inability 
to provide IC of whom the majority was admitted with AMI. Given the high C-index, predictors as 
age, sex, acute MI, and treatment during off-hours adequately predicted mortality in these patients. 
All these predictors reflected the most critically ill patients. As discussed above proxy consent could 
contribute to resolve this issue.
In the context of this paper it is relevant to consider that the nomenclature “all-comers” refers specifi-
cally to the trial design, and does not refer (at least not in first instance) to the observed result. In this 
design inclusion criteria are kept comprehensive, and there are limited exclusion criteria, so that “real 
world” clinical practice is thought to be reflected. Apparently, as our analysis demonstrates, even in an 
AC-RCT not all eligible patients will be included, as patients themselves still need to provide informed 
consent, irrespectively of clinical inclusion and exclusion criteria. Although based on our results the 
question arises whether the nomenclature “all-comers” is a misnomer, it should be noted that this 
design included more patients than observed in classical RCTs.4, 11  Moreover, in a selection of classi-
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cal RCTs it was observed that 84-98% of the eligible patients were, due to a variety of reasons, not 
enrolled.4   
Limitations
It is important to note that the presented results are a single centre experience only. To further in-
vestigate whether multicenter all-comers trials are representative of real-world populations, data on 
screened patients in all participating sites are needed. Therefore, we recommend that future all-comers 
studies will maintain a systematic screening log.
Furthermore due to the small sample size and limited number of events the results may have limited 
external validity. In addition proxy consent was not allowed by our medical ethical committee, resulting 
in the underrepresentation of the critically ill patients in the AC-RCT. 
Conclusion
Applying the all-comers design did not result in inclusion of all consecutive patients, as only half of the 
target population was enrolled. It should be noted, however, that this design included more patients 
than observed in classical RCTs. AC-RCT participants and non-participants were different in terms of 
baseline characteristics and outcome.
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TRIAL-PARTICIPANTS VERSUS EVERY DAY CLINICAL CARE PATIENTS: TRIAL PARTICIPA-
TION AS A DETERMINANT OF ADVERSE OUTCOME IN THE FIELD OF INTERVENTIONAL 
CARDIOLOGY.
ABSTRACT
Background
This study examines differences in clinical outcome between trial-participants and non-participants 
after percutaneous coronary intervention (PCI).
Methods and results
This study compromised of 11,931 consecutive patients who underwent PCI in a high volume center, 
during the period 2000 – 2009. Of these patients, 1787 (15%) participated in an interventional clinical 
trial with a follow-up period of at least six months. The maximum follow-up duration was 11.8 years, 
with a median of 3.8 years (IQR: 2.6 – 6.5). Baseline and procedural characteristics differed between 
trial-participants and non-participants. Trial-participants were more often male, were younger, had 
more cardiovascular risk factors and were treated more often for stable angina pectoris and single 
vessel disease. Overall mortality at maximum follow-up was lower for trial-participants compared 
to non-participants (8.1% versus 17.6%, p < 0.001, adjusted HR, 0.62, 95% CI: 0.52–0.74). There was 
no difference in the incidence of non-fatal MI and CABG. Repeat PCI was seen more often in trial-
participants (18.1% versus 30.7%, p < 0.001, adjusted HR 1.91, 95%CI 1.73–2.10). Consequently, a 
higher incidence of the composite of mortality, repeat revascularization, and non-fatal MI was seen in 
the trail-participants (adjusted HR.1.36 95% CI 1.25 – 1.47), but this association was primarily driven 
by the occurrence of repeat PCI.
Conclusion
Participants in clinical trials in the field of interventional cardiology with a follow-up of at least six 
months differed considerably from non-participants in baseline and procedural characteristics. Trial-
participants had better survival than non-participants. In contrast, a two-fold higher incidence of repeat 
PCI was observed in trial-participants.
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INTRODUCTION
Randomized controlled trials (RCTs) are the gold standard by which the efficacy and safety of thera-
peutic strategies are evaluated 1. Randomization results in valid estimates of treatment effect, as it mini-
mizes bias due to differential selection and confounding 2. However, patients who participate in these 
clinical trials are, often due to the strict in- and exclusion criteria, considered being a selective group of 
patients, questioning the external validity.
Furthermore, generalizability can be limited due to the fact that not all consecutive patients who fulfill 
the study criteria actually do participate. Due to a number of reasons, including willingness of patients 
to participate, “burden” of additional procedures (i.e. follow-up angiography), distrust in clinical re-
search among patients and health care providers, it is observed that fewer than half of eligible patients 
participate in clinical trials 3, 4. Moreover, study participation is considered as hazardous by some since 
the therapeutic strategy under investigation may deviate from the applicable standards and guidelines. 
On the other hand, it is advocated that trial-participants may have a higher likelihood of beneficial 
outcome due to the most up-to-date treatment provided by qualified physicians embracing novel 
treatments5, 6, 7, 8.
A restriction of previous studies comparing trial-participants with non-participants is the heterogeneity 
of interventions and patient populations. Consequently, it remains unclear whether the observed dif-
ferences reflect trial participation or differences due to heterogeneity in interventions 9. In the current 
study we focus on patients with coronary artery disease (CAD) undergoing a clinically indicated per-
cutaneous coronary intervention (PCI). The objective of this study was to evaluate the extent to which 
participation in a clinical trial affects clinical outcome of patients with CAD who underwent a PCI.
METHODS
This study was conducted in the Thoraxcenter of the Erasmus MC from January 2000 to December 
2009. The Erasmus MC is a tertiary referral and teaching hospital in Rotterdam, The Netherlands that 
serves a region of over 1 million inhabitants. Approximately 4000 PCIs are performed annually in the 
Rotterdam region (in three PCI centres), including 1600 patients in the Erasmus MC.
All consecutive patients of 18 years of age or older, who were admitted with stable angina pectoris 
(sAP), non ST-segment elevation acute coronary syndrome (NSTE-ACS) or ST-segment elevation 
myocardial infarction (STEMI) and underwent PCI in our institution were included in the analysis. In 
total, 15,102 PCIs in 11,931 patients were performed. In patients who underwent multiple procedures 
(n = 2470), only the initial procedure was included in this analysis.
In the context of this study we identified trial participants as those patients who were enrolled in 
a clinical trial, irrespective of treatment arm, with a follow-up period of at least six months. In total 
1787 participants, enrolled in 76 clinical trials (including 35 randomized controlled trials with 1058 
patients), were identified. In 59 out of 76 trials (78%), a repeat angiography was mandated, including 
1380 patients. Non-participants (n = 10,144) were those who fulfilled enrolment criteria but were not 
included (e.g. patient or physician refusal), participated in a trial without follow-up (e.g. cross-sectional 
and feasibility studies) evaluating the technical safety and feasibility of a new imaging catheter, using only 
procedural information) or those who did not fulfil the enrolment criteria.
Patient management was in accordance with the clinical treatment guidelines of the European Society 
of Cardiology (ESC), which are implemented in our center. The Thoraxcenter has (since the year 2000) 
the policy to use one particular coronary stent as default in a given time period. The default stent 
between January 2000 and April 2002 was a bare metal stent (BMS), between April 2002 and March 
2003 a sirolimus eluting stent (SES), between March 2003 and March 2007 a paclitaxel eluting stent 
(PES), and the everolimus eluting stent (EES) since March 2007. Of note, patients could be treated with 
another stent when participating in a clinical trial.
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According to the standard data-management procedures in our department, data are collected pro-
spectively on demographics, cardiovascular history, clinical risk factors and treatment characteristics for 
all patients undergoing PCI, which are stored in an electronic database. Data-elements are filled out 
immediately after the completion of the PCI by the interventional cardiologist and the technician who 
assisted during the procedure. The database, which is maintained by a dedicated IT-officer, is mainly 
designed for administrative purposes. A systematic evaluation of data-completion and data-integrity is 
implemented for all data used for research purposes.
Vital status of the entire study cohort was obtained from the municipal civil registries between April 
and September 2011. Subsequently, a health questionnaire was sent to all living patients with specific 
inquiries on rehospitalisation and cardiovascular events, including repeat PCI, coronary artery bypass 
graft (CABG) and non-fatal myocardial infarction (MI). For patients who reported adverse events, 
medical records or discharge summaries were reviewed systematically. General practitioners, referring 
cardiologists, and patients were contacted in case further information was required. Patients lost to 
follow-up were considered at risk until the date of last contact, at which point they were censored.
Endpoint definitions
The primary endpoint was all-cause mortality, evaluated at 31 days, 1 year and 4 years. The second-
ary endpoints included repeat revascularization, non-fatal MI, and the composite of all-cause mortality, 
repeat revascularization and non-fatal MI at follow-up (31 days, 1 year and 4 years). Furthermore we 
also evaluated all-cause mortality at maximum available duration of follow-up (approximately 10 years 
for the first included patients).
Repeat revascularization was defined as a repeat PCI or CABG of any lesion located in the epicardial 
vessels. The definition of MI was in accordance with the guidelines of the European Society of Cardiol-
ogy 10.
Statistical methods
Continuous variables are presented as mean values and corresponding standard deviations (± SD), or 
median values with corresponding interquartile ranges (IQR). Categorical variables are expressed as 
numbers and percentages. Student’s t tests, Chi-square tests (or Fisher’s exact tests), or Mann–Whit-
ney tests were applied to evaluate differences in baseline variables, treatment and outcome between 
trial-participants and non-participants.
Kaplan–Meier mortality curves were used to describe the incidence of adverse events during follow-
up. Log-rank tests were applied to evaluate differences in long-term outcome between trial-partici-
pants and non-participants. Subsequently, we repeated the analysis for patients who survived the first 
month, thereby excluding patients who were unable to participate (i.e. not able to sign the informed 
consent form and/or not fulfilling study criteria) in a clinical study due to their critical illness. In addi-
tion, univariate and multivariate analysis (Cox proportional hazard) were performed to study the as-
sociation in clinical variables and mortality, repeat revascularization and myocardial infarction between 
trial-participants and non-participants. In the multivariate analysis we adjusted for a range of potential 
confounders, including all variables as presented in Table 1. These variables are: age, gender, smok-
ing, hypercholesterolemia, hypertension, diabetes, family history, renal failure, prior PCI, prior CABG, 
prior myocardial infarction, indication for PCI, off-hours treatment, severity of coronary artery disease, 
treated coronary vessel (left main, LAD, LCx, RCA, and/or graft), and use of glycoprotein (GP) IIb/IIIa 
Inhibitors.
For all tests, a p-value of < 0.05 (two-sided) was considered statistically significant. All calculations were 
performed using the SPSS 20 software package (SPSS Inc. IL. USA).
Ethics
All patients participating in clinical trials provided written informed consent. All trials were approved 
by the Medical Ethical Committee of the Erasmus MC and were performed in accordance with the 
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Variable All Non-participants Trial-participants 
p-
value 
 N (%) 11,931 10,144 (85) 1787 (15)  
Mean age, yr (± SD) 62.2 (± 11.8) 62.4 (± 12.0) 60.8 (± 10.9) < .001 
Male gender, n (%) 8588 (72) 7243 (71) 1345 (75) .001 
Smoking status, n (%)    .020 
 Current 3213 (27) 2688 (27) 525 (30)  
 Former smoker (! 1 yr) 65 (1) 59 (1) 6 (0)  
Medical history, n (%)     
 Hypercholesterolemia 9213 (77) 7725 (76) 1488 (83) < .001 
 Hypertension 5577 (47) 4756 (47) 821 (46) .46 
 Diabetes mellitus 2054 (17) 1763 (17) 291 (16) .26 
 Family history of CAD 3882 (33) 3197 (32) 685 (38) < .001 
 Risk factorsa per patient, mean (± SD) 1.7 (± 1.0) 1.7 (± 1.0) 1.8 (± 0.9) .002 
 Renal failure 593 (5) 518 (5) 75 (4) .10 
 Prior PCI 1411 (12) 1209 (12) 202 (11) .46 
 Prior CABG 1015 (9) 895 (12) 120 (7) .003 
 Prior myocardial infarction 3125 (26) 2699 (27) 426 (24) .035 
Indication for PCI, n (%)    < .001 
 sAP 4422 (37) 3631 (36) 791 (44)  
 NSTE-ACS 3280 (28) 2794 (28) 486 (27)  
 STEMI 4229 (35) 3719 (37) 510 (29)  
Off-hoursb, n (%) 2746 (23) 2404 (24) 342 (19) < .001 
 Severity of CAD, n (%)    < .001 
 Single-vessel disease 5886 (49) 4871 (48) 1015 (57)  
 Two-vessel disease 3565 (30) 3069 (30) 496 (28)  
 Three-vessel disease 2399 (20) 2127 (21) 272 (15)  
Treated vessel, mean (± SD) 1.4 (± 0.7) 1.4 (± 0.7) 1.4 (± 0.6) .69 
 RCA, n (%) 4492 (38) 3819 (38) 673 (38) .99 
 LAD, n (%) 6005 (50) 5112 (50) 893 (50) .74 
 LCx, n (%) 3389 (28) 2887 (29) 502 (28) .75 
 LM, n (%) 504 (4) 466 (5) 38 (2) < .001 
 Graft, n (%) 2336 (20) 1947 (19) 389 (22) .011 
GP IIb/IIIa inhibitor, n (%) 1534 (13) 1345 (13) 189 (11) .001 
 
PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; sAP, stable Angina Pectoris; 
NSTE-ACS, non ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; CAD, 
coronary artery disease; RCA, right coronary artery; LAD, left anterior descending; LCx, left circumflex 
artery; LM, left main stem. 
‡) Antithrombotic: aspirin, thienopyridines, and/or coumadin. 
a) Risk factors included, smoking, diabetes, hypercholesterolemia and hypertension. 
b) Off-hours, weeknights (from 06.00 PM to 08.00 AM) and weekends (from Friday 06:00 PM to Monday 
08:00 AM). 
Table 1 Baseline and procedural characteristics
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Variable All Non-participants Trial-participants 
p-
value 
 N (%) 11,931 10,144 (85) 1787 (15)  
Mean age, yr (± SD) 62.2 (± 11.8) 62.4 (± 12.0) 60.8 (± 10.9) < .001 
Male nder, n (%) 8588 (72) 7243 (71) 1345 (75) .001 
Smoki g status, n (%)   .020 
 Current 3213 (27) 2688 (27) 525 (30)  
 Former smoker (! 1 yr) 65 (1 59 (1) 6 (0)  
Medical history, n (%)     
 Hypercholesterolemia 9213 (77) 7725 (76) 1488 (83) < .001 
 Hypertension 5577 (47) 4756 (47) 821 (46) .46 
 Diabetes mellitus 2054 (17) 1763 (17) 291 (16) .26 
 Family history of CAD 3882 (33) 3197 (32) 685 (38) < .001 
 Risk factorsa per patient, mean (± SD) 1.7 (± 1.0) 1.7 (± 1.0) 1.8 (± 0.9) .002 
 Renal failure 593 (5) 518 (5) 75 (4) .10 
 Prior PCI 1411 (12) 1209 (12) 202 (11) .46 
 Prior CABG 1015 (9) 895 (12) 120 (7) .003 
 Prior myocardial infarction 3125 (26) 2699 (27) 426 (24) .035 
Indication for PCI, n (%)    < .001 
 sAP 4422 (37) 3631 (36) 791 (44)  
 NSTE-ACS 3280 (28) 2794 (28) 486 (27)  
 STEMI 4229 (35) 3719 (37) 510 (29)  
Off-hoursb, n (%) 2746 (23) 2404 (24) 342 (19) < .001 
 Severity of CAD, n (%)    < .001 
 Single-vessel disease 5886 (49) 4871 (48) 1015 (57)  
 Two-vessel disease 3565 (30) 3069 (30) 496 (28)  
 Three-vessel disease 2399 (20) 2127 (21) 272 (15)  
Treated vessel, mean (± SD) 1.4 (± 0.7) 1.4 (± 0.7) 1.4 (± 0.6) .69 
 RCA, n (%) 4492 (38) 3819 (38) 673 (38) .99 
 LAD, n (%) 6005 (50) 5112 (50) 893 (50) .74 
 LCx, n (%) 3389 (28) 2887 (29) 502 (28) .75 
 LM, n (%) 504 (4) 466 (5) 38 (2) < .001 
 Graft, n (%) 2336 (20) 1947 (19) 389 (22) .011 
GP IIb/IIIa inhibitor, n (%) 1534 (13) 1345 (13) 89 (11) .001 
 
PCI, percutaneous coronary int rvention; CABG, coron y artery bypass graft; sAP, stable Angina Pectoris; 
NSTE-ACS, on ST-elevation myocardial infarction; STEMI, ST-elevation myocardi l infarction; CAD, 
c ronary artery disease; RCA, right coronary artery; LAD, left anterior descending; LCx, left circumflex 
artery; LM, left main stem. 
‡) Antithrombotic: aspirin, thienopyridines, and/or coumadin. 
a) Risk factors included, smoking, diabetes, hypercholesterolemia and hypertension. 
b) Off-hours, weeknights (from 06.00 PM to 08.00 AM) and weekends (from Friday 06:00 PM to Monday 
08:00 AM). 
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declaration of Helsinki. Patients not enrolled into clinical trials were not subject to interventions under 
investigation, neither was any mode of behaviour imposed, otherwise than as part of their regular 
treatment. Therefore, according to Dutch law, written informed consent was not required for these 
patients. This study was conducted according to the Privacy Policy of the Erasmus MC, and according 
to the Erasmus MC regulations for the appropriate use of data in patient oriented research 11.
RESULTS
Baseline and procedural characteristics
Baseline and procedural characteristics of the total study sample (n = 11,931) are displayed in Table 
1. Of these patients, 1787 (15%) participated in a clinical trial with a follow-up period of at least six 
months. Baseline and procedural characteristics differed considerably between trial-participants and 
non-participants. Trial-participants were more often men (75% versus 71%, p = 0.001) and on aver-
age 1.6 years younger (60.8 vs. 62.4, p < 0.001) as compared to non-participants. In addition, trial-
participants more often had a history of hypercholesterolemia (p < 0.001) and had a positive family 
history of CAD (p < 0.001). While most trial-participants were treated for sAP, the leading indication 
for PCI in non-participants was STEMI, whereas non-participants were also treated more often dur-
ing off-hours (i.e. during the weekend, and evening-, and night shifts). At the same time, 57% of the 
trial-participants as compared to 48% non-participants were treated for a single vessel disease. No 
differences were observed in the treatment of the coronary vessels, with exception of the left main 
coronary artery (more often in non-participants) and coronary artery bypass grafts (trial-participants 
more often). The administration of GP IIb/IIIa inhibitors was seen more often in non-participants.
(p b 0.001) and had a positive family history of CAD (p b 0.001). While
most trial-participants were treated for sAP, the leading indication for
PCI in non-participants was STEMI, whereas non-participants were
also treated more often during off-hours (i.e. during the weekend, and
evening-, and night shifts). At the same time, 57% of the trial-
participants as compared to 48% non-participants were treated for a
single vessel disease. No differences were observed in the treatment
of the coronary vessels, with exception of the left main coronary artery
(more often in non-participants) and coronary artery bypass grafts
(trial-participants more often). The administration of GP IIb/IIIa inhibi-
tors was seen more often in non-participants.
3.2. Mortality
Information on survival status was complete in 96.4% of all patients
(97.3% for trial-participants and 96.3% for non-participants, p=0.037).
The maximum follow-up duration was 11.8 years, with a median of
3.8 years (IQR: 2.6 - 6.5). Based on 1927 fatalities and a total follow-up
duration of 52,162 person-years, we observed 36.9 fatal events/1000
person-years in the total cohort. Among trial-participants the number
of fatal events/1000 person-years was 18.3 (95% CI 15.5  21.4) com-
pared to 40.3 (95% CI 38.4  42.2) in non-participants. As also shown
in Fig. 1 and Table 2, overall mortality was lower for trial-participants
compared to non-participants (8.1% versus 17.6%, (KM-estimate),
p b 0.001, unadjusted Hazard Ratio (uHR) 0.45, 95% CI 0.38  0.54). Of
note, when the analysis was repeated in those patients who survived
the first month, similar results were obtained (uHR 0.56, 95% CI 0.47 
0.67).
After adjustment for potential confounders, mortality remained
lower in trial-participants than in non-participants (adjusted Hazard
Ratio (aHR) 0.62, 95% CI: 0.520.74) (Table 2). When focusing on the
indication for PCI (e.g. sAP, NSTE-ACS, STEMI), similar results were
observed. As shown in Fig. 3, trial-participation was associated with
better survival at 31 days, 1 year and 4 years of follow-up (5.9% versus
13.6%; aHR 0.58, 95%CI 0.480.71 at 4 years).
3.3. Non-fatal endpoints and the combined endpoint
Repeat PCI was seen more often in trial-participants (18.1% versus
30.7% (KM estimate), p b 0.001); uHR 1.81, 95%CI 1.652.00). Similar
results were obtained after multivariate adjustment for potential con-
founders of the relation between trial participation and the incidence
of rePCI (aHR 1.91, 95%CI 1.732.10), Table 2, and Fig. 2A. Results were
comparable at short-term and long-term follow-up (Fig. 3) and in the
different indication groups (Table 2).Trial-participants underwent
re-PCI in an earlier phase as compared to non-participants (median
114 (IQR: 35  195 days) versus 55 days (IQR: 10  148 days), p b .001
resp ctiv ly).
We did not find any clinically relevant difference in the incidence of
CABG nd on-fatal MI between trial participants and non-participants.
Resultswere similar at short-term and long-term follow-up (Fig. 3), and
similar in the patients treated for different indications (Table 2). The
cumulative incidence curves were superimposed for these endpoints
(Fig. 2C and D). Trial participation had no contribution in multivariable
Cox PH models that related patient characteristics with CABG and non-
fatal MI. Adjusted HRs of trial participation were non-significant and
close to 1 for CABG and non-fatal MI at all three investigated follow-
up moments (Fig. 3).
The composite endpoint of all-cause mortality, repeat PCI, CABG or
MI was observed more often in trial-participants as compared to non-
participants (aHR.1.36 95% CI 1.25  1.47), Table 2, and Fig. 2B.
4. Discussion
Clinical trials are important to evaluate the efficacy and safety of CAD
treatment, however, due to strict in- and exclusion criteria their gener-
alizability is often limited. We studied the effect of trial participation in
all consecutive patients undergoing PCI within the last decade at our PCI
centre. As expected,we observed important differences in baseline char-
acteristics between trial-participants and non-participants. Mortality
was higher in non-participants than in trial-participants, even in those
who survived the first month. There was no difference in occurrence
of non-fatal MI between both groups. Interestingly, trial-participants
had an almost 2-fold higher incidence of repeat PCI. As a result, the
composite of mortality, repeat revascularization, and non-fatal MI was
(in contrast to mortality) higher in trail-participants. These results
show that trial-participation does not fully represent real world
clinical practice and indicate that the external validity of trial results is
limited.
The better survival of trial participants may be related to the
increased likelihood (strict inclusion and exclusion criteria) of excluding
high risk patients from trials. For example, patients presenting with
STEMI (high risk patients) were less likely to be enrolled in clinical
trials: 37% of the non-participants had a STEMI versus 29% of the trial
participants. Another explanation, as we demonstrated previously in a
subset of these patients, is that critically-ill patients are not able to
provide informed consent, whereas physicians tend to avoid including
a patient with high risk of adverse effects [4]. Secondly, in patients
who survived the first month, excluding acute treatment effects, we
also observed a higher mortality in the non-participants. This may be
due to the fact that trial participants, in the years following the index-
procedure, are subjected to strict adherence to the carefully developed
protocol and extra visits to the outpatient clinic. Third, as indicated by
others, trial-participants may have had better education and be of
higher socioeconomic status, which may contribute to better overall
treatment adherence [12]. Fourth, it can also be hypothesized that due
to the informed consent procedure and more frequent contacts
(phone and outpatient clinic) trial-participants are better informed
and motivated to adhere to the initiated treatment and life-style
changes, resulting in improved clinical outcome [13].
Within this study we observed a significant difference in subsequent
PCI procedures between trial participants and non-participants,whereas
CABG and non-fatal MI did not differ between the two groups. Univari-
ate as well as multivariate analysis revealed that almost twice as many
trial-participants underwent repeat PCI within 1 year after the initial
PCI. Importantly, in the vast majority of trial-participants a follow-up
angiography was mandated by the study protocol. This observation is
in line with others who reported increased repeat PCI in patients who
undergo routine follow-up angiography [14,15]. In addition, Uchida
et al. demonstrated that the majority of those patients were treated for
intermediate non-ischemic lesions. Importantly, no survival benefit
was observed in patients undergoing angiographic follow-up as com-
pared to clinical follow-up alone (e.g. repeat angiography limited to
symptomatic patients only) [16].
Conducting clinical research is an important part of clinical practice
in an academic hospital and essential to the further improvement ofFig. 1. Unadjusted mortality curves for trial-participants and non-participants.
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Figure 1 Unadjusted mortality curves for trial-participants and non-participants
Mortality
Information on survival status was complete in 96.4% of all patients (97.3% for trial-participants and 
96.3% for non-participants, p = 0.037). The maximum follow-up duration was 11.8 years, with a me-
dian of 3.8 years (IQR: 2.6 - 6.5). Based on 1927 fatalities and a total follow-up duration of 52,162 
person-years, we observed 36.9 fatal events/1000 person-years in the total cohort. Among trial-
participants the number of fatal events/1000 person-years was 18.3 (95% CI 15.5 – 21.4) compared 
to 40.3 (95% CI 38.4 – 42.2) in non-participants. As also shown in Fig. 1 and Table 2, overall mortality 
was lower for trial-participants compared to non-participants (8.1% versus 17.6%, (KM-estimate), p 
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< 0.001, unadjusted Hazard Ratio (uHR) 0.45, 95% CI 0.38 – 0.54). Of note, when the analysis was 
repeated in those patients who survived the first month, similar results were obtained (uHR 0.56, 95% 
CI 0.47 – 0.67).
After adjustment for potential confounders, mortality remained lower in trial-participants than in 
non-participants (adjusted Hazard Ratio (aHR) 0.62, 95% CI: 0.52–0.74) (Table 2). When focusing on 
the indication for PCI (e.g. sAP, NSTE-ACS, STEMI), similar results were observed. As shown in Fig. 3, 
trial-participation was associated with better survival at 31 days, 1 year and 4 years of follow-up (5.9% 
versus 13.6%; aHR 0.58, 95%CI 0.48–0.71 at 4 years).
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Variable  
Non-
participants 
Trial-
participants Unadjusted HR (95%CI) Adjusted HR (95%CI) 
 All     
 n (%) 11,931 10,144 (85) 1787 (15)   
Death 1927 (16.2) 1783 (17.6) 144 (8.1) 0.45 (0.38–0.54) 0.62 (0.52–0.74) 
Repeat PCI 2381 (20.0) 1833 (18.1) 548 (30.7) 1.81 (1.65–2.00) 1.91 (1.73–2.10) 
(repeat) CABG 337 (2.8) 289 (2.8) 48 (2.7) 0.92 (0.68–1.25) 0.94 (0.69–1.28) 
Myocardial 
infarction 
492 (4.1) 413 (4.1) 79 (4.4) 1.06 (0.84–1.35) 1.13 (0.89–1.45) 
Any of the above 4283 (36.0) 3603 (35.5) 680 (38.1) 1.17 (1.08–1.27) 1.36 (1.25–1.47) 
PCI indication: sAP     
 n (%) 4422 3631 (82) 791 (18)   
Death 592 (13.4) 528 (14.5) 64 (8.1) 0.51 (0.40–0.67) 0.65 (0.50–0.85) 
Repeat PCI 982 (22.2) 730 (20.1) 252 (31.9) 1.68 (1.46–1.94) 1.71 (1.48–1.98) 
(repeat) CABG 174 (3.9) 144 (4.0) 30 (3.8) 0.91 (0.61–1.34) 0.97 (0.65–1.44) 
Myocardial 
infarction 
156 (3.5) 125 (3.4) 32 (4.0) 1.12 (0.76–1.66) 0.88 (0.57–1.34) 
Any of the above 1587 (35.9) 1272 (35.0) 315 (39.8) 1.22 (1.08–1.38) 1.33 (1.17–1.51) 
PCI indication: NSTE-ACS     
 n (%) 3280 2794 (85) 486 (15)   
Death 571 (17.4) 523 (18.7) 48 (9.9) 0.48 (0.35–0.64) 0.65 (0.48–0.88) 
Repeat PCI 704 (21.5) 540 (19.3) 164 (33.7) 1.85 (1.55–2.20) 1.90 (1.59–2.27) 
(repeat) CABG 85 (2.8) 72 (2.6) 13 (2.7) 0.97 (0.54–1.75) 1.05 (0.57–1.92) 
Myocardial 
infarction 
133 (4.1) 111 (4.0) 22 (4.5) 1.07 (0.68–1.69) 0.95 (0.59–1.53) 
Any of the above 1241 (37.8) 1039 (37.2) 202 (41.6) 1.18 (1.02–1.37) 1.37 (1.18–1.60) 
PCI indication: STEMI     
 n (%) 4229 3719 (88) 510 (12)   
Death 764 (18.1) 732 (19.7) 32 (6.3) 0.35 (0.25–0.50) 0.46 (0.32–0.66) 
Repeat PCI 695 (16.4) 563 (15.1) 132 (25.9) 1.85 (1.53–2.23) 1.90 (1.57–2.31) 
(repeat) CABG 78 (1.8) 73 (2.0) 5 (1.0) 0.53 (0.21–1.30) 0.55 (0.22–1.36) 
Myocardial 
infarction 
203 (4.8) 178 (4.8) 25 (4.9) 1.10 (0.72–1.68) 1.12 (0.74–1.72) 
Any of the above 1455 (34.4) 1292 (34.7) 163 (32.0) 1.05 (0.89–1.24) 1.20 (1.01–1.41) 
 
PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; sAP, stable Angina Pectoris; 
NSTE-ACS, non ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction. 
 
 
 
 
 
 
 
 
 
Table 2 Outcome
!
!
Variable  
Non-
participants 
Trial-
participants Unadjusted HR (95%CI) Adjusted HR (95%CI) 
 All     
 n (%) 11,931 10,144 (85) 1787 (15)   
Death 1927 (16.2) 1783 (17.6) 144 (8.1) 0.45 (0.38–0.54) 0.62 (0.52–0.74) 
Repeat PCI 2381 (20.0) 1833 (18.1) 548 (30.7) 1.81 (1.65–2.00) 1.91 (1.73–2.10) 
(repeat) CABG 337 (2.8) 289 (2.8) 48 (2.7) 0.92 (0.68–1.25) 0.94 (0.69–1.28) 
Myocardial 
infarction 
492 (4.1) 413 (4.1) 79 (4.4) 1.06 (0.84–1.35) 1.13 (0.89–1.45) 
Any of the above 4283 (36.0) 3603 (35.5) 680 (38.1) 1.17 (1.08–1.27) 1.36 (1.25–1.47) 
PCI indication: sAP     
 n (%) 4422 3631 (82) 791 (18)   
Death 592 (13.4) 528 (14.5) 64 (8.1) 0.51 (0.40–0.67) 0.65 (0.50–0.85) 
Repeat PCI 982 (22.2) 730 (20.1) 252 (31.9) 1.68 (1.46–1.94) 1.71 (1.48–1.98) 
(repeat) CABG 174 (3.9) 144 (4.0) 30 (3.8) 0.91 (0.61–1.34) 0.97 (0.65–1.44) 
Myocardial 
infarction 
156 (3.5) 125 (3.4) 32 (4.0) 1.12 (0.76–1.66) 0.88 (0.57–1.34) 
Any of the above 1587 (35.9) 1272 (35.0) 315 (39.8) 1.22 (1.08–1.38) 1.33 (1.17–1.51) 
PCI indication: NSTE-ACS     
 n (%) 3280 2794 (85) 486 (15)   
Death 571 (17.4) 523 (18.7) 48 (9.9) 0.48 (0.35–0.64) 0.65 (0.48–0.88) 
Repeat PCI 704 (21.5) 540 (19.3) 164 (33.7) 1.85 (1.55–2.20) 1.90 (1.59–2.27) 
(repeat) CABG 85 (2.8) 72 (2.6) 13 (2.7) 0.97 (0.54–1.75) 1.05 (0.57–1.92) 
Myocardial 
infarction 
133 (4.1) 111 (4.0) 22 (4.5) 1.07 (0.68–1.69) 0.95 (0.59–1.53) 
Any of the above 1241 (37.8) 1039 (37.2) 202 (41.6) 1. 8 (1.02–1.37) 1.37 (1.18–1.60) 
PCI indication: STEMI     
 n (%) 4229 3719 (88) 510 (12)   
Death 764 (18.1) 732 (19.7) 32 (6.3) 0.35 (0.2 –0.50) 0.46 (0.32–0.66) 
Repeat PCI 695 (16.4) 563 ( 5.1) 132 (25.9) 1.8  (1.53–2.23) 1.90 (1.57–2.31) 
(repeat) CABG 78 (1.8) 73 (2.0) 5 (1.0) 0.53 (0.21–1.30) 0.55 (0.22–1.36) 
Myocardial 
infarction 
203 (4.8) 178 (4.8) 25 (4.9) 1.10 (0.72–1.68) 1.12 (0.74–1.72) 
Any of the above 1455 (34.4) 1292 (34.7) 163 (32.0) 1.05 (0.89–1.24) 1.20 (1.01–1.41) 
 
PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; sAP, stable Angina Pectoris; 
NSTE-ACS, non ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction. 
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pharmacological therapies, diagnostics, and interventional devices in
the management of patients with CAD. However, trial participation
might also be regarded as burdensome for participants and potentially
hazardous as the effect of an experimental treatment has not always
been proven effective in the population of interest. In contrast, trial par-
ticipation also includes access to novel and potentially better treatment
Table 2
Outcome.
Variable Non-participants Trial-participants Unadjusted HR (95%CI) Adjusted HR (95%CI)
All
n (%) 11,931 10,144 (85) 1787 (15)
Death 1927 (16.2) 1783 (17.6) 144 (8.1) 0.45 (0.380.54) 0.62 (0.520.74)
Repeat PCI 2381 (20.0) 1833 (18.1) 548 (30.7) 1.81 (1.652.00) 1.91 (1.732.10)
(repeat) CABG 337 (2.8) 289 (2.8) 48 (2.7) 0.92 (0.681.25) 0.94 (0.691.28)
Myocardial infarction 492 (4.1) 413 (4.1) 79 (4.4) 1.06 (0.841.35) 1.13 (0.891.45)
Any of the above 4283 (36.0) 3603 (35.5) 680 (38.1) 1.17 (1.081.27) 1.36 (1.251.47)
PCI indication: sAP
n (%) 4422 3631 (82) 791 (18)
Death 592 (13.4) 528 (14.5) 64 (8.1) 0.51 (0.400.67) 0.65 (0.500.85)
Repeat PCI 982 (22.2) 730 (20.1) 252 (31.9) 1.68 (1.461.94) 1.71 (1.481.98)
(repeat) CABG 174 (3.9) 144 (4.0) 30 (3.8) 0.91 (0.611.34) 0.97 (0.651.44)
Myocardial infarction 156 (3.5) 125 (3.4) 32 (4.0) 1.12 (0.761.66) 0.88 (0.571.34)
Any of the above 1587 (35.9) 1272 (35.0) 315 (39.8) 1.22 (1.081.38) 1.33 (1.171.51)
PCI indication: NSTE-ACS
n (%) 3280 2794 (85) 486 (15)
Death 571 (17.4) 523 (18.7) 48 (9.9) 0.48 (0.350.64) 0.65 (0.480.88)
Repeat PCI 704 (21.5) 540 (19.3) 164 (33.7) 1.85 (1.552.20) 1.90 (1.592.27)
(repeat) CABG 85 (2.8) 72 (2.6) 13 (2.7) 0.97 (0.541.75) 1.05 (0.571.92)
Myocardial infarction 133 (4.1) 111 (4.0) 22 (4.5) 1.07 (0.681.69) 0.95 (0.591.53)
Any of the above 1241 (37.8) 1039 (37.2) 202 (41.6) 1.18 (1.021.37) 1.37 (1.181.60)
PCI indication: STEMI
n (%) 4229 3719 (88) 510 (12)
Death 764 (18.1) 732 (19.7) 32 (6.3) 0.35 (0.250.50) 0.46 (0.320.66)
Repeat PCI 695 (16.4) 563 (15.1) 132 (25.9) 1.85 (1.532.23) 1.90 (1.572.31)
(repeat) CABG 78 (1.8) 73 (2.0) 5 (1.0) 0.53 (0.211.30) 0.55 (0.221.36)
Myocardial infarction 203 (4.8) 178 (4.8) 25 (4.9) 1.10 (0.721.68) 1.12 (0.741.72)
Any of the above 1455 (34.4) 1292 (34.7) 163 (32.0) 1.05 (0.891.24) 1.20 (1.011.41)
PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; sAP, stable Angina Pectoris; NSTE-ACS, non ST-elevationmyocardial infarction; STEMI, ST-elevationmyocar-
dial infarction.
Fig. 2. Unadjusted adverse event curves for trial-participants and non-participants.
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pharmacological therapies, diagnostics, and interventional devices in
the management of patients with CAD. However, trial participation
might also be regarded as burdensome for participants and potentially
hazardous as the effect of an experimental treatment has not always
been proven effective in the population of interest. In contrast, trial par-
ticipation also includes access to novel and potentially better treatment
Table 2
Outcome.
Variable Non-participants Trial-participants Unadjusted HR (95%CI) Adjusted HR (95%CI)
All
n (%) 11,931 10,144 (85) 1787 (15)
Death 1927 (16.2) 1783 (17.6) 144 (8.1) 0.45 (0.380.54) 0.62 (0.520.74)
Repeat PCI 2381 (20.0) 1833 (18.1) 548 (30.7) 1.81 (1.652.00) 1.91 (1.732.10)
(repeat) CABG 337 (2.8) 289 (2.8) 48 (2.7) 0.92 (0.681.25) 0.94 (0.691.28)
Myocardial infarction 492 (4.1) 413 (4.1) 79 (4.4) 1.06 (0.841.35) 1.13 (0.891.45)
Any of the above 4283 (36.0) 3603 (35.5) 680 (38.1) 1.17 (1.081.27) 1.36 (1.251.47)
PCI indication: sAP
n (%) 4422 3631 (82) 791 (18)
Death 592 (13.4) 528 (14.5) 64 (8.1) 0.51 (0.400.67) 0.65 (0.500.85)
Repeat PCI 982 (22.2) 730 (20.1) 252 (31.9) 1.68 (1.461.94) 1.71 (1.481.98)
(repeat) CABG 174 (3.9) 144 (4.0) 30 (3.8) 0.91 (0.611.34) 0.97 (0.651.44)
Myocardial infarction 156 (3.5) 125 (3.4) 32 (4.0) 1.12 (0.761.66) 0.88 (0.571.34)
Any of the above 1587 (35.9) 1272 (35.0) 315 (39.8) 1.22 (1.081.38) 1.33 (1.171.51)
PCI indication: NSTE-ACS
n (%) 3280 2794 (85) 486 (15)
Death 571 (17.4) 523 (18.7) 48 (9.9) 0.48 (0.350.64) 0.65 (0.480.88)
Repeat PCI 704 (21.5) 540 (19.3) 164 (33.7) 1.85 (1.552.20) 1.90 (1.592.27)
(repeat) CABG 85 (2.8) 72 (2.6) 13 (2.7) 0.97 (0.541.75) 1.05 (0.571.92)
Myocardial infarction 133 (4.1) 111 (4.0) 22 (4.5) 1.07 (0.681.69) 0.95 (0.591.53)
Any of the above 1241 (37.8) 1039 (37.2) 202 (41.6) 1.18 (1.021.37) 1.37 (1.181.60)
PCI indication: STEMI
n (%) 4229 3719 (88) 510 (12)
Death 764 (18.1) 732 (19.7) 32 (6.3) 0.35 (0.250.50) 0.46 (0.320.66)
Repeat PCI 695 (16.4) 563 (15.1) 132 (25.9) 1.85 (1.532.23) 1.90 (1.572.31)
(repeat) CABG 78 (1.8) 73 (2.0) 5 (1.0) 0.53 (0.211.30) 0.55 (0.221.36)
Myocardial infarction 203 (4.8) 178 (4.8) 25 (4.9) 1.10 (0.721.68) 1.12 (0.741.72)
Any of the above 1455 (34.4) 1292 (34.7) 163 (32.0) 1.05 (0.891.24) 1.20 (1.011.41)
PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; sAP, stable Angina Pectoris; NSTE-ACS, non ST-elevationmyocardial infarction; STEMI, ST-elevationmyocar-
dial infarction.
Fig. 2. Unadjusted adverse event curves for trial-participants and non-participants.
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Figure 2 Unadjusted adverse event curves for trial-participants and non-participants
Non-fatal endpoints and the combined endpoint
Repeat PCI was seen more often in trial-participants (18.1% versus 30.7% (KM estimate), p < 0.001); 
uHR 1.81, 95%CI 1.65–2.00). Similar results were obtained after multivariate adjustment for potential 
confounders of the relation between trial participation and the incidence of rePCI (aHR 1.91, 95%CI 
1.73–2.10), Table 2, and Fig. 2A. Results were comparable at short-term and long-term follow-up ( Fig. 
3) and in the different indication groups ( Table 2).Trial-participants underwent re-PCI in an earlier 
phase as compared to non-participants (median 114 (IQR: 35 – 195 days) versus 55 days (IQR: 10 – 
148 days), p < .001 respectively).
We did not find any clinically relevant difference in the incidence of CABG and non-fatal MI between 
trial participants and non-participants. Results were similar at short-term and long-term follow-up 
(Fig. 3), and similar in the patients treated for different indications (Table 2). The cumulative incidence 
curves were superimposed for these endpoints (Fig. 2C and D). Trial participation had no contribu-
tion in multivariable Cox PH models that related patient characteristics with CABG and non-fatal MI. 
Adjusted HRs of trial participation were non-significant and close to 1 for CABG and non-fatal MI at 
all three investigated follow-up moments (Fig. 3).
The composite endpoint of all-cause mortality, repeat PCI, CABG or MI was observed more often in 
trial-participants as compared to non-participants (aHR.1.36 95% CI 1.25 – 1.47), Table 2, and Fig. 2B.
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with an increased focus on standard treatment, co-morbid conditions
and events as dictated by the protocol and comprehensive case record
forms [8]. In addition to this, it is important to note that scientific
concerns and ethical dilemmas regarding a clinical trial are judged and
approved by an institutional review board [3]. Moreover, the evaluation
of the scientific design and assurance of safeguards for the protection of
patients, and the patients' autonomy inmaking a decision to participate
are essential parts of the review process.
The present study has several limitations. The presented results are
based on a single centre experience, which limits the external validity.
Nevertheless, the Thoraxcenter Rotterdam can be considered represen-
tative for larger tertiary referring and teaching (academic) hospitals in
Western populations. Second, for the follow-up of non-fatal endpoints
we were dependent on the patient's response of health questionnaires
that were systematically sent to all living patients, with specific inqui-
ries on rehospitalisation and major adverse cardiac events. Thus, we
might have missed some non-fatal endpoints, particularly those that
did not result in hospital admissions. Possibly, more effort was under-
taken in trial participants to collect these data, which may partially
explain the higher rate of rePCI in trial participants. Third, it is impossi-
ble to study the effects of trial-participation in a randomized controlled
trial, which is the gold standard to evaluate treatment efficacy and
safety. However, we studied a large population over a long period
(10 years) of time in which many trials were performed at our centre.
Non-participants represent a heterogeneous group of patients,
i.e.: patients who did not meet the study criteria, patients who refused
to participate and patients who were unable to provide informed
consent. Unfortunately, we did not systematically collect the reasons
of non-participation in all studies. Therefore,wewere unable to perform
a stratified analysis based on the reasons for non-participation.
5. Conclusion
The current study showed that participants of PCI trials differed
considerably in clinical and procedural characteristics from non-
participants. Trial-participants had a better survival but a two-fold
higher incidence of repeat PCI as compared to non-participants. The
higher incidence of the composite ofmortality, repeat revascularization,
and non-fatal MI in the trail-participants was primarily driven by the
occurrence of repeat PCI. These results illustrate that clinical trials do
not fully reflect every day clinical practice.
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Fig. 3. Adjusted hazard ratios for outcome at different follow-up periods.
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Figure 3 Adjusted hazard ra ios fo  outcome at different foll w-up riods
DISCUSSION
Clinical trials are important to evaluate the efficacy and safety of CAD treatment; however, due to 
strict in- and exclusion criteria their generalizability is often limited. We studied the effect of trial 
particip tion i  all consecutive pa ients underg ing PCI within th  last decade at our PCI ntre. As 
expected, we observed important differences in baseline characteristics between trial-participants and 
non-participants. Mortality was higher in non-participants than in trial-participants, even in those who 
survived the first month. There was no difference in occurrence of non-fatal MI between both groups. 
Interestingly, trial-participants had an almost 2-fold higher incidence of repeat PCI. As a result, the com-
posite of mortality, repeat revascularization, and non-fatal MI was (in contrast to mortality) higher in 
trail-participants. These results show that trial-participation does not fully repres t “real world” clinical 
practice and indicate that the external validity of trial results is limited.
The better survival of trial participants may be related to the increased likelihood (strict inclusion and 
exclusio  criteria) of xcluding high risk patients from trials. For example, patients presenting with STE-
MI (high risk p ti ts) were less likely to be enrolled in clinical trials: 37% of the non-participants had 
a STEMI ver us 29% of the trial participants. Another explanation, as we demonstrated previously in a 
subset of these patients, is that critically-ill patients are not able to provide informed consent, whereas 
physicians tend to avoid including a patient with high risk of adverse effects 4. Secondly, in patients who 
survived the first month, excluding acute treatment effects, we also observed a higher mortality in the 
non-participants. This may be due to the fact that trial participants, in the years following the index-
procedure, are subjected to strict adherence to the carefully developed protocol and extra visits to 
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the outpatient clinic. Third, as Within this study we observed a significant difference in subsequent PCI 
procedures between trial participants and non-participants, whereas CABG and non-fatal MI did not 
differ between the two groups. Univariate as well as multivariate analysis revealed that almost twice 
as many trial-participants underwent repeat PCI within 1 year after the initial PCI. Importantly, in the 
vast majority of trial-participants a follow-up angiography was mandated by the study protocol. This 
observation is in line with others who reported increased repeat PCI in patients who undergo routine 
follow-up angiography 14, 15. In addition, Uchida et al. demonstrated that the majority of those patients 
were treated for intermediate non-ischemic lesions. Importantly, no survival benefit was observed in 
patients undergoing angiographic follow-up as compared to clinical follow-up alone (e.g. repeat angiog-
raphy limited to symptomatic patients only) 16.
Conducting clinical research is an important part of clinical practice in an academic hospital and essen-
tial to the further improvement of pharmacological therapies, diagnostics, and interventional devices in 
the management of patients with CAD. However, trial participation might also be regarded as burden-
some for participants and potentially hazardous as the effect of an experimental treatment has not 
always been proven effective in the population of interest. In contrast, trial participation also includes 
access to novel and potentially better treatment with an increased focus on standard treatment, co-
morbid conditions and events as dictated by the protocol and comprehensive case record forms 8. In 
addition to this, it is important to note that scientific concerns and ethical dilemmas regarding a clini-
cal trial are judged and approved by an institutional review board 3. Moreover, the evaluation of the 
scientific design and assurance of safeguards for the protection of patients, and the patients’ autonomy 
in making a decision to participate are essential parts of the review process.
The present study has several limitations. The presented results are based on a single centre experi-
ence, which limits the external validity. Nevertheless, the Thoraxcenter Rotterdam can be considered 
representative for larger tertiary referring and teaching (academic) hospitals in Western populations. 
Second, for the follow-up of non-fatal endpoints we were dependent on the patient’s response of 
health questionnaires that were systematically sent to all living patients, with specific inquiries on rehos-
pitalisation and major adverse cardiac events. Thus, we might have missed some non-fatal endpoints, 
particularly those that did not result in hospital admissions. Possibly, more effort was undertaken in 
trial participants to collect these data, which may partially explain the higher rate of rePCI in trial 
participants. Third, it is impossible to study the effects of trial-participation in a randomized controlled 
trial, which is the gold standard to evaluate treatment efficacy and safety. However, we studied a large 
population over a long period (10 years) of time in which many trials were performed at our centre. 
Non-participants represent a heterogeneous group of patients, i.e.: patients who did not meet the 
study criteria, patients who refused to participate and patients who were unable to provide informed 
consent. Unfortunately, we did not systematically collect the reasons of non-participation in all studies. 
Therefore, we were unable to perform a stratified analysis based on the reasons for non-participa-
tion.
Conclusion
The current study showed that participants of PCI trials differed considerably in clinical and proce-
dural characteristics from non-participants. Trial-participants had a better survival but a two-fold higher 
incidence of repeat PCI as compared to non-participants. The higher incidence of the composite of 
mortality, repeat revascularization, and non-fatal MI in the trial-participants was primarily driven by the 
occurrence of repeat PCI. These results illustrate that clinical trials do not fully reflect every day clinical 
practice.
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RELATION OF GENETIC PROFILE AND NOVEL CIRCULATING BIOMARKERS WITH 
CORONARY PLAQUE PHENOTYPE AS DETERMINED BY INTRAVASCULAR ULTRASOUND: 
RATIONALE AND DESIGN OF THE ATHEROREMO-IVUS STUDY
ABSTRACT
Aims
The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis 
– Intravascular Ultrasound (ATHEROREMO-IVUS) study aims to investigate the relations of genetic 
profile and novel circulating biomarkers with coronary plaque phenotype and vulnerability as deter-
mined by intravascular ultrasound (IVUS) 
Methods and results: ATHEROREMO-IVUS is a prospective, observational cohort study of 846 pa-
tients with stable angina pectoris or acute coronary syndrome (ACS) who are referred for coronary 
angiography. Prior to the catheterization procedure, blood samples are drawn for biomarker measure-
ments and genetic analyses. During the catheterization procedure, IVUS is performed in a non-culprit 
coronary artery. The primary endpoint is the presence of vulnerable plaque as determined by IVUS 
virtual histology. Secondary endpoints include the incidence of major adverse cardiac events during 
long-term follow-up.
Expected results: Results from ATHEROREMO-IVUS are expected to improve our knowledge on the 
role of genetic profile and circulating biomarkers in relation to the development of atherosclerosis and 
vulnerable plaques. Assessment and early validation of the prognostic value of novel biomarkers and 
intracoronary imaging techniques will be performed. (Clinicaltrials.gov number: NCT01789411) 
INTRODUCTION
Coronary artery disease is projected to become the largest single cause of disease-burden world-
wide.1 The traditional view that atherosclerosis is simply a lipid storage disease has been evolved, 
considering the growing body of evidence that genetic profile, inflammation and blood coagulation 
play a pivotal role in all stages of atherosclerotic disease, from endothelial dysfunction to late-stage 
plaque rupture.2-5 Genetic markers and circulating biomarkers of inflammation, lipids and coagulation 
may potentially improve risk stratification in patients with atherosclerotic cardiovascular disease, since 
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they provide information on the biological processes in individuals.6-7 Furthermore, these markers may 
also have a role in the development of new therapeutical targets. Genome wide scanning of single 
nucleotide polymorphisms (SNPs) and plasma lipidomics are two potential methods to identify novel 
genetic and lipid-related markers of coronary artery disease. In-vivo intracoronary imaging may fur-
ther improve coronary risk stratification. Intravascular ultrasound (IVUS) backscattering analysis allows 
for in-vivo differentiation of various plaque phenotypes and may therefore be well suited for detection 
of plaques that are at high risk to rupture.8-9 
The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis 
- Intravascular Ultrasound (ATHEROREMO-IVUS) is designed as an exploratory (non-pivotal) clini-
cal study to investigate the associations between genetic profile, circulating biomarkers and coronary 
atherosclerosis phenotype and vulnerability as determined by IVUS virtual histology Additionally, novel 
intracoronary imaging techniques, including near-infrared spectroscopy (NIRS), will be explored to 
identify lipid core plaques in the coronary arterial wall.10 Finally, the prognostic implications of (the 
combination) of established and novel biomarkers and plaque phenotypes will be studied. 
METHODS
Target population
The ATHEROREMO-IVUS target population consists of patients with stable angina pectoris or acute 
coronary syndrome (ACS) who are referred for coronary angiography. The in- and exclusion criteria 
are presented in table 1. Stable angina pectoris was defined as having at least two of the following 
three criteria: 1. substernal chest discomfort of characteristic quality and duration; 2. provoked by 
exertion or emotional stress; 3. relieved by rest and/or glyceryl trinitrate.11 ACS include ST-segment 
elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) or 
unstable angina pectoris. STEMI was defined by ischaemic symptoms, persistent (>20 min) ST-segment 
elevation in two contiguous electrocardiogram (ECG) leads and a raise in cardiac enzymes.12 Patients 
with acute chest pain and a typical raise and fall in cardiac enzymes but without persistent ST-segment 
elevation were classified as NSTEMI. Unstable angina was defined by acute or worsened chest pain 
without persistent ST-segment elevation and without elevated cardiac enzymes.13 
Study sample
The ATHEROREMO-IVUS study cohort mainly consists of patients who were included between 2008 
and 2011 in the Erasmus MC, Rotterdam, the Netherlands, which is an academic tertiary referral hos-
pital serving a population of approximately 1.9 million. This cohort was enriched with eligible patients 
who participated in the Integrated Biomarker and Imaging Study-2 (IBIS-2) trial of darapladib versus 
placebo (inclusion period 2005-2006).14 
The ATHEROREMO-IVUS study was approved by the medical ethics committee of the Erasmus MC. 
The study was performed in accordance with the criteria described in the declaration of Helsinki. Writ-
ten informed consent was obtained from all included patients.
Blood sampling
Blood samples were collected to enable genome wide scans, lipid mass spectrometry and the analysis 
of circulating biomarkers. Blood samples were drawn from the arterial sheath prior to the coronary 
angiography or percutaneous coronary intervention (PCI) procedure. Blood samples were transport-
ed to the local clinical chemistry laboratory for further processing (i.e. centrifugation followed by se-
rum, citrate- and EDTA-plasma aspiration and buffy coat separation from the EDTA tube) and storage 
at a temperature of -80oC within two hours.  
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Genome wide scans
Genome wide scans are preformed to identify a set of genetic variants that correlate with the extent 
and phenotype of coronary atherosclerosis. The Affymetrix GeneChip Human Mapping 6.0 Array is 
used for the genome wide scans of 906,.600 SNPs. Quality control was performed, including correc-
tion for population structure, removal of related samples or samples with mismatched gender.  
Lipid extraction and mass spectrometry
An aliquot of plasma or serum is subjected to lipid extraction. Known amounts of internal standards 
are added to the samples before extraction and the final lipid extracts are dried under nitrogen. The 
extracts are reconstituted as described elsewhere.15  Sphingolipids are analyzed on a 4000 QTRAP 
mass spectrometer (Applied Biosystems/MDS Analytical Technologies) equipped with an ultra-high 
pressure liquid chromatography (UHPLC) system; CTC PAL autosampler (Leap Technologies) and 
Rheos Allegro UHPLC (Flux Instruments) using multiple reaction monitoring.16 Shotgun lipidomics is 
performed by multiple precursor ion and neutral loss scanning on a QTRAP® 5500 mass spectrom-
eter (Applied Biosystems/MDS Analytical Technologies) equipped with a robotic nanoflow ion source 
Table 1. Inclusion and exclusio  criteria 
 
Inclusion criteria: 
1. Aged 21 years or older. 
2. Presenting with stable angina pectoris (CCS angina class 1, 2, 3 or 4), unstable angina pectoris 
(Braunwald class 1-3, B-C), documented silent ischemia or acute myocardial infarction (STEMI and 
NSTEMI). 
3. Eligible for coronary revascularization in the native coronary artery/arteries. 
4. Willing and able to comply with the specified follow-up evaluation. 
5. Willing to sign informed consent. 
6. Presence of a flow-limiting stenosis (diameter stenosis !50% by QCA or visual estimate) that is held 
responsible for angina pectoris or acute coronary syndrome 
7. The study vessel has not undergone percutaneous coronary intervention in the last 8 months.  
 
Exclusion criteria: 
1. Angina caused by a non-cardiac illness (Braunwald class IA, IIA, IIIA). 
2. Pregnant women or women of childbearing potential who do not use adequate contraception. 
3. Known allergies to aspirin, clopidogrel, ticlopdine, heparin, stainless steel, copper or a sensitivity to 
contrast media which cannot be adequately pre-medicated. 
4. Previous participation in this study or participation in another study with any investigational drug or 
device within the past 30 days (study participation ends after completion of the final follow-up). 
5. Life expectancy of less than one year or factors making clinical and/or angiographic follow-up difficult. 
6. Planned or being status post coronary bypass surgery. 
7. Planned major non-cardiac surgery. 
8. Impaired renal function (creatinine>2 mg/dl or !150 µmol/l). 
9. History of bleeding diathesis or coagulopathy. 
10. History of disabling stroke within the past year. 
 
Exclusion criteria for intravascular ultrasound and near-infrared spectroscopy: 
11. Three-vessel coronary artery disease or left main disease with !50% stenosis. 
12. Minimal lumen diameter <2mm in the segments to be analyzed within the study vessel. 
13. Diameter stenosis >70% or total occlusion of the study vessel. 
14. In case the study-vessel has been stented previously (>8 months ago), more than 1/3 proximal of the 
study vessel (at least 40mm in length) should be available for examination (i.e. outside the length of 
the stent plus 5mm proximal to the stent). 
15. Poor left ventricular function as assessed by echocardiography or by angiography. 
16. Moderate or severe tortuosity of the study segment (i.e. 2 bends >75° or one bend > 90°). 
17. Known tendency for coronary vasospasm.   
 
CCS: Canadian Cardiovascular Society; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: 
ST-segment elevation myocardial infarction; QCA: quantitative coronary angiography. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Inclusion and exclusion citeria
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NanoMate HD (Advion).17 Mass spectrometry data files are processed using MultiQuant™ 1.1.0.26 or 
Lipid Profiler™ (Applied Biosystems/MDS Analytical Technologies).18 Identified lipids are quantified by 
normalizing against their respective internal standard and tissue wet weight for aorta and volume for 
plasma. Quality control (QC) samples are utilized to monitor the overall quality of the lipid extraction 
and mass spectrometry analyses.19 The QC samples are mainly used to remove technical outliers and 
lipid species that are detected below the lipid class based lower limit of quantification (LLOQ).
Intravascular imaging
Following the standard coronary angiography, eligibility for intracoronary imaging was assessed. IVUS 
data was acquired in a non-culprit coronary vessel. The order of preference for selection of the non-
culprit vessel was: 1. left anterior descending (LAD) artery; 2. right coronary artery (RCA); 3. left cir-
cumflex (LCX) artery. All IVUS data were acquired with the Volcano s5/s5i Imaging System (Volcano 
Corp., San Diego, CA, USA) using a Volcano Eagle Eye Gold IVUS catheter (20 MHz). An automatic 
pullback system was used with a standard pull back speed of 0.5 mm per second. 
A number of selected patients in the Erasmus MC also participated in the ATHEROREMO-NIRS sub-
study (details are described in the online supplement). In these patients, NIRS was performed in the 
same segment of the non-culprit vessel. 
IVUS virtual histology
The IVUS gray-scale and IVUS radiofrequency backscatter analyses, also known as IVUS virtual histol-
ogy, were performed using pcVH 2.1 and qVH (Volcano Corp., San Diego, CA, USA) software. The 
baseline IVUS images were analyzed offline in an independent core laboratory (Cardialysis BV, Rotter-
dam, the Netherlands). The core laboratory personnel were blinded for baseline patient characteristics 
as well as for biomarker, genetic and clinical outcomes data. The external elastic membrane and luminal 
borders were contoured for each frame (median interslice distance, 0.40 mm). Extent and phenotype 
of the atherosclerotic plaque were assessed. Plaque burden was defined as the plaque and media 
cross-sectional area divided by the external elastic membrane cross-sectional area. A coronary lesion 
was defined as a segment with a plaque burden of more than 40% in at least 3 consecutive frames 
(Figure 1). Using IVUS radiofrequency analyses, the composition of the atherosclerotic plaque was 
characterized into 4 different tissue types: fibrous, fibro-fatty, dense calcium and necrotic core.8 In con-
sensus sessions with three investigators who were blinded to the patient characteristics and outcomes, 
the lesions were further classified into different lesion types (Table 2).9 A thin-cap fibroatheroma 
(TCFA) lesion was defined as a lesion with presence of >10% confluent necrotic core in direct contact 
with the lumen. Remodeling of a lesion was assessed by means of the remodelling index, expressed as 
the external elastic membrane cross-sectional area at the site of minimal luminal area divided by the 
reference external elastic membrane cross-sectional area. The reference site was selected <10 mm 
proximal to the lesion, with no major side branches between the site of the minimal luminal area and 
the reference.
Follow-up
Clinical follow-up started at inclusion and will last for at least 1 year. Post-discharge survival status will 
be obtained from municipal civil registries. Post-discharge rehospitalizations will be prospectively as-
sessed during follow-up. Questionnaires focusing on the occurrence of major adverse cardiac events 
(MACE) will be sent to all living patients. Treating physicians and institutions will be contacted for ad-
ditional information whenever necessary. If possible and clinically relevant, culprit and non-culprit lesion 
related events will be distinguished. The occurrence of MACE will be adjudicated by an independent 
clinical events committee on the basis of original source data and without knowledge of other patient, 
biomarker, genetic or intracoronary imaging characteristics.
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Study endpoints
The primary objective of ATHEROREMO-IVUS is to correlate genetic markers and circulating (lipid) 
biomarkers with coronary plaque phenotype as determined by IVUS virtual histology. Therefore, the 
primary endpoint is defined as the presence of TCFA lesions on the imaged non-culprit coronary 
segment. 
 
 
Table 2. Classification of lesions on intravascular ultrasound 
  
Lesion Type Definition 
  
1. Adaptive intimal thickening Intimal thickening of <600 µm for <20% of the circumference 
2. Pathological intimal thickening Intimal thickening !600 µm for >20% of the circumference 
with >15% fibrofatty tissue and no confluent necrotic core or 
dense-calcium 
3. Fibrotic plaque Lesion consisting predominantly of fibrous tissue without 
confluent necrotic core or dense-calcium 
4. Fibrocalcific plaque Presence of >10% confluent dense-calcium without 
confluent necrotic core 
5. Fibroatheroma Presence of >10% confluent necrotic core with an overlying 
layer of fibrous tissue 
6. Calcified fibroatheroma Fibroatheroma containing >10% confluent dense-calcium 
7. Thin-cap fibroatheroma Presence of >10% confluent necrotic core in direct contact 
with the lumen 
8. Calcified thin-cap fibroatheroma Thin-cap fibroatheroma containing >10% of confluent dense-
calcium 
  
 
Figure 1 Methodology for detection of lesion and reference segments
 MLA: minimal luminal area; REF: reference segments; ROI: region of interest. 
Table 2 Classification of lesions on intravascular ultrasound
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The secondary objective is to assess the prognostic value of established biomarkers,  novel genetic and 
lipid biomarkers and plaque phenotypes as determined by IVUS virtual histology. Therefore, the sec-
ondary endpoint is defined as the 1-year incidence of MACE, which includes all-cause mortality, ACS 
or unplanned coronary revascularization. All-cause mortality is defined as death due to any cause.20 
ACS was defined as the clinical diagnosis of STEMI, NSTEMI or unstable angina pectoris in accordance 
with the guidelines of the European Society of Cardiology.21 Unplanned coronary revascularization 
was defined as unplanned repeat PCI or coronary artery bypass grafting (CABG) due to progressive 
angina or ACS. 
Sample size
ATHEROREMO-IVUS is designed to explore multiple relations. Its sample size is fixed at  800 patients, 
which is sufficient to reveal relations between ‘abnormal’ biomarkers (of any kind) and the presence 
of TCFA lesions with reasonable statistical certainty. We acknowledge that confirmatory studies might 
be required to more firmly establish relations that we will discover. 
Based on prior studies, we expected that 30% of the patients will have a TCFA lesion in at least one 
coronary artery (i.e. TCFA positive), while 70% of the patients will not have any TCFA lesion (i.e. true 
TCFA negative) (Figure 2).9 Since TCFA lesions are more or less randomly distributed across the coro-
nary system, we expected that 10% of the patients will have a TCFA lesion in the imaged coronary 
artery (i.e. classified as TCFA positive), while 90% of the patient will not have a TCFA lesion in the im-
aged coronary artery (i.e. classified as TCFA negative). In patients who are classified as TCFA negative, 
77.8% is expected to be true TCFA negative.   
A biomarker level in the upper quintile of its sample distribution is considered as ‘abnormal’. We 
expect to observe abnormal biomarker levels in 5-15% of the true TCFA negative patients and in 10-
40% of the TCFA positive patients. Hence, the proportion of abnormal biomarker levels in the patients 
who are classified as TCFA negative are expected to range from 6.1-20.6% (Table 3). Table 4 presents 
the statistical power to detect differences in the frequency of abnormal biomarker levels between 
patients who are classified as TCFA negative versus those who are classified as TCFA positive (α-error 
Figure 2 Expected prevalence of thin-cap fibroatheroma lesions
 TCFA: thin-cap fibroatheroma. 
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5%, two-sided test). The power is adequate (≥80%) for the most realistic scenarios. 
Power calculations were not performed for the secondary endpoint. Based on the results of other 
studies and previous registries in our hospital, we expect that MACE will occur in 5-10% of the patients 
within the first year of follow-up.22-25  
Statistical analyses
Conventional linear regression will be applied to relate SNPs, sphingolipids and other biomarkers with 
IVUS virtual histology measures, corrected for segment length. Mixed linear models will be used for 
per-lesion analyses. The relation between biomarkers (in a broad sense) and clinical endpoints will be 
studied by Cox proportional hazard models. 
The p-values that appear in the analyses of genetic variants and sphingolipids will be corrected for 
multiple testing with appropriate methods to adjust for inflation of the type I error (e.g. Bonferroni or 
simulation). Significant SNPs and lipid fractions need (and will be proposed for) validation in different 
datasets.
Table 3 Expected percentage of patients with abnormal biomakers levels. 
Table 3. Expected percentage of patients with abnormal biomarker levels 
 
   Frequency of abnormal biomarker levels in true TCFA negative patients 
   5% 7.5% 10% 12.5% 15% 
        
Frequency of 
abnormal 
biomarker 
levels in TCFA 
positive 
patients  
10%  6.1% 6.9% -- -- -- 
15%  7.2% 9.2% 11.1% 13.1% -- 
20%  8.3% 10.3% 12.2% 14.2% 16.1% 
25%  9.4% 11.4% 13.3% 15.3% 17.2% 
30%  10.6% 12.5% 14.4% 16.4% 18.3% 
40%  12.8% 14.7% 16.7% 18.6% 20.6% 
 
Presented data is the expected percentage of patients with abnormal biomarker levels in those who did not 
have a TCFA in the imaged coronary artery (i.e. classified as TCFA negative). The results are displayed for 
different expected frequencies of abnormal biomarker levels in patients who have a TCFA in the imaged 
coronary vessel (i.e. TCFA positive) and for different expected frequencies of abnormal biomarker levels in 
patients who do not have any TCFA in any coronary vessel (i.e. true TCFA negative).        
TCFA: thin-cap fibroatheroma. 
 
 
 
 
 
 
Table 4. Expected statistical power 
   Frequency of abnormal biomarker levels in true TCFA negative patients 
   5% 7.5% 10% 12.5% 15% 
        
Frequency of 
abnormal 
biomarker 
levels in TCFA 
positive 
patients 
10%  18% 12% -- -- -- 
15%  47% 26% 12% 5% -- 
20%  73% 54% 35% 20% 10% 
25%  88% 76% 61% 44% 29% 
30%  96% 90% 81% 68% 54% 
40%  100% 99% 98% 95% 89% 
 
Presented data is the statistical power to detect differences in the frequency of abnormal biomarker levels 
between patients with a TCFA in the imaged coronary vessel (i.e. TCFA positive) versus patients without a 
TCFA in the imaged coronary vessel (i.e. classified as TCFA negative) (α-error 5%, two-sided test). The 
results are displayed for different expected frequencies of abnormal biomarker levels in TCFA positive 
patients and for different expected frequencies of abnormal biomarker levels in patients who do not have a 
TCFA in any coronary vessel (true TCFA negative). The statistical power is adequate for the most realistic 
scenarios (grey shaded area). 
TCFA: thin-cap fibroatheroma. 
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Actual inclusion 
A total of 846 patients with complete data for genetic and lipidomics analyses are included in ATHER-
OREMO-IVUS: 581 patients were enrolled in the Erasmus MC and 265 participated in IBIS-2 (Figure 
3).14 Blood samples are available for 1098 patients. NIRS was performed in 203 patients.    
DISCUSSION
The ATHEROREMO-IVUS study was primarily designed to assess correlations of genetic profile and 
novel circulating biomarkers with the extent, phenotype and vulnerability of coronary atherosclerotic 
plaques as determined in-vivo by IVUS. Furthermore we would like to assess the potential prognostic 
value of novel biomarkers, IVUS and NIRS compositional features of atherosclerotic plaques in major 
cardiac events at long term follow-up. 
Acute coronary syndromes are mostly caused by rupture of TCFA lesions that contain a lipid-rich ne-
crotic core covered by a thin fibrous cap.2, 26-29 IVUS virtual histology may be suitable for the detection 
of such  vulnerable plaques. The PROSPECT study has shown that TCFA lesions as identified in-vivo 
by IVUS virtual histology were associated with increased risk for recurrent cardiovascular events in 
ACS patients. However, the events in PROSPECT were mainly driven by rehospitalizations for unstable 
or progressive angina, while less is known about the prognostic value of IVUS virtual histology for 
acute cardiac events as a consequence of spontaneous plaque rupture (i.e. recurrent ACS or death). 
The prognostic value of IVUS virtual histology in patients with stable angina remains unclear as well. 
Furthermore, the prognostic value of NIRS for the occurrence of MACE has not yet been investigated. 
The results of the ATHEROREMO-IVUS study will provide data on these questions.
Coronary artery disease has a strong genetic component. Epidemiological studies suggest that up to 
Figure 3 Actual patient inclusion
Finally, blood samples were stored for 1098 patients, IVUS of a non-culprit vessel was per-
formed in 846 patients (red shaded) and NIRS was performed in 203 patients. 
IBIS-2: Integrated Biomarker and Imaging Study-2; IVUS: intravascular ultrasound; NIRS: near-
infrared spectroscopy.
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50% of its susceptibility is heritable30. Genome wide scans may measure hundreds of thousands of 
SNPs that can be tested for an association with a coronary atherosclerosis. Although this method is 
shown to be successful in identifying genetic associations with complex traits,31 genotyping research 
programs for atherosclerosis have been of limited importance so far. One of the bottlenecks was 
the phenotypic complexity of atherosclerotic vascular diseases. The ATHEROREMO-IVUS study is 
therefore regarded as a unique opportunity to link genotypes with extensive intracoronary imaging 
data that reach far beyond the limited knowledge of luminal patency (or stenosis) from conventional 
coronary angiography. 
Several biomarkers of inflammation, coagulation, myocardial necrosis and neurohumoral activation 
(e.g. C-reactive protein, high-sensitive troponin-T and natriuretic peptides) have more or less been 
established.27 Our aim is to explore novel lipid biomarkers in first instance, while validation of more 
established biomarkers will be done in a later stage of the study.
The design of the ATHEROREMO-IVUS study has several strengths. To our best knowledge, this is 
the first (large-scale) study to combine several novel intracoronary imaging techniques with extensive 
genetic analyses, biomarker exploration and validation and adverse clinical outcome during follow-up. 
Secondly, in this study we examine a single non-culprit vessel. Ex vivo as well as in vivo studies using 
IVUS in patients with myocardial infarction have demonstrated the presence of  TCFAs in other than 
the culprit lesion or even culprit artery.5 Our approach will allow us to test the hypothesis that the 
phenotype of a non-culprit artery segment (indicating the patient’s atherosclerotic disease burden) 
can be linked to biomarker, genetic and outcome data. If the imaging characteristics of the non-culprit 
artery appear to be related to the incidence of MACE, then this can be seen as a confirmation that the 
non-culprit artery reflects atherosclerotic disease burden of the larger coronary vasculature. 
Some limitations of this study have to be acknowledged. Firstly, the genetic profile and biomarkers will 
be correlated with the phenotype of the imaged non-culprit coronary artery only. Although we expect 
that the presence of TCFA lesions is randomly distributed through the coronary system, we may miss 
the patient’s dominant phenotypic characteristic if this phenotype is only expressed in a coronary 
segment that has not been imaged (e.g. culprit lesion). Secondly, the ATHEROREMO-IVUS study was 
designed to explore and discover new genetic and circulating biomarkers. Newly discovered SNPs and 
lipid biomarkers remain to be validated in another patient cohort. 
The results from the ATHEROREMO-IVUS study will improve our understanding on the role of ge-
netic profile and circulating biomarkers in the development of atherosclerosis and vulnerable plaques. 
Genome wide scans and lipidomics may identify novel biomarkers in coronary artery disease. Further-
more, the prognostic value of novel circulating biomarkers as well as in-vivo detection of vulnerable 
plaques by IVUS virtual histology and NIRS will be assessed. These findings may further contribute to 
improve risk assessment in patients with coronary artery disease, which may be important for the 
optimal choice of treatment in the individual patient.     
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THE EUROPEAN COLLABORATIVE PROJECT ON INFLAMMATION AND VASCULAR WALL 
REMODELING IN ATHEROSCLEROSIS - INTRAVASCULAR ULTRASOUND (ATHEROREMO-
IVUS)
ABSTRACT
Background
The European Collaborative Project on Inflammation and Vascular Wall Remodelling in Atherosclerosis 
- Intravascular Ultrasound (ATHEROREMO-IVUS) study has been designed as an exploratory clinical 
study to investigate the associations between genetic variation, coronary atherosclerosis phenotypes, 
and plaque vulnerability as determined by IVUS.
Methods 
The ATHEROREMO-IVUS study is a prospective, observational study of 846 patients with stable 
angina pectoris or acute coronary syndrome (ACS) who were referred for coronary angiography to 
the Thoraxcenter, Rotterdam. Prior to catheterization, blood samples were drawn for genetic analyses. 
During the catheterization procedure, IVUS was performed in a non-culprit coronary artery. The pri-
mary endpoint was the presence of vulnerable plaque as determined by IVUS virtual histology (VH). 
In addition, we performed a genome wide association study of plaque morphology.
Results
We observed strong signals associated with plaque morphology in several chromosomal regions: 
twelve SNPs (rs17300022, rs6904106, rs17177818, rs2248165, rs2477539, rs16865681, rs2396058, 
rs4753663, rs4082252, rs6932, rs12862206, rs6780676) in or near eight different genes (GNA12, 
NMBR, SFMBT2, CUL3, SESN3, SLC22A25, EFBN2, SEC62) reached significance.
Conclusion
In conclusion, we found twelve SNPS in or in the proximity of eight genes, which were associated with 
markers of vulnerable plaque.
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INTRODUCTION
Despite improved understanding of the pathophysiology of atherosclerosis, the application of novel 
techniques for early diagnosis, and the availability of more powerful pharmacological therapies, coro-
nary artery disease (CAD) remains the leading cause of death in Europe.1 The early view that athero-
sclerosis simply represents increased lipid deposition in the vascular wall has changed, considering the 
growing body of evidence that inflammation plays a central role in atherosclerotic CAD from early 
lesion initiation to late-stage plaque rupture.2-5 Intravascular ultrasound (IVUS) backscattering analysis 
has the potential of in-vivo differentiation of plaque phenotypes, and may therefore be suited for the 
detection of inflammatory, vulnerable coronary plaques.6, 7
Genetic factors play an important role in the aetiology of CAD,8 9 and genetic markers may potentially 
further improve risk stratification. Genetic markers can also be instrumental in the development of 
new therapeutic targets, as they are stable, and can be objectively measured and evaluated as indica-
tors of normal biologic processes, pathogenic processes, or pharmacologic responses to therapeutic 
interventions. Therefore, genome wide association studies in CAD patients are warranted to further 
unravel the complexity of coronary atherosclerosis.10 The European Collaborative Project on Inflam-
mation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound (ATHEROREMO-
IVUS) was designed as an exploratory clinical study to investigate the associations between the genetic 
profile and coronary atherosclerosis phenotype and vulnerability as determined by IVUS.11
METHODS
Patients
Methods of the ATHEROREMO-IVUS study have been described in detail elsewhere.11 
Briefly, the target population consisted of patients aged 21 years or older with stable angina pectoris 
(SAP) or an acute coronary syndrome (ACS) who were referred for coronary angiography (CAG) or 
percutaneous intervention (PCI). Patients had to have at least one non-culprit coronary artery with-
out obstructive disease (<50% diameter stenosis) of at least 40 mm in length as assessed by on-line 
angiography to be used as the study vessel. Consequently, patients with significant three-vessel disease 
were excluded, as were patients with left main disease.
The study cohort mainly consisted of 581 patients who were included between 2008 and 2011 at 
the Erasmus MC, Rotterdam, the Netherlands. This cohort was enriched with 265 eligible patients 
who participated in the Integrated Biomarker and Imaging Study-2 (IBIS-2) trial of darapladib versus 
placebo (inclusion period 2005-2006), with consent of the sponsor.12 Thus, the total sample comprised 
846 patients, slightly more than the anticipated 800.11
The ATHEROREMO-IVUS study was approved by the Medical Ethics Committee of the Erasmus MC, 
performed in accordance to the Declaration of Helsinki (2008, sixth revision) and has been registered 
at the Dutch Central Committee on Research involving Human Subjects under EMC MEC 2008-210 
and at Clinicaltrials.gov under NCT01789411. Written informed consent was obtained from all par-
ticipants.
Phenotyping by intravascular ultrasound
Intravascular ultrasound imaging of the non-culprit study vessel was conducted for coronary plaque 
phenotyping. The IVUS gray-scale and IVUS radiofrequency backscatter analyses, also known as IVUS 
virtual histology (VH), were performed using pcVH 2.1 and qVH (Volcano Corp., San Diego, CA, USA) 
software. IVUS images were analyzed offline in an independent core laboratory (Cardialysis BV, Rotter-
dam, the Netherlands). The core laboratory personnel were blinded for baseline patient characteristics 
as well as for biomarker, genetic and clinical outcomes.
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The external elastic membrane and luminal borders were contoured for each frame (median interslice 
distance, 0.40 mm). Extent and phenotype of the atherosclerotic plaque were assessed. Plaque burden 
was defined as the plaque and media cross-sectional area divided by the external elastic membrane 
cross-sectional area. A coronary lesion was defined as a segment with a plaque burden of more than 
40% in at least 3 consecutive frames. Using IVUS radiofrequency analyses, the composition of the 
atherosclerotic plaque was characterized into 4 different tissue types: fibrous, fibro-fatty, dense calcium 
and necrotic core.6 In consensus sessions with three investigators who were blinded to the patient 
characteristics and outcomes, the lesions were further classified into different lesion types (Table 2).7 
A thin-cap fibroatheroma (TCFA) lesion was defined as a lesion with presence of >10% confluent 
necrotic core in direct contact with the lumen. Remodelling of a lesion was assessed by means of 
the remodelling index, expressed as the external elastic membrane cross-sectional area at the site 
of minimal luminal area divided by the reference external elastic membrane cross-sectional area. The 
reference site was selected <10 mm proximal to the lesion, with no major side branches between the 
site of the minimal luminal area and the reference.
Genotyping
Blood samples were drawn from the arterial sheath prior to the CAG or PCI procedure, which were 
then transported to the clinical chemistry laboratory of the Erasmus MC for further processing and 
Table 1 Patient baseline characteristics
Table 1 Patient baseline characteristics 
 
   
Patient baseline characteristics AtheroRemo (N=718)  
Age, years  61.4 (53.1, 69.9)  
Man, n (%) 558 (77.7)  
Diabetes mellitus, n (%) 109 (15.2)  
Hypertension, n (%) 404/717 (56.3)  
Hypercholesterolemia, n (%) 411/717 (57.3)  
Low density lipoprotein, mmol/l 2.56 (2.00, 3.38)/579  
High density lipoprotein, mmol/l 1.13 (0.95, 1.37)/592  
Total cholesterol, mmol/l 4.5 (3.7, 5.3)/599  
Current smoker, n (%) 219 (30.5)  
Previous MI, n (%) 147/472 (31.1) ¶ 
Previous PCI, n (%) 237 (33.0)  
Previous CABG, n (%) 18/472  (3.8) ¶ 
Previous stroke, n (%) 24/472  (5.1) ¶ 
Peripheral artery disease, n (%) 40 (5.6)  
Presentation with ACS, n (%) 334/711 (47.0)  
Coronary artery disease   
No significant vessel disease, n (%) 142/615 (23.0) ¶ 
 1-vessel disease, n (%)                     315/615 (36.5) ¶ 
 2-vessel disease, n (%) 198/615 (23.0) ¶ 
 3-vessel disease, n (%) 60/615 (7) ¶ 
 
¶ Unavailable for the IBIS-2 patients 
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storage at a temperature of -80°C within two hours. This material was used for the extraction of DNA 
needed for genome wide scanning, as well as for analyses of serum biomarkers. 
Blood samples were transported to the genotyping facility at the Mannheim Medical Faculty, Germany, 
for batch DNA extraction and genotyping. The Affymetrix GeneChip Human Mapping 6.0 Array was 
used for genome wide analysis of 906,600 SNPs.
Quality Control
The dataset was filtered to include only autosomal SNPs with non-complementary alleles and geno-
typing rate >=0.9. PLINK’s Multi Dimensional Scaling (MDS) analysis was performed jointly on the 
study samples and the European samples from the POPRES dataset13. First, the POPRES SNPs were 
pruned to decrease linkage disequilibrium (LD) using PLINK, so that no pair of SNPs with r2 ≥0.8 
remained within sliding windows of 50 SNPs, offset by 5. Additional SNPs or samples with genotyping 
rate ≤0.1 were removed. Next, the study SNP set and the POPRES SNP set were intersected, and 
MDS was performed on the resulting set. 89 outliers (individuals who were located outside of the 
main European cluster in the MDS plot) were detected in this step and discarded from further analysis. 
The results of both the European MDS and a global MDS (using also non-European POPRES samples) 
appear in Supplementary , Figure 1. The first four axes of variation from the European MDS were used 
as covariates in all association tests.
Additional sample filtering and imputation
PLINK’s IBD analysis was performed and 6 samples were removed so as to eliminate any pair with 
estimated proportion of IBD (PLINK’s PI_HAT) greater than 0.1875. In addition, following PLINK’s 
heterozygosity analysis 17 samples with outlier inbreeding factor (< -0.15 or > 0.1) were removed. 
The genotypes used for imputation were filtered to exclude SNPs with genotyping rate ≤0.04 or mi-
nor allele frequency ≤0.0125. Imputation was performed with the 1000 genomes European reference 
panel14 using BEAGLE version 3.3.2.15 Prior to that, strand consistency between the two datasets was 
verified using BEAGLE’s strand-checking utility.
Figure 1 Flowchart
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Association
Samples whose reported sex did not match the sex detected by PLINK 15 were removed to yield a 
final sample size of 719 individuals, figure 1. SNPs with minor allele frequency ≤10/719 = 0.0139 were 
discarded.
We used 28 IVUS measurements as phenotypes: 14 quantities describe the vascular segment that 
was analysed, and 14 quantities described the lesions detected in that segment, up to 4 lesions per 
individual. For each such phenotype, individuals with missing measurements or outliers (distant from 
the mean by over 3 standard deviations) were excluded. Phenotypes representing length or tissue 
percentages were square root-transformed. Phenotypes corresponding to volumes where cubic-root 
transformed, and divided by the vascular segment length.
Linear and logistic regression models assuming an additive genetic model were used for testing associa-
tion between SNPs and quantitative and categorical phenotypes, respectively. Each model included, in 
addition to the SNP and the phenotype, the following covariates: site (Erasmus MC/IBIS-2), sex, age, 
body mass index (BMI), segment length, and the sample’s coordinates along the first 4 MDS axes. Miss-
ing BMI values were imputed by the sex-specific median sample BMI.
In addition to the basic SNP vs phenotype association tests, we examined the extended models, which 
included an interaction effect between SNPs and sex. We used two degrees of freedom test for the 
combined marginal and interaction effects. An alpha error of 5.0e-07 was considered significant in this 
genome-wide association study.  
Treating special phenotypes
In order to increase the statistical power for the lesion-specific phenotypes, we employed two different 
strategies. The first approach involved considering as a phenotype the weighted average of multiple 
lesions in each individual. We used 1, 1.5, 2 and 3 as the weights for lesions 1, 2, 3 and 4, respectively. 
The second approach was to duplicate individuals with multiple discovered lesions, ending up with one 
lesion per individual. To account for the strong relatedness introduced by this step, we tested associa-
tion with this phenotype using EMMAX,16 which uses a mixed model that corrects for relatedness.
Association with lesion type was tested by dividing the lesions into two categories: The benign cat-
egory included adaptive intimal thickening, pathological intimal thickening, fibrous and fibrocalcific, 
and the severe category included fibroatheroma, calcified fibroatheroma, TCFA and calcified thin cap 
fibroatheroma.
Demographics
Continuous variables are presented as arithmetic mean values and corresponding standard deviations 
(± SD), or medians together with corresponding interquartile ranges (IQR). Categorical variables 
are expressed as numbers and percentages. All demographic data were analyzed with SPSS software 
(SPSS 20.0; IBM Corp., Armonk, NY). 
LURIC and CARDIoGRAM
Additionally, we studied within the LURIC and CARDIoGRAM dataset the association between the 
SNPs we found and different phenotypes, biomarkers, and outcome. LURIC is a prospective, hospital-
based study in 3316 patients of German ancestry who underwent coronary angiography. Patients 
were recruited between July 1997 and January 2000 at a single tertiary care centre in southwestern 
Germany (Herzzentrum Ludwigshafen). Inclusion criteria were as follows: Caucasian origin, availability 
of a coronary angiogram and clinical stability with the exception of acute coronary syndromes. Exclu-
sion criteria were: any acute illness other than acute coronary syndromes, any chronic disease where 
non-cardiac disease predominated and a history of malignancy within the past five years. All partici-
pants underwent comprehensive assessment of cardiovascular and metabolic phenotypes. A ten years 
follow up for mortality and causes of death has been completed. 17 CARDIoGRAM combines data 
from all published and several unpublished GWAS in individuals with European ancestry, and include 
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22,000 cases with CAD, MI, or both. 18
RESULTS
Patient characteristics
Baseline and procedural characteristics of the included patients are presented in Tables 1 and 2. The 
population consisted mostly of men (78%) and the mean age was 61 years. Most patients were treated 
for stable angina pectoris (53%), but prior MI (31%) and prior PCI (33%) were common. Hypercho-
lesterolemia, multi-vessel disease and/or hypertension were seen in more than 50% of patients. More 
than 15% of the patients suffered from diabetes mellitus. The median total cholesterol concentration 
was 4.5 (IQR 3.7-5.3) mmol/l; low-density lipoprotein (LDL) cholesterol was 2.6 (2.0-3.4) mmol/l, and 
high-density lipoprotein (HDL) cholesterol was 1.1 (1.0-1.4) mmol/l. The mean length of the studied 
segment was 45.3 mm, with a mean plaque burden of 40.6%. On average, the plaques consisted mostly 
of fibrotic tissue (59%), and 19% had a necrotic core. The number of lesions, given as a ratio per patient, 
was 1.14; 32% of them were TCFA’s. 
GWAS analysis of vulnerable plaque
Multiple genomic locations were shown to be potentially associated with vulnerable plaque (Figure 2). 
We observed strong association signals in several chromosomal regions: twelve SNPs in or near eight 
different genes reached significance (table 3).  
Rs17300022 in the GNA12 gene was significantly associated with fibrotic volume of the vulnerable 
plaque, p=8.61E-08.  The SNP rs6780676 on chromosome 3 was associated with the percentage 
Table 2 Study segment characteristics 
 
 
 
 
¶ Data on lesion level 
 
!
!
!
!
Study segment characteristics AtheroRemo (N=718)  
Length, mm 45.3 (35, 56.9) /687  
Lumen volume, mm3 352.5 (243.3, 508.2) /687  
Vessel volume, mm3 604.8 (427.9, 839.3) /687  
Plaque volume, mm3 242.5 (155.3, 347.4) /687  
Plaque burden, % 40.6 (32, 47.1) /687  
Fibrotic tissue volume, mm3 61.5 (32.6, 105.3) /705  
Fibro-fatty tissue volume, mm3 11.7 (5.1, 24.7) /705  
Necrotic core volume, mm3 19.4 (7.6, 35.4) /705  
Dense calcium volume, mm3 8.8 (2.7, 18.6) /705  
Fibrotic tissue percentage, % 58.7 (51.7, 65.3) /701  
Fibro-fatty tissue percentage, % 11.3 (7.4, 17.1) /701  
Necrotic core percentage, % 18.7 (12.8, 24.2) /701  
Dense calcium percentage, % 8.2 (4.4, 13.5) /701  
Number of lesions, n (ratio per patient) 820 (1.14)  
TCFA lesion, n (%) 264/820 (32.2%) ¶ 
Lesion remodeling 0.95 (0.81, 1.02) /819 ¶ 
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of dense calcium within the plaque, p=8.43E-08. A gene in the proximity of rs6780676 is SEC62 at 
a distance 7kb, SEC 62is part of the protein translocation apparatus in the membrane of the endo-
plasmic reticulum, and has been linked to prostate and lung cancer19. The rs6904106 and rs17177818 
were associated with the percentage fibrofatty material within the vulnerable plaque, and are in the 
proximity (530kb) of the NMBR gene. NMBR gene, a Neuromedin B receptor binds to neuromedin 
B protein, and is involved in a number of physiological processes including immune defence, thyroid, 
adrenocortical function and cognition. NMB is also aberrantly expressed by a variety of cancers and is 
involved in tumour proliferation.20
Associated with dense calcium percentage of the plaque are rs2248165 and rs2477539, which are 
in the proximity (46kb) of the SFMBT2 (Scm-like with four mbt domains 2) gene, which is a protein-
coding gene and has been linked to prostate cancer21 and placental development.22 Rs16865681 and 
rs2396058 are linked to volume of fibrofatty material of the plaque, and are close to the CUL3 gene, 
which encodes a member of the cullin protein family. Rs4753663 and rs4082252 are associated with 
the percentage of fibrofatty material of the plaque and are in close proximity of the SESN3 gene. 
This gene encodes for a member of the sestrin family of stress-induced proteins. Rs6932 is associated 
with remodelling and in closeness of the SLC22A25gene, which encodes for the Solute carrier family 
22 member 25 protein, SLC22A25 is also known as organic anion transporter UST6. Rs12862206 is 
associated with the volume of fibrofatty material of the plaque and is in the proximity of the EFBN2 
gene, which encodes for the Ephrin-B2 protein.
Figure 2 Association between multiple genomic with vulnerable plaque
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LURIC 
We studied within the LURIC dataset the association between the SNPs we found and clinical, bio-
markers, and outcomes. Several associations with significant p-values were found, however after Bon-
ferroni correction, all were attenuated and p-values became non-significant, Supplementary Table 1.
CARDIOGRAM
Using the Cardiogram18 dataset we studied the association between the identified SNPs and MI as 
well as CAD. We found a significant association between rs4082252 (OR 1,05- lnSE 0.02, p=0.0009), 
rs475366 (OR 0.96- lnSE 0.02, p=0.012) and MI/ CAD, Supplementary table 2.
eQTL and HaploReg
We searched the Genotype-Tissue Expression (GTEx) project 23  and HaploReg 24 for an association 
of our SNPs with the expression of nearby genes or the alteration of regulatory sequences. While 
we did not find any direct association with gene expression, a number of SNPs could alter regulatory 
motifs (Supplementary Table 3).
DISCUSSION
We performed an exploratory clinical study to investigate the associations between genetic profile 
and coronary atherosclerosis phenotype and vulnerability as determined by IVUS 11, in a cohort of 
719 patients. We found a strong association between indicators of vulnerable plaque and twelve SNPS, 
in or near 8 different genes.
We further studied these SNPs in the LURIC dataset, and found several significant associations, which 
however, after Bonferroni correction, lost statistical significance. Therefore we decided to further ex-
plore our results in the CARDIoGRAM dataset, in which we found additionally three significant asso-
ciations between SNPs and CAD/MI; these 3 SNPS encode for 2 genes, namely GNA12 and SESN3.
The GNA12 gene was significantly associated with the vulnerable plaque (dense calcium) and CAD/
MI. The GNA12 gene encodes for the Guanine nucleotide-binding protein subunit alpha-12 proteins, 
which are involved as modulators or transducers in various transmembrane signalling systems, and may 
play a role in the control of cell migration through the TOR signalling cascade25.  
The SESN3 gene encodes for a member of the sestrin family of stress-induced proteins. The encoded 
protein reduces the levels of intracellular reactive oxygen species induced by activated Ras down-
stream of RAC-alpha serine/threonine-protein kinase (Akt) and FoxO transcription factor. The protein 
is required for normal regulation of blood glucose, insulin resistance, and plays a role in lipid storage 
in obesity.26  
Our findings need to be seen in light of several considerations. There may simply be no direct causal 
link between the SNPs and vulnerable plaque, due to the phenotypic complexity of atherosclerotic 
vascular disease. Alternatively, there could be indeed a causal relationship, which we had not been able 
to detect. First, in this study we visualized 40mm of a single non-culprit vessel, and therefore cannot 
exclude that we might have missed the patient’s dominant phenotypic characteristic if this phenotype 
is only expressed in a coronary segment that has not been imaged (e.g. culprit lesion).  However, ex 
vivo as well as in vivo studies using IVUS in patients with MI have demonstrated the presence of TCFAs 
in other than the culprit lesion or even culprit artery. 5 Second, is IVUS virtual histology suitable for the 
detection of such vulnerable plaques? We believe it is, as we demonstrated earlier, based on data from 
a large subset of this patient population, that the presence of IVUS-VH derived TCFA lesions in a non-
culprit coronary artery is strongly and independently predictive for the occurrence of MACE within 1 
year, particularly of death and ACS. Also, TCFAs with a large plaque burden carry higher risk than small 
TCFA lesions, especially on the short-term.27 Third, the presented results are based on a single centre 
experience, which may limit its external validity. 
However, this is the first (large-scale) study to combine several novel invasive coronary imaging tech-
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niques with extensive genetic analyses and we extended our analyses by investigating the associations 
found in our IVUS study with a CAD/MI phenotype in CARDIoGRAM and with the Friesinger Score, 
a measure of the extent and severity of coronary atherosclerosis in the LURIC dataset. We identified 
two genes in particular, which, besides being related to vulnerable plaque, were also related to clinical 
outcome. Our results are hypothesis generating, and need to be replicated in other, larger popula-
tions.
In conclusion, we found twelve SNPs in or in the proximity of eight genes, which were associated with 
indicators of vulnerable plaque. 
The supplementary figures and tables are available online.
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IN VIVO DETECTION OF HIGH-RISK CORONARY PLAQUES BY RADIOFREQUENCY 
INTRAVASCULAR ULTRASOUND AND CARDIOVASCULAR OUTCOME: RESULTS OF 
THE ATHEROREMO-IVUS STUDY
ABSTRACT
Aims 
Acute coronary syndromes (ACS) are mostly caused by plaque rupture. This study aims to investigate 
the prognostic value of in vivo detection of high-risk coronary plaques by intravascular ultrasound 
(IVUS) in patients undergoing coronary angiography.
Methods and results 
Between November 2008 and January 2011, IVUS of a non-culprit coronary artery was performed 
in 581 patients who underwent coronary angiography for ACS (n = 318) or stable angina (n = 
263). Primary endpoint was major adverse cardiac events (MACEs) defined as mortality, ACS, or 
unplanned coronary revascularization. Culprit lesion-related events were not counted. Cumulative 
Kaplan–Meier incidence of 1-year MACE was 7.8%. The presence of IVUS virtual histology-derived 
thin-cap fibroatheroma (TCFA) lesions (present 10.8% vs. absent 5.6%; adjusted HR: 1.98, 95% CI: 
1.09–3.60; P = 0.026) and lesions with a plaque burden of ≥70% (present 16.2% vs. absent 5.5%; 
adjusted HR: 2.90, 95% CI: 1.60–5.25; P < 0.001) were independently associated with a higher MACE 
rate. Thin-cap fibroatheroma lesions were also independently associated with the composite of death 
or ACS only (present 7.5% vs. absent 3.0%; adjusted HR: 2.51, 95% CI: 1.15–5.49; P = 0.021). Thin-cap 
fibroatheroma lesions with a plaque burden of ≥70% were associated with a higher MACE rate within 
(P= 0.011) and after (P < 0.001) 6 months of follow-up, while smaller TCFA lesions were only associ-
ated with a higher MACE rate after 6 months (P = 0.033).
Conclusion 
In patients undergoing coronary angiography, the presence of IVUS virtual histology-derived TCFA le-
sions in a non-culprit coronary artery is strongly and independently predictive for the occurrence of 
MACE within 1 year, particularly of death and ACS. Thin-cap fibroatheroma lesions with a large plaque 
burden carry higher risk than small TCFA lesions, especially on the short term.
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INTRODUCTION
Acute coronary syndromes (ACS) are expected to remain the leading cause of mortality and morbid-
ity in the upcoming years.1 Patients with a history of cardiovascular disease have an increased risk for 
ACS.2Post-mortem studies have shown that ACS is mostly caused by thin-cap fibroatheroma (TCFA) 
lesions.3–5 Detection of these coronary lesions that are at high risk to rupture may be highly relevant for 
further improvement of prognostication and for optimal choice of treatment. However, these high-risk 
lesions cannot be easily detected by coronary angiography.6
Intravascular ultrasound (IVUS) radiofrequency analyses, also known as IVUS virtual histology, allow for 
differentiation of various plaque phenotypes and may therefore be well suited for detection of plaques 
that are at high risk to rupture.7–9 The Providing Regional Observations to Study Predictors of Events 
in the Coronary Tree (PROSPECT) study has shown that plaque characteristics as assessed by IVUS 
were independently predictive for recurrent cardiac events in patients admitted with an ACS.10 How-
ever, the events in PROSPECT were mainly driven by rehospitalizations for unstable or progressive an-
gina, while less is known about the prognostic value of IVUS for acute cardiac events as a consequence 
of spontaneous plaque rupture (i.e. recurrent ACS or death). Furthermore, the prognostic value of 
IVUS in patients with stable angina remains unclear. This study aims to investigate the prognostic value 
of in vivo detection of high-risk plaques by IVUS in patients undergoing coronary angiography for ACS 
or stable angina.
METHODS
Study population
The design of the European Collaborative Project on Inflammation and Vascular Wall Remodeling in 
Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study has been described else-
where.11 In brief, 581 patients who underwent diagnostic coronary angiography or percutaneous coro-
nary intervention (PCI) for ACS or stable angina pectoris have been included between 2008 and 
2011 in the Erasmus MC, Rotterdam, the Netherlands (see Supplementary material online, Figure S1). 
Although this original ATHEROREMO-IVUS cohort was further enriched with eligible patients who 
participated in the Integrated Biomarker and Imaging Study-2 (IBIS-2) trial of darapladib vs. placebo, 
these additional IBIS-2 patients were not included in the present analysis in order to prevent possible 
treatment interaction from darapladib.12
The ATHEROREMO-IVUS study was approved by the medical ethics committee of the Erasmus MC. 
The study was performed in accordance with the criteria described in the declaration of Helsinki. 
Written informed consent was obtained from all included patients. This study is registered with Clini-
calTrials.gov, number NCT01789411.
Intravascular ultrasound imaging
Following the standard coronary angiography procedure, IVUS imaging of a non-culprit coronary 
artery was performed. Selection of the non-culprit vessel was predefined in the study protocol. The 
order of preference for selection of the non-culprit vessel was: (i) left anterior descending artery; (ii) 
right coronary artery; (iii) left circumflex artery. All IVUS data were acquired with the Volcano s5/s5i 
Imaging System (Volcano Corp., San Diego, CA, USA) using a Volcano Eagle Eye Gold IVUS catheter 
(20 MHz). An automatic pullback system was used with a standard pull back speed of 0.5 mm/s. The 
baseline IVUS images were sent to an independent core laboratory (Cardialysis BV, Rotterdam, the 
Netherlands) for offline analysis. The core laboratory personnel were blinded for baseline patient 
characteristics and clinical outcomes data. The IVUS grey-scale and virtual histology analyses were 
performed using the pcVH 2.1 and qVH (Volcano Corp., San Diego, CA, USA) software. The external 
elastic membrane and luminal borders were contoured for each frame of the virtual histology-derived 
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data set. Extent and phenotype of the atherosclerotic plaque were assessed. The plaque burden was 
defined as plaque and media cross-sectional area divided by an external elastic membrane cross-
sectional area. A coronary lesion was defined as a segment with a plaque burden of >40% in at least 
three consecutive frames (see Supplementary material online, Figure S2). Using IVUS virtual histol-
ogy, the composition of the atherosclerotic lesions was characterized into four different tissue types: 
fibrous, fibro-fatty, dense calcium, and necrotic core.7 Confluence of the necrotic core and dense 
calcium and the contact of the necrotic core with the lumen were independently assessed by visual 
examination, which was performed independently by three investigators (H.M.G., S.P.B., and J.H.H.) 
who were blinded to the clinical outcomes. Consensus was reached in case of disagreement. The 
lesions were further classified into: (i) adaptive intimal thickening (intimal thickening of <600 μm for 
<20% of the circumference); (ii) pathological intimal thickening (intimal thickening ≥600 μm for >20% 
of the circumference with >15% fibrofatty tissue and no confluent necrotic core or dense calcium); 
(iii) fibrotic plaque (consisting predominantly of fibrous tissue without confluent necrotic core or 
dense calcium); (iv) fibrocalcific plaque (presence of >10% confluent dense calcium without conflu-
ent necrotic core); (v) fibroatheroma (presence of >10% confluent necrotic core with an overlying 
layer of fibrous tissue); (vi) calcified fibroatheroma (fibroatheroma containing >10% confluent dense 
calcium); (vii) non-calcified TCFA (presence of >10% confluent necrotic core in direct contact with the 
lumen); (viii) calcified TCFA (TCFA containing >10% of confluent dense calcium) (Figure 1).8 All of the 
above-mentioned criteria should be present in three consecutive frames for a lesion to be considered 
of a particular category. Thin-cap fibroatheroma lesions with a plaque burden of at least 70% were 
classified as large TCFA lesions.
Figure 1 Methodology for detection of lesion and reference segments
Study endpoints
Clinical follow-up started at inclusion and lasted 1 year. Post-discharge survival status was obtained 
from municipal civil registries. Post-discharge rehospitalizations were prospectively assessed during 
the follow-up. Questionnaires focusing on the occurrence of MACEs were sent to all living patients. 
Subsequently, hospital discharge letters were obtained and treating physicians and institutions were 
contacted for additional information whenever necessary. Acute coronary syndrome was defined as 
the clinical diagnosis of ST-segment elevation myocardial infarction (STEMI), non-STEMI, or unstable 
angina pectoris in accordance with the guidelines of the European Society of Cardiology.13 Unplanned 
coronary revascularization was defined as unplanned repeat PCI or coronary artery bypass grafting 
(CABG). All events were adjudicated as related to a coronary site that was treated during the index 
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procedure (culprit lesion-related event) or as related to a coronary site that was not treated during 
the index procedure (non-culprit lesion-related event). Events that were related to both the culprit 
lesion and a non-culprit site (e.g. revascularization of multiple vessels with CABG) were classified into 
both categories. When information was not sufficient to classify an event as either culprit lesion related 
or non-culprit lesion related, the event was classified as indeterminate.
The primary endpoint was MACE, defined as non-culprit lesion related or indeterminate mortality, 
ACS, or unplanned coronary revascularization. The secondary endpoint was defined as the composite 
of non-culprit lesion related or indeterminate mortality or ACS. Definite culprit lesion-related events 
were not counted in the primary and secondary endpoint. The occurrence of culprit lesion-related 
events is most probably caused by in-stent restenosis or in-stent thrombosis, while we were only 
interested in unanticipated, spontaneous MACE. The endpoints were adjudicated by a clinical event 
committee that had no knowledge of the IVUS data.
Statistical analysis
Under the previously described assumptions (design paper) that high-risk lesions (e.g. TCFA) will be 
present in 30% of the patients and that MACE will occur in 10% of the total study population, our 
sample size of 581 patients would provide 85–99% power to detect a hazard ratio (HR) in the range 
of 2.0–2.5 with a two-sided alpha of 0.05.11
Normally distributed continuous variables are presented as means ± standard deviation. Non-normally 
distributed continuous variables are presented as median and inter-quartile range. Categorical vari-
ables are presented in numbers and percentages. Patients lost to follow-up were considered at risk 
until the date of last contact, at which time-point they were censored. Cumulative event rates were 
estimated according to the Kaplan–Meier method. Cumulative Kaplan–Meier event curves were com-
pared by the 
log-rank test. Cox proportional hazards regression analyses were performed to evaluate the associa-
tions between IVUS characteristics and study endpoints. In multivariable analyses, the variables age, 
gender, diabetes mellitus, hypertension, history of PCI, and indication for coronary angiography were 
considered as potential confounders and were entered into the full model. These covariates (except 
for indication for coronary angiography) were chosen based on the multivariable model that was used 
in the PROSPECT study, taking into account the number of events available.10 The final results are 
presented as HRs with 95% confidence interval (95% CI). The z-test for heterogeneity was performed 
to test for heterogeneity in effect estimates between patients admitted with and without ACS. All 
statistical analyses were performed at the patient level. All data were analysed with the SPSS software 
(SPSS 20.0, IBM corp., Armonk, NY, USA). All statistical tests were two-tailed and P-values <0.05 were 
considered statistically significant.
RESULTS
Baseline characteristics
The mean age of the study population was 61.6 ± 11.3 years, 75.6% were men and 17.0% had dia-
betes mellitus (Table 1). Coronary angiography or PCI was performed for various indications: 28.7% 
of the patients had an acute myocardial infarction (STEMI and non-STEMI), 26.0% of the patients 
had unstable angina pectoris, and 43.7% of patients had stable angina pectoris. The median length 
of the imaged coronary segment was 44.3 (33.8–55.4) mm. The median interslice distance was 0.40 
mm. A total of 724 lesions were identified in the imaged coronary segment of 508 (87.4%) patients, 
including 127 (17.5%) lesions with a plaque burden of at least 70% in 124 (21.3%) patients and 206 
(28.5%) lesions with a minimal luminal area of 4.0 mm2 or less in 182 (31.3%) patients (Figure 2 and 
seeSupplementary material online, Table S1). On the basis of radiofrequency IVUS, 271 (37.4%) of the 
lesions have been classified as TCFA in 242 (41.7%) patients, including 71 (9.8%) TCFA lesions with a 
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Table 1 
Baseline characteristics 
Patient characteristics                                                                                            n = 581 patients 
 Age, years 61.6 ± 11.3 
 Men, n (%) 439 (75.6) 
 Diabetes mellitus, n (%) 99 (17.0) 
 Hypertension, n (%) 300 (51.6) 
 Hypercholesterolaemia, n (%) 321 (55.2) 
 Smoking, n (%) 169 (29.1) 
 Positive family history, n (%) 301 (51.8) 
 Previous MI, n (%) 184 (31.7) 
 Previous PCI, n (%) 186 (32.0) 
 Previous CABG, n (%) 18 (3.1) 
 Previous stroke, n (%) 26 (4.5) 
 History of peripheral artery disease, n (%) 36 (6.2) 
 History of renal insufficiency, n (%) 32 (5.5) 
 History of heart failure, n (%) 19 (3.3) 
 C-reactive protein, mg/L 2.1 (0.9–5.4) 
Procedural characteristics 
 Indication for angiography 
  Acute MI, n (%) 167 (28.7) 
  Unstable angina, n (%) 151 (26.0) 
  Stable angina, n (%) 254 (43.7) 
  Other, n (%) 9 (1.5) 
 Coronary artery diseasea 
  No significant stenosis, n (%) 43 (7.4) 
Table 1. Baseline characteristics (see other side)
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  One-vessel disease, n (%) 308 (53.0) 
  Two-vessel disease, n (%) 168 (28.9) 
  Three-vessel disease, n (%) 62 (10.7) 
 PCI performed, n (%) 511 (88.0) 
IVUS characteristics 
 Imaged coronary artery 
  Left anterior descending, n (%) 210 (36.1) 
  Left circumflex, n (%) 195 (33.6) 
  Right coronary artery, n (%) 176 (30.3) 
 Imaged segment length, mm 44.3 (33.8–55.4) 
• aA significant stenosis was defined as a stenosis !50% of vessel diameter by visual assessment on the coronary 
angiogram. 
• CABG, coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention. 
  
IVUS, intravascular ultrasound: MLA, minimal lumen area; PB, plaque burden, TCFA, thin cap 
fibroatheroma
Figure 2. Study participants and intravascular ultrasound-derived coronary lesions
Table 1. Baseline characteristics
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plaque burden of at least 70% in 69 (11.9%) patients, 61 (8.4%) TCFA lesions with a minimal luminal 
area of 4.0 mm2 or less in 61 (10.5%) patients, and 35 (4.8%) TCFA lesions with a plaque burden of 
at least 70% and a minimal luminal area of 4.0 mm2 in 35 (6.0%) patients. Antiplatelet medications 
and statins were prescribed to the majority of patients at the time of discharge (see Supplementary 
material online,Table S2).
Major adverse cardiac events
Vital status was complete for 580 (99.8%) patients. The response rate of the questionnaires that were 
sent to all living patients was 91.5%. After 1 year of follow-up, 56 patients had at least 1 event (Table 
2). Unplanned coronary revascularization was performed in four patients who did not have PCI during 
the index procedure. A total of 11 patients had a definite culprit lesion-related event, while 27 patients 
had a definite non-culprit lesion-related event. Another 18 patients had an event that could not be 
judged to be either culprit lesion related or non-culprit lesion related and were therefore classified 
as having an indeterminate event. The cumulative Kaplan–Meier incidence of the 30-day, 6-month, and 
1-year MACE (primary endpoint) was 0.7, 4.7, and 7.8%, respectively. The cumulative Kaplan–Meier 
incidence of the 30-day, 6-month, and 1-year composite of death or ACS (secondary endpoint) was 
0.7, 3.1, and 4.8%, respectively.
Table 2 
Patients with major adverse cardiac events 
 
Definite 
culprit 
lesion-
related 
events 
Definite 
non-culprit 
lesion-
related 
events 
Indeterminate 
events 
Non-culprit lesion 
related and 
indeterminate 
events combined 
All 
events 
Composite of major 
adverse cardiac 
events, n 11 27 18 45a 56 
Death from any 
cause, n 1 1 16 17 18 
Definite cardiac or 
unexplained death, n 1 1 6 7 8 
Acute coronary 
syndrome, n 3 9 2 11 14 
Myocardial infarction, n 2 3 2 5 7 
Unplanned coronary 
revascularization,n 7 17 0 17 24 
Composite of death or 
acute coronary 
syndrome, n 4 10 18 28b 32 
• aPrimary endpoint. 
• bSecondary endpoint. 
Table 3 
Associations with major adverse cardiac events 
 
Table 2. Patients with major adverse cardiac events 
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Unadjusted 
model 
P-
value 
Age and 
gender 
adjusted 
model 
P-
value 
Age, gender, 
and 
indication for 
angiography-
adjusted 
model 
P-
value 
Full 
modela P-value 
Major adverse cardiac events (primary endpoint) 
 Thin-cap 
fibroatheroma 
HR 1.96 
(1.08–3.53) 0.026 
HR 1.97 
(1.09–
3.57) 0.024 
HR 2.00 
(1.10–3.62) 0.022 
HR 
1.98 
(1.09–
3.60) 0.026 
 Plaque 
burden !70% 
HR 3.15 
(1.75–5.68) <0.001 
HR 2.83 
(1.57–
5.13) 0.001 
HR 2.83 
(1.56–5.12) 0.001 
HR 
2.90 
(1.60–
5.25) <0.001 
 MLA "4.0 
mm2 
HR 1.36 
(0.74–2.48) 0.32 
HR 1.24 
(0.68–
2.28) 0.48 
HR 1.24 
(0.68–2.28) 0.48 
HR 
1.23 
(0.67–
2.26) 0.50 
Composite of death or acute coronary syndrome (secondary endpoint) 
 Thin-cap 
fibroatheroma 
HR 2.56 
(1.18–5.54) 0.017 
HR 2.60 
(1.20–
5.64) 0.015 
HR 2.54 
(1.17–5.51) 0.019 
HR 
2.51 
(1.15–
5.49) 0.021 
 Plaque 
burden !70% 
HR 2.11 
(0.97–4.56) 0.059 
HR 1.90 
(0.87–
4.15) 0.11 
HR 1.92 
(0.88–4.20) 0.10 
HR 
2.01 
(0.92–
4.39) 0.079 
 MLA "4.0 
mm2 
HR 1.23 
(0.57–2.67) 0.60 
HR 1.12 
(0.52–
2.43) 0.78 
HR 1.13 
(0.52–2.45) 0.76 
HR 
1.14 
(0.53–
2.49) 0.73 
• aVariables entered into the full model were age, gender, diabetes mellitus, hypertension, history of percutaneous 
coronary intervention, and indication for coronary angiography. 
• HR, hazard ratio, MLA, minimal luminal area.!
Table 3 Associtaions with major adverse cardiac events
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Figure 3 Cumulative Kaplan-Meier incidence estimates of non-culprit lesion related or 
 indeterminate major adverse cardiac events 
Percentages are 1-year cumulative Kaplan-Meier incidence estimates. Hazard ratios are es-
timated using univariate Cox proportional hazard regression analysis. P values are obtained 
with log-rank test. MLA; minimal lumen area; PB, plaque burden; TCFA thin-cap fibroathero-
ma
P values are obtained with log-rank test. Overall P value 0-6months is 0.009, overall P value 
6-12 months is 0.002.
PB, plaque burden; TCFA, thin-cap fibroatheroma.
Figure 4 Associations with of short- and long-term major adverse cardiac events
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Associations with incident major adverse cardiac events
Patients who did not had any lesion in the imaged coronary segment seemed to have a lower oc-
currence of MACE (absent 4.1% vs. present 8.3%; HR: 0.48, 95% CI: 0.15–1.54; P = 0.22) and a lower 
occurrence of the composite of death or ACS only (absent 1.4% vs. present 5.4%; HR: 0.25, 95% CI: 
0.034–1.83; P = 0.17), although these associations were not statistically significant. The amount of the 
necrotic core in the imaged coronary segment was associated with MACE (see Supplementary mate-
rial online, Table S3).
After adjustment for clinical characteristics, the presence of TCFA lesions (present 10.8% vs. absent 
5.6%; adjusted HR: 1.98, 95% CI: 1.09–3.60; P = 0.026) and lesions with a plaque burden of at least 70% 
(present 16.2% vs. absent 5.5%; adjusted HR: 2.90, 95% CI: 1.60–5.25; P < 0.001) were independently 
associated with a higher occurrence of MACE, while the presence of lesions with a minimal luminal 
area of 4.0 mm2 or less was not (present 9.4% vs. absent 7.1%; adjusted HR: 1.23, 95% CI: 0.67–2.26; P 
= 0.50) (Table 3 and see Supplementary material online, Table S4). There was no heterogeneity in the 
HR estimates between patients admitted with and without ACS (heterogeneity P = 0.31 for TCFA, P 
= 0.58 for the plaque burden of at least 70% and P = 0.65 for the minimal luminal area of 4.0 mm2 or 
less). Calcified TCFA lesions seemed to carry higher risk than non-calcified TCFA lesions, although the 
difference was not statistically significant (P = 0.32) (see Supplementary material online,Figure S3). The 
presence of TCFA lesions was also significantly associated with the composite of death or ACS only 
(present 7.5% vs. absent 3.0%; adjusted HR: 2.51, 95% CI: 1.15–5.49; P = 0.021).
Risk for the occurrence of MACE was further increased if the TCFA lesions had a minimal luminal area 
of 4.0 mm2 or less, had a plaque burden of at least 70%, or a combination of these three characteristics 
(Figure 3 and see Supplementary material online, Figure S4). Thin-cap fibroatheroma lesions with a 
plaque burden of at least 70% were associated with a higher MACE rate both in the first 6 months (P 
= 0.011) and after 6 months (P < 0.001) of follow-up, while smaller TCFA lesions were only associated 
with a higher MACE rate after 6 months (P = 0.033) (Figure 4).
DISCUSSION
This study investigated the prognostic value of in vivo high-risk plaque detection by IVUS for the occur-
rence of MACE in patients undergoing coronary angiography. In line with previous studies, we found 
that the presence of a TCFA lesion as assessed by IVUS in a non-culprit coronary artery was indepen-
dently predictive for the occurrence of MACE that was not related to the index procedure.10,14The 
event rate was even further increased when patients had a TCFA lesion with a minimal luminal area 
of 4.0 mm2 or less, a plaque burden of at least 70%, or a combination thereof. Our study is the first 
to demonstrate that the presence of such vulnerable coronary lesions as assessed in vivo by IVUS is 
significantly associated with the occurrence of acute cardiac events (composite of death or ACS only) 
that were not related to the index procedure. Furthermore, we found that patients with a large TCFA 
lesion (with a plaque burden of at least 70%) were at a higher risk than patients with a small TCFA 
lesion. The presence of a small TCFA lesion was only predictive for clinical events occurring on the 
longer term (after 6 months).
Although the PROSPECT and the Virtual histology Intravascular ultrasound in Vulnerable Atheroscle-
rosis (VIVA) studies have previously reported on the prognostic value of vulnerable plaque detection 
by IVUS, there are some limitations to the conclusion of these studies.10,14 First, the PROSPECT study 
only enrolled ACS patients. Therefore, the conclusions of this study cannot be directly extrapolated 
to patients with stable angina. In contrast, our study presents a patient population that underwent 
coronary angiography for ACS or stable angina and that may better reflect the ‘real world’ clinical 
practice. Secondly, the vast majority of events in the PROSPECT study consisted of rehospitalizations 
for unstable or progressive angina (69 out of the 74 patients with primary composite endpoint), while 
the majority of events in the VIVA study consisted of coronary revascularizations (14 out of the 16 
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patients with primary composite endpoint). Our study demonstrated that vulnerable coronary lesions 
as assessed in vivo by IVUS are significantly associated with the occurrence of acute cardiac events 
(composite of death or ACS only) that were not related to the index procedure. Finally, an important 
difference is that IVUS was performed in three coronary vessels in the PROSPECT and VIVA studies. 
Our study demonstrated that IVUS in only one non-culprit vessel is sufficient for prognostication. This 
finding is relevant for the use of IVUS in daily clinical practice, since IVUS acquisition and analysis of 
three vessels is more time consuming and may increase risk for complications.
Previous studies have demonstrated that coronary atherosclerotic plaque burden as assessed with 
coronary computed tomography angiography or IVUS is associated with the progression of the le-
sion and with incident clinical events during the follow-up.15–17 Similarly, the PROSPECT and the VIVA 
studies have shown that lesions with a plaque burden of at least 70% were strongly associated with 
their primary endpoint.10,14 In the Prediction of Progression of Coronary Artery Disease and Clinical 
Outcome Using Vascular Profiling of Shear Stress and Wall Morphology (PREDICTION) study, large 
plaque burden and low local endothelial shear stress were also independently associated with the pro-
gression of the lesion and narrowing of the lumen.18 In accordance with these observations, we found 
that patients with a coronary lesion that had a plaque burden of at least 70% were at a higher risk for 
MACE. However, the presence of a lesion with a plaque burden of at least 70% was not significantly 
predictive for the composite of death or ACS only. These findings suggest that lesions with a high 
plaque burden are at high risk to cause a flow-limiting stenosis, requiring coronary revascularizations, 
and rehospitalizations for progressive angina.
Thin-cap fibroatheroma is the most common pathological substrate of ACS and has been found to be 
associated with incident cardiac events.19 In the PROSPECT study, non-culprit lesions associated with 
recurrent events (mainly driven by rehospitalizations) were more likely to be classified as TCFA on the 
basis of radiofrequency IVUS (adjusted HR: 3.35, 95% CI: 1.77–6.36; P < 0.001).10 In the VIVA study, the 
presence of a non-calcified TCFA lesion was the only factor that was associated with MACE, which was 
mainly driven by coronary revascularizations (unadjusted HR: 1.79; 95% CI: 1.20–2.66, P = 0.004).14 
Likewise, we found that the presence of TCFA lesions as assessed with IVUS was independently pre-
dictive for MACE (adjusted HR: 1.98, 95% CI: 1.09–3.60; P = 0.026). Furthermore, the predictive value 
of TCFA lesions for the occurrence of acute cardiac events (composite of death or ACS only) was 
even stronger (adjusted HR: 2.51, 95% CI: 1.15–5.49; P = 0.021). These findings emphasize the biologi-
cal importance of TCFA for plaque rupture.
We have also found that patients with a large TCFA lesion (with a plaque burden of at least 70%) 
were at a higher risk than patients with a small TCFA lesion. Furthermore, large TCFA lesions were 
associated with a higher MACE rate within and after 6 months of follow-up, while smaller TCFA le-
sions were only associated with a higher MACE rate after 6 months. Based on these observations, it 
can be hypothesized that large TCFA lesions are more vulnerable and more prone to rupture, while 
small TCFA lesions may grow in time and may become more vulnerable in the future. In line with our 
findings, two previous studies have demonstrated that the majority of the untreated non-culprit TCFA 
lesions retain their TCFA morphology during the follow-up (6–13 months), and may be accompanied 
by a decrease in the minimal luminal area and an increase in the necrotic core.20–21 An other small study 
of patients with a lower risk profile, however, has demonstrated that the majority of the TCFA lesions 
was healed after 1 year.22
Different MACE definitions have been used in the above-mentioned studies (death, ACS and un-
planned revascularization in our study; cardiovascular death, cardiac arrest, myocardial infarction and 
rehospitalization due to unstable or progressive angina in the PROSPECT study; death, myocardial 
infarction, and unplanned revascularization in the VIVA study).10,14 Therefore, MACE rates of these 
studies cannot be directly compared. Nevertheless, the incidence of MACE seemed to be relatively 
high in our study population. For example, 18 deaths occurred in 581 patients within 1 year in our 
study compared with 2 deaths in 170 patients within 625 days in the VIVA, 31 deaths in 697 patients 
within 3.4 years in the PROSPECT, and 4 deaths in 506 patients within 9 months in the PREDICTION 
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study.10,14,18However, the MACE rate in our study was consistent with that of previous ‘all-comer’ reg-
istries in our hospital, which further emphasizes that our study population may better reflect the ‘real 
world’ clinical practice.23,24
Some limitations of this study need to be acknowledged. First, this is a prospective observational 
cohort study. Although we aimed to include a patient population that reflects clinical practice, those 
patients with any of the exclusion criteria could not be included in this study.11 Secondly, the spatial 
resolution of IVUS virtual histology (150 μm) is insufficient to exactly replicate histopathological defini-
tions of a thin fibrous cap (<65 μm).25 Therefore, IVUS virtual histology tends to over-estimate the 
number of TCFA lesions. Nevertheless, the presence of IVUS virtual histology detected TCFA lesions 
has prognostic information and is therefore clinically relevant. Thirdly, the relatively small number of 
endpoints did not allow us to evaluate whether adding IVUS imaging to a prognostic model with con-
ventional risk factors would result in improved risk prediction. Finally, repeat intracoronary imaging with 
IVUS virtual histology was not performed. Therefore, the dynamic nature of coronary artery lesion 
morphology could not be investigated. Large, future studies (e.g. IBIS-3, www.trialregister.nl identifier 
NTR2872) may provide useful data in this respect.26
In conclusion, IVUS virtual histology appeared to be a useful tool for in vivo detection of high-risk 
coronary lesions. In patients undergoing coronary angiography, the presence of IVUS virtual histology-
derived TCFA lesions in a non-culprit coronary artery is strongly and independently predictive for 
the occurrence of MACE, particularly of death and ACS. Thin-cap fibroatheroma lesions with a large 
plaque burden are of a higher risk than small TCFA lesions, especially on the short term.
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DETERMINANTS OF HIGH CARDIOVASCULAR RISK IN RELATION TO PLAQUE-COMPOSI-
TION OF A NON-CULPRIT CORONARY SEGMENT VISUALIZED BY NEAR-INFRARED 
SPECTROSCOPY IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVEN-
TION
ABSTRACT
Aim
The aim of this study was to determine the relation between clinical and blood characteristics of a vas-
cular inflammatory milieu and coronary plaque composition visualized by near-infrared spectroscopy 
(NIRS) in percutaneous coronary intervention (PCI) patients.
Methods and results
Between April 2009 and January 2011 we performed NIRS in 208 patients who underwent PCI or 
invasive diagnostic coronary exploration for various indications. Imaging was performed of one non-
intervened coronary segment after the initial procedure. Univariate and multivariate linear regression 
analyses were applied to evaluate the relationship between the acquired NIRS-derived lipid core 
burden index (LCBI) and clinical and blood (lipids and hs-CRP) characteristics. Patients with a his-
tory of hypercholesterolemia (median 48 (interquartile range 21-101) vs. 38 (13-70), p=0.043) and 
multi-vessel disease (55 (24-104) vs. 32 (12-71), p=0.012) had higher LCBI levels. Men had higher 
LCBI than women (48 (21-95) vs. 27 (9-59), p=0.003). Hypercholesterolemia and gender remained 
significant in multivariate regression analysis, whereas also a history of noncardiac vascular disease and 
beta-blockers were positively associated with LCBI. Altogether 23.2% of the variability in LCBI could 
be explained by clinical and blood characteristics.
Conclusion
Clinical characteristics reflecting patients with a high cardiovascular risk profile explained 23.2% of the 
variability in LCBI, whereas blood biomarkers added little. Further research is warranted to evaluate 
if NIRS has the potential to provide additional prognostic information about patients’ cardiovascular 
risk.
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INTRODUCTION
Acute coronary syndromes are a major cause of mortality and morbidity in Western countries.1, 2 
Rupture of vulnerable coronary plaques, often inflamed lipid rich lesions with large necrotic cores 
with only a thin overlying fibrous layer of intimal tissue, are most likely to cause these acute coronary 
syndromes. 3-7 Several well-established and emerging cardiovascular risk factors have been related to 
the occurrence and progression of coronary atherosclerosis 8-10 and the predisposition of patients to 
plaque rupture or acute coronary thrombosis. 11 An important risk factor for the development of 
coronary atherosclerosis is the lipid profile12, which accounts for approximately 50% of the population 
attributable risk of first acute myocardial infarction (AMI). 13 A meta-analysis of 26 randomised trials 
showed that lowering low-density lipid (LDL) cholesterol is inversely associated with rates of both 
major coronary and vascular events.14 Therefore the lipid profile is widely accepted as a determinant 
for risk stratification15 and primary target of therapy. 16 Another established risk factor for coronary 
atherosclerosis is hs-CRP. Subjects with elevated levels of hs-CRP are at increased risk of coronary 
heart disease.17 Furthermore, as demonstrated by the Jupiter trial, rosuvastatin significantly reduced 
the incidence of major cardiovascular events in seemingly healthy persons without hyperlipidaemia but 
with elevated hsCRP levels. 18
Near-infrared spectroscopy (NIRS), a novel catheter based imaging modality that determines composi-
tion of tissue, has the potential to identify lipid-core containing coronary plaques (LCP) in patients. The 
accuracy of NIRS has been validated in coronary autopsy specimens and subsequently in vivo. This in-
tra-coronary system utilizes the variation in reflection of the emitted near-infrared light to detect LCP, 
which is visualized as a (block) chemogram and qualified by a lipid-core burden index (LCBI) score. 
19, 20 Detection of these LCPs in coronary arteries might potentially be used for enhanced risk strati-
fication, prevention and treatment of coronary events. We have reported on the relation between 
NIRS, Framingham Risk Score and renal function in patients who underwent successful percutaneous 
coronary intervention (PCI) or invasive diagnostic coronary exploration. 21, 22
The aim of the current study was to provide a thorough and broad analysis of the patient characteris-
tics that are (potentially) associated with NIRS derived LCBI, in particular blood lipids and hs-CRP. Logi-
cally, we do expect higher LCBI levels in patients with a clinical profile corresponding with increased 
CHD risk.
METHODS
Study population
We studied 208 patients who underwent NIRS, between April 2009 and January 2011, in the Thorax-
center, Erasmus MC, Rotterdam, the Netherlands, a tertiary referral hospital. Patients were 18 years of 
age or older, had stable angina pectoris (AP) or an acute coronary syndrome (ACS) and underwent 
successful PCI or invasive diagnostic coronary exploration of one or more lesions in one or two native 
coronary arteries. Patients who underwent CABG were not included in this study. After the initial pro-
cedure (PCI or invasive diagnostic coronary exploration) patients underwent invasive imaging (NIRS 
and intravascular ultrasound (IVUS)) of one non-culprit vessel (i.e. the vessel of interest for this study), 
with a diameter stenosis <50% throughout a target segment of at least 40 mm in length by angio-
graphic visual estimation. These study vessels were accessible to the LipiScan (InfraReDx, Burlington, 
Massachusetts) catheters and per protocol selected in the following way:
If LAD vessel has been treated, RCA should be selected (if not possible: LCX);
If RCA vessel has been treated, LAD should be selected (if not possible: LCX);
If LCX has been treated, LAD or RCA should be selected.
In case patients underwent an invasive diagnostic procedure, the selection of the study vessel was left 
to the discretion of the interventional cardiologist.
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The medical ethical committee of our hospital approved the study and a written informed consent 
was obtained of every patient.
Near-infrared spectroscopy (NIRS)
The NIRS system consists of a rapid exchange catheter, a pullback and rotation device, and a console. 
The catheter is 3.2 F in diameter and 165 cm in usable length. The catheter is intended to be intro-
duced into the vasculature via a 0.014-inch coronary guidewire, which is allowed to exit approximately 
25 mm proximal to the distal tip. Two low-profile polymer markers are placed on the stiff proximal 
shaft to aid the user in locating the exit of the distal tip through the tip of a guiding catheter.
All the study coronary vessels included were accessible to the Lipiscan (InfraReDx, Burlington, Mas-
sachusetts) catheters and had a <50% reduction in lumen diameter by angiographic visual estimation 
throughout a target segment of at least 40 mm in length. Coronary vessels that received a bypass 
graft with a minimal lumen diameter <2 mm or with a diameter stenosis >50% by angiographic visual 
estimation in the segments to be analyzed were excluded. There were no complications related to the 
imaging procedure. A motorized catheter pullback, at 0,5 mm/s and 240rpm, was performed starting 
distal to a side branch and acquiring 1000 NIRS measurements/12,5 mm of scanned coronary artery. 
The region of interest (ROI) was defined as the longest coronary segment, between two clearly iden-
tifiable landmarks (i.e. side branches).
The measured probability of the LCP from each scanned coronary segment was displayed as a map, 
the chemogram; yellow regions represent those with highest probability for the presence of the LCP, 
while red regions represent those with lowest probability. The chemogram displays the pullback posi-
tion against the circumferential position of the measurement in degrees (Figure 1).
Based on the chemogram the LCBI was calculated, representing the fraction of valid pixels in the 
chemogram that are yellow, multiplied by a factor of 1000. The LCBI is a summary measure of the 
amount of LCP along the entire interrogated length of the vessel on a 0-to-1000 scale.
NIRS images were prospectively analyzed offline by an independent core laboratory (Cardialysis BV, 
Rotterdam, the Netherlands) unaware of the clinical or lab data.
Intravascular ultra sound (IVUS)
IVUS was acquired with Volcano™ s5/s5i Imaging System using Volcano™ Eagle Eye™ Gold IVUS 
catheter (20 MHz) at a standard pull back speed of 0.5mm per second with automatic pullback system. 
During motorized catheter pullback, at 0.5 mm/s, grayscale IVUS and raw radiofrequency data capture 
Figure 1 Chemogram of two patients
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gated to the R-wave were recorded.
All baseline IVUS images were prospectively analyzed offline by an independent core laboratory 
(Cardialysis BV, Rotterdam, the Netherlands). The IVUS analyses were performed with VIAS software 
(Volcano Corporation). Contour detection was performed by experienced IVUS analysts who were 
blinded to the NIRS results. Quantitative grayscale IVUS measurements included vessel area, lumen 
area, plaque area (vessel area - lumen area) and plaque burden ([plaque area/vessel area] * 100%).
Biomarker analysis
Routine blood for biomarker assessment was drawn prior to the index procedure and analyzed at our 
department of medical microbiology & infectious diseases, diagnostic laboratory Erasmus MC, Rotter-
dam, the Netherlands (accreditation based on ISO/IEC 15189:2003 and CCKL-regulations).
Data analysis
We present patient-level analyses. NIRS and IVUS-VH data are derived from measurements in the 
non-culprit (study) vessel and are presented as one quantity for each patient.
Continuous variables are presented as mean ± standard deviation or median and interquartile ranges 
(IQR) as appropriate, categorical variables are expressed as numbers and percentages. The Kolmogo-
rov-Smirnov test was used to analyse whether continuous data were normally distributed. Nonpara-
metric continuous variables were compared using the Mann-Whitney U test, and are presented as 
median and interquartile range(IQR). If further statistical tests required normal distribution of the data, 
then log or square root transformations were applied.
We intended to obtain complete information in all patients, but failed to do for the following 7 vari-
ables: hs-CRP, HDL, LDL, creatinine, total cholesterol, triglycerides and BMI. Using missing value analysis 
(MVA) we evaluated the extent of missing data and searched for patterns of missing data. MVA showed 
that there were 3.3% missing values on average. For the patients with at least one of the variables of 
interest missing, we decided to impute the missing values by multiple imputation.23 (We also applied a 
complete case sensitivity analysis, showing consistent results, which we will not present.)
The baseline creatinine values were used to calculate the creatinine clearance according to the Cock-
roft and Gault formula: creatinine clearance (millilitres/minute) = (140-age) x weight (kilograms) ÷ 72 
x serum creatinine (milligrams/decilitre) (x0.85 for women).24
Correlation plots were constructed, and univariate and multivariate linear regression (LR) analyses 
were applied to reveal clinical characteristics that were related to LCBI. LCBI was considered the 
dependent variable, and all variables of interest (table1) were considered potential determinants. All 
baseline variables described in table 1 entered the multivariate stage. All variables that had a p-value 
<0.5 in univariate analysis, based on Wald’s chi-square test, were used to construct the multivariate 
model. The R-squared statistic is presented, which indicates the percentage of the variance in the de-
pendent variable that can be “explained” by the determinant.
Subsequently, we studied the correlation between NIRS derived LCBI and IVUS-derived plaque bur-
den. We present correlation plots and report Pearson’s correlation coefficient. This analysis has caveats, 
which are mainly due to the fact that we used different cathethers for the IVUS-VH and NIR measure-
ments. The described correlation was based on segment-level data, whereas, for technical and logistic 
reasons, the analysed segments for IVUS-VH and NIR were not synchronized at the level of frames. 
Furthermore, the length of the analysed segments was not necessarily the same for both techniques.
Univariate and multivariate linear regression analyses were applied to study the association between 
NIRS derived LCBI and clinical risk factors (independent variables) and IVUS-derived plaque burden 
(dependent variable). The data of 12 patients could not be used, because of problems with the IVUS 
analysis software.
Finally, we studied the relation between blood lipid levels, hs-CRP and LCBI according to the quartiles 
of their distribution.For all tests, a two-sided P-value of 0.05 or less was considered significant. All sta-
tistical analyses were performed using SPSS 17.0 for Windows (SPSS, Inc., Chicago, IL).
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Table 1: Baseline and procedural characteristics of the NIRS-patients (n=208) 
  
   Clinical characteristics LCBI 
   n (%) median (IQR) 
Demographic characteristics     
  Age mean years ±SD   63.5±10.9  
  Male   153 (73.6) 48 (21-98) 
  Female   55 (26.4) 27 (9-59) 
Indication for invasive coronary 
procedure 
    
  Stable angina   110 (52.9) 37,5 (15-94) 
  NSTE-ACS   68 (32.7)  48 (16-94) 
  STEMI   30 (14.4) 36,5 (15-68) 
Cardiovascular history     
  Cardiac history  Yes 107 (51.4) 46 (15-87) 
  No  41 (16-87) 
  History of PAD, CVA/TIA  Yes 18 (8.7) 63,5 (40-108) 
  No  40 (15-82) 
Risk factors     
  Current smoking  Yes 50 (24.0) 44.5 (14-93) 
  No  40.5 (23-70) 
  Hypertension  Yes 117 (56.3) 43 (16-89) 
  No  41 (16-89) 
  Hypercholesterolemia  Yes 118 (56.7) 47.5 (21-101) 
  No  38 (13-70) 
  Diabetes  Yes 41 (19.7) 55 (12-93) 
  No  40 (16-87) 
 Non-insulin dependent   28 (68.3)  
 Insulin dependent            13 (31.7)  
  Multi-vessel disease  Yes 84 (59.6) 55 (24-104) 
  No  32 (12-71) 
  Family history  Yes 123 (59.1) 40 (13-95) 
  No  43 (21-70) 
  GFR       mean±SD   107±37  
  Body-mass index mean±SD   27.7±4.4  
     
Non-culprit vessel      
  RCA   60 (28.8) 46.5 (15-109) 
  LAD   75 (36.1) 32 (13-67) 
  LCX   73 (35.1) 48 (24-82) 
Medication     
  Aspirin   203 (97.5  
  Clopidogrel    194 (93.3)  
  Beta-blocker    159 (76.4)  
  RAAS inhibitor   150 (72.1)  
  Statin     187 (89.9)  
     
Blood lipid levels and hs-CRP (mmol/L) Median (IQR)  
  Total cholesterol  4.20 (3.60-5.20)  
  High-density lipoprotein  1.14 (0.92-1.35)  
  Low-density lipoprotein   2.46 (1.92-3.20)  
  Triglycerides   1.27 (0.92-1.79)  
  HS-CRP (mg/l)  3.34 (1.26-5.78)  
 
Data are presented as percentages or means (±SD). SD = Standard deviation; NSTE-ACS= non-ST-segment 
elevation acute coronary syndrome (NSTE-ACS) STEMI= ST-segment elevation myocardial infarction; PCI = 
Percutaneous Coronary Intervention; CABG = Coronary Artery Bypass Graft; PAD = Peripheral Arterial 
Disease; COPD = Chronic Obstructive Pulmonary Disease; HS-CRP = High-Sensitive CRP; GFR= glomerular 
filtration rate;  LCBI = Lipid Core Burden Index;RCA = Right Coronary Artery; LAD = Left Anterior Descending 
Coronary Artery; LCX = Left Circumflex Coronary Artery. 
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RESULTS
Study population and baseline characteristics
The baseline and procedural characteristics of the included patients are presented in Table 1. The stud-
ied population consisted mostly of men (79.6%) and the mean age was 63.5 years. Most patients were 
treated for stable AP (52.9%) or non-ST-segment elevation acute coronary syndrome (NSTE-ACS) 
(32.7%). Prior MI (38.0%) and prior PCI (38.9%) in the cardiac history were common. The prevalence 
of hypercholesterolemia, positive family history for CHD, multi-vessel disease and/or hypertension was 
more than 50%. Almost 20% of the patients were diabetic; the non-insulin dependent type was most 
common. The distribution of the studied coronary vessels (RCA 28.8%, LAD 36.1%, and LCX 35.1%) 
was about equally divided. The median total cholesterol level was 4.20 (IQR 3.60-5.20) mmol/l, LDL 
level 2.46 (1.92-3.20) mmol/l, high-density lipoprotein (HDL) of 1.14 (0.92-1.35) mmol/l, triglycerides 
1.27 (0.92-1.79) mmol/l, and a high-sensitive CRP 3.34 (1.26-5.78) (mg/dl). The median NIRS-derived 
LCBI was 42.5 (16.0-85.0).
 
 
Table 2a: Baseline variables and their univariate association with LCBI. 
 
 
Univariate     Beta  S.E.  p-value  R-squared  
 
Demographic characteristics 
    Age       -0.035  0.025  0.16  0.010  
    Male       1.75   0.60  0.004  0.039   
              
 
Indication for invasive coronary procedure              
          0.34  0.011 
    Stable angina     1 
    NSTE-ACS     0.76  0.61       
    Acute MI      -0.32  0.80      
 
Cardiovascular history 
    Cardiac history    0.03  0.54  0.96  0.000 
    history of PAD and/or CVA/TIA   1.51  0.96  0.12  0.007 
 
Risk factors                        
    Current smoking     -0.17  0.63  0.79  0.000   
    Hypertension      -0.11  0.55  0.85  0.000   
    Hypercholesterolemia     1.38  0.54  0.011  0.031   
    Diabetes      0.02  0.68  0.98  0.000  
    Multi-vessel disease n, %      1.11  0.58  0.044  0.020  
    Family history     0.52  0.54  0.34  0.004 
    GFR      0.006  0.009  0.54  0.006 
    Body-mass index     -0.02  0.06  0.71  0.001 
 
Medication  
    Aspirin      2.14  1.76  0.23  0.007   
    Clopidogrel     1.00  1.08  0.36  0.004 
    Beta-blocker      -1.50  0.63  0.019  0.027 
    RAAS inhibitor    -0.96  0.60  0.11  0.012 
    Statin      -0.12  0.86  0.89  0.000 
 
Blood lipid levels and hs-CRP 
     Total cholesterol (mmol/l)    -0.33  0.29  0.26  0.009   
     High-density lipoprotein(mmol/l)  0.41  0.32  0.97  0.000 
     Low-density lipoprotein (mmol/l)  0.20  0.02  0.52  0.003 
     Triglycerides (mmol/l)    0.41  0.32  0.20  0.011 
     HS-CRP (mg/l)    0.026  0.02  0.25  0.035 
      
  
 
SE = Standard error; MI = Myocardial Infarction; HS-CRP = High-Sensitive CRP; GFR=glomerular filtration rate; LCBI = Lipid Core 
Burden Index  
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    Current smoking     -0.17  0.63  0.79  0.000   
    Hypertension      -0.11  0.55  0.85  0.000   
    Hypercholesterolemia     1.38  0.54  0.011  0.031   
    Diabetes      0.02  0.68  0.98  0.000  
    Multi-vessel disease n, %      1.11  0.58  0.044  0.020  
    Family history     0.52  0.54  0.34  0.004 
    GFR      0.006  0.009  0.54  0.006 
    Body-mass index     -0.02  0.06  0.71  0.001 
 
Medication  
    Aspirin      2.14  1.76  0.23  0.007   
    Clopidogrel     1.00  1.08  0.36  0.004 
    Beta-blocker      -1.50  0.63  0.019  0.027 
    RAAS inhibitor    -0.96  0.60  0.11  0.012 
    Statin      -0.12  0.86  0.89  0.000 
 
Blood lipid levels and hs-CRP 
     Total cholesterol (mmol/l)    -0.33  0.29  0.26  0.009   
     High-density lipoprotein(mmol/l)  0.41  0.32  0.97  0.000 
     Low-density lipoprotein (mmol/l)  0.20  0.02  0.52  0.003 
     Triglycerides (mmol/l)    0.41  0.32  0.20  0.011 
     HS-CRP (mg/l)    0.026  0.02  0.25  0.035 
      
  
 
SE = Standard error; MI = Myocardial Infarction; HS-CRP = High-Sensitive CRP; GFR=glomerular filtration rate; LCBI = Lipid Core 
Burden Index  
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Table 2b: Baseline variables and their multivariate association with LCBI. 
 
 
Multivariate      Beta  S.E.  p-value  R-squared  
 
              0.232 
    Age        -0.03  0.03  0.23   
    Sex       1.62  0.61  0.007  
    
    Stable angina      1 
    NSTE-ACS       1.12  0.65  0.08     
    Acute MI       -0.36  0.92  0.70      
     
    History of PAD and/or CVA/TIA    2.32  0.96  0.015 
                          
    Hypercholesterolemia     1.29  0.55  0.020 
    Family history         0.55  0.52  0.29 
    Multi-vessel disease            0.94  0.54  0.08 
 
      
    Aspirin      2.31  1.65  0.16 
    Clopidogrel      -1.09  0.63  0.16 
    Betablocker      -1.91  0.63  0.003 
    RAAS inhibitor     -0.37  0.53  0.49 
      
    Total cholesterol (mmol/l)     0.52  0.30  0.09  
    Triglycerides (mmol/l)     0.002  0.35  0.99   
    HS-CRP (mg/l)     0.02  0.02  0.23  
 
  
SE = Standard error; MI = Myocardial Infarction; HS-CRP = High-Sensitive CRP; LCBI = Lipid Core Burden Index  
GFR=glomerular filtration rate 
 
                      
   
  Table 2b Baseline variables and their unvariable association with LCBI
Association between cardiovascular risk factors and LCBI
The univariate and multivariate association between baseline characteristics and LCBI is shown in table 
2a and 2b. When patients were stratified on indication for invasive coronary procedure no differences 
(p=0.49) in LCBI was observed: median (interquartile range) in stable angina 37.5 (15-94), NSTE-ACS 
48 (16-94) and STEMI 36.5 (15-68). Patients with history of hypercholesterolemia (median 48 (IQR 
21-101) vs. 38 (13-70), p=0.043) and multi-vessel disease (55 (24-104) vs. 32 (12-71), p=0.012) had 
higher LCBI levels. Men had higher LCBI than women (48 (21-95) vs. 27 (9-59), p=0.003). Except for 
multi-vessel disease, these variables remained significantly associated with LCBI after adjustment for 
the selected confounders in multivariate analysis. Also a significant association between history of PAD 
and/or CVA/TIA, beta-blockers, and LCBI was found. Altogether 23.2% of the variability in LCBI could 
be explained by the variables that compose the model.
LCBI and and IVUS-derived plaque burden
Figure 2 shows the correlation between LCBI and IVUS-derived plaque burden, as well as the relation 
between the quartiles of the distributions of LCBI and plaque burden. We observed a significant cor-
relation between the two imaging modalities based on the datapoints in individual patients (Pearson’s 
r = 0.289, p<0.001), and the quartiles of the distributions of % plaque burden and LCBI, p<0.001.
Except for a history of PAD and/or CVA/TIA none of the baseline characteristics were significantly 
associated with IVUS-derived plaque burden in univariate analysis. This variable remained significantly 
associated with IVUS-derived plaque burden after adjustment for the selected (p<0.5) confounders 
(age, sex, indication, hypertension, multi vessel disease, aspirin, clopidogrel, beta-blockers, statins and to-
tal cholesterol). Altogether 14.0% of the variability in IVUS-derived plaque burden could be explained 
by the variables that compose the model.
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Table 2b: Baseline variables and their multivariate association with LCBI. 
 
 
Multivariate      Beta  S.E.  p-value  R-squared  
 
           0.232 
   Age       -0.03  0.03  0.23   
   Sex       1.62  0.61  0.007  
    
    Stable angina       
    NSTE-ACS       1.12  0.65  0.08     
    Acute MI       -0.36  0.92  0.70      
     
    History of PAD and/or CVA/TIA    2.32  0.96  0.015 
                          
    Hypercholesterolemia     1.29  0.55  0.020 
    Family history         0.55  0.52  0.29 
    Multi-vessel disease            0.94  0.54  0.08 
 
      
    Aspirin      2.31  1.65  0.16 
    Clopidogrel      -1.09  0.63  0.16 
    Betablocker      -1.91  0.63  0.003 
    RAAS inhibitor     -0.37  0.53  0.49 
      
    Total cholesterol ( mol/l)     0.52  0.30  0.09  
    Triglycerides ( mol/l)     .   0.35  0.99   
    HS-CRP (mg/l)     .   0.02  0.23  
 
  
SE = Standard error; MI = Myocardial Infarction i - ensit ve CRP; LCBI = Lip d Core Burden I dex  
GFR=glomerular filtration rate 
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Figure 3 Scatter plots of lipid levels and hs-C-reactive in relationship wit lipid core burden index
Figure 2A Scatter plot of plaque burden (%) in relationship with LCBI 
Figure 2B Quartiles of the distribution of lipid core burden index (LCBI) in relation to  
  the quartiles of plaque burden (%).
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Association blood biomarkers and LCBI
Correlation plots (figure 3) and regression analyses showed no (significant) correlation between blood 
biomarkers and LCBI. The R-squared for blood lipid levels and hs-CRP rated between 0.000 and 
0.035 (table 2a), indicating that these variables only explain little of the variability in LCBI between 
the enrolled patients. Figure 4 shows the lipid core burden index according to quartiles of blood lipid 
levels and hs-CRP. A weak, but non-significant relation is visible between hs-CRP and LCBI: 40 % of the 
patients in the lowest quartile (Q1) of hs-CRP had LCBI in Q1, whereas 12 % of the patients in the 
highest quartile (Q4) of hs-CRP had LCBI a in the first quartile. No relations were visible between 
other blood biomarkers and LCBI.
Figure 4 Quartiles of the distribution of lipid core burden index in relation to the quartiles of 
blood lipid levels and hs-Creactive protein
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DISCUSSION
In this single centre cross-sectional study clinical characteristics and blood biomarkers explained 23.2% 
of the variability in NIRS-derived LCBI score, an indicator for LCP in coronary arteries. As increased 
levels of lipids and hs-CRP increase the likelihood of LCPs in the coronary vessel, relations between 
these blood biomarkers and LCBI were expected. However, lipid profile and hs-CRP provided little ad-
ditional information about the LCBI score in a non-intervened coronary artery segment: a maximum 
of 3.5 % of the variability in LCBI could be explained by these biomarkers.
The clinical characteristics; hypercholesterolemia, male sex, use of beta-blockers and history of periph-
eral artery disease PAD and/or cerebral vascular accident/ transient ischemic attack (CVA/TIA) were 
all significantly associated with LCBI, reflecting patients with a high cardiovascular risk profile. Our find-
ing of an association between history of hypercholesterolemia and LCP in the coronary vessels is in 
accordance with previous studies that found an association between (treated) hypercholesterolemia 
and IVUS-derived necrotic core-rich coronary plaques.25 26 Simsek et al. found no ‘dose-dependent’ 
effect of creatinine (as a measure of renal function) on NIRS-derived LCBI score in a previous report 
of this study.21
The relation between gender and LCBI supported other investigations that demonstrated that men 
have more severe structural and functional atherosclerotic disease in epicardial coronary arteries than 
women.27 In fact, the pathophysiology of cardiovascular disease (in particular coronary artery disease) 
differs significantly between men and women.28-30 Several study reports suggest that signs and symp-
toms of CVD experienced by women are related to microvascular ischemia and endothelial dysfunc-
tion, more so than in men. Symptomatic women usually have less flow limiting stenoses than men, and 
are more prone to have plaque erosion with subsequent thrombus formation.31 Myocardial ischemia 
in the absence of obstructive coronary disease, but with an increased high risk of adverse outcomes, 
is an emerging paradigm for women. More research in this field is warranted.
None of the blood biomarkers were independently predictive of LCP in the coronary vessels. This 
lack of association might have various reasons. First, we might have studied the wrong biomarkers. 
However both blood lipid levels and hs-CRP are well-established risk factors/ markers for the devel-
opment/ identification of coronary atherosclerosis. A reason for this lack in association between blood 
biomarkers and LCBI might be that the vast majority of the patients (89%) were already treated with 
statins at the time of the procedure. We found relatively low level of cholesterol, LDL and triglycerides 
in our study population. As shown previously there is a linear relation between LDL cholesterol and 
annual changes in plaque size, however in patients with low LDL values no plaque progression was 
found.32 Apparently, LDL levels influence plaque growth and probably consequently also plaque size. 
So, since patients treated with statins have lower levels of LDL, they might have as a result relatively 
small plaques. Furthermore, statins influence coronary plaques via other mechanisms as in patients 
without hyperlipidaemia the incidence of major cardiovascular events is also reduced by statin use.18 
Consequently, the use of blood biomarkers in statin users as determinant for LCP may be confounded. 
In accordance, Nicholls et al. found no relation between LDL cholesterol and hsCRP and IVUS derived 
disease burden. It should be noted that all patients in this study were treated with statins.33
Another explanation for the lack of association might be that we visualized 40 mm of a non-culprit 
vessel, in patients undergoing PCI or invasive diagnostic coronary exploration for various indications, 
and therefore cannot exclude the possibility that the blood biomarkers are related to the culprit le-
sion. However ex vivo as well as in vivo studies using IVUS in patients with myocardial infarction have 
demonstrated the presence of vulnerable plaques in other than the culprit lesion or even culprit artery. 
34 Also atherosclerosis in the peripheral vascular system or clinical circumstances can influence blood 
biomarker levels.
When patients were stratified on indication for invasive coronary procedure (stable angina, NSTE-
ACS, or STEMI) no difference in LCBI was observed. This is in contrast with Madder and colleagues 
who revealed that both target and remote LCPs were more common in patients with ACS than in 
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those with stable angina.35
The expression of atherosclerosis is depended on the interaction of multiple risk factors, including ge-
netic susceptibility, abnormal lipid levels and inflammation. Although we found no association between 
blood biomarkers and NIRS derived LCBI, there is data to support the hypothesis that blood lipid 
levels and hs-CRP are independently associated with (the promotion of) plaque vulnerability.11, 17
Historical predictors, like blood lipid levels, are frequently used as determinants of cardiovascular risk. 
If we had demonstrated a strong correlation between these factors and LCP, then NIRS would not 
provide additional information about a patients’ cardiovascular risk. Consequently, as NIRS has the 
potential of identifying LCP in coronary arteries, indicative of plaque vulnerability, this novel imaging 
technique might be a promising tool to provide additional information about patients’ cardiovascular 
risk, independent of blood lipid levels. It should be noted; however that NIRS has not yet proved to 
be a predictor of cardiovascular events at long-term follow-up. Nevertheless, since NIRS is able to 
indentify extensive LCPs that are associated with a high risk of peri-procedural MI,36 it is a promising 
tool that needs further exploration.
This study has some limitations. First, as only one non-culprit vessel was imaged, we lack information 
on the culprit artery, which may flaw our efforts to assess a relationship between LCBI and blood 
biomarkers. For the same reason, we were unable to assess the correlation of clinical presentation 
with LCBI findings as reasons for intervention are closely related to the culprit lesions. Second, this 
study might lack power to show strong correlations. Third, this is a cross-sectional study; therefore no 
information is available on the (reversed) progression of LCPs and its relation with lipid levels in this 
population over time. Future research might focus on the effect of lipid level changes on LCP. Finally, 
although we had unique information on NIRS-derived and IVUS-derived parameters in the same seg-
ment, the observed results should be interpreted with caution, because the analysed segments were 
not synchronized at the level of frames.
The single centre design of this study guarantees limited variability in the NIRS and blood collection 
procedures (consistent environment and care protocols) and the use of an independent core labora-
tory to analyze the NIRS images, assures an independent and accurate analysis according to uniform 
standards.
Concluding, clinical characteristics reflecting patients with a high cardiovascular risk profile explained 
23.2% of the variability in LCBI, whereas blood biomarkers added little. Further research is needed 
whether NIRS has the potential to provide additional information about patients’ cardiovascular risk.
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ANTIBODIES TO PERIODONTAL PATHOGENS ARE ASSOCIATED WITH CORONARY 
PLAQUE REMODELING BUT NOT WITH VULNERABILITY OR BURDEN
ABSTRACT
Objective
Previous studies have suggested positive associations between periodontal infection and cardiovascular 
disease. We aimed to investigate the associations of circulating antibodies against periodontal patho-
gens with 1-year cardiovascular outcome, as well as the extent of coronary atherosclerosis, plaque 
vulnerability and lesion remodeling on intravascular ultrasound (IVUS) imaging. 
Methods
Between 2008 and 2011, radiofrequency IVUS imaging of a non-culprit coronary artery was per-
formed in 581 patients who underwent coronary angiography. Immunoglobulin G (IgG) and A (IgA) 
against P.gingivalis, A.actinomycetemcomitans, T.forsythia and P.intermedia were measured in plasma. 
Results
None of the antibody levels were associated with coronary plaque burden, radiofreqeuncy-IVUS-de-
rived thin-cap fibroatheroma lesion morphology or 1-year incidence of major adverse cardiac events 
(MACE), which included all-cause mortality, acute coronary syndrome and unplanned coronary revas-
cularization. IgA against A.actinomycetemcomitans, T.forsythia and P.intermedia were inversely associ-
ated with extent of positive lesion remodeling (OR for highest versus lowest tertile 0.55, 95%CI 0.35-
0.88, p=0.012; 0.53, 95%CI 0.32-0.87, p=0.012; and 0.64, 95%CI 0.40-1.02, p=0.061, respectively). In 
diabetic patients specifically, IgG against P.gingivalis tended to be associated with coronary plaque bur-
den (p=0.080), while IgA against P.gingivalis tended to be associated with incident MACE (p=0.060).
Conclusion
Plasma IgG and IgA against major periodontal pathogens were not associated with the extent of coro-
nary atherosclerosis (with the exception of a trend in diabetics) nor with coronary plaque vulnerability. 
IgA against periodontal pathogens were inversely associated with extent of coronary remodeling. Al-
together, these results do not add evidence for a substantial role of systemic exposure to periodontal 
pathogens in coronary artery disease.
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INTRODUCTION
Periodontitis is a bacterially induced chronic inflammatory disease of tissues supporting the teeth and 
is highly prevalent (20 to 50%) in the adult population.1 In the past decades, several epidemiological 
studies have suggested positive associations between clinically established periodontal and cardiovas-
cular disease,2-4 and several small experimental studies have proposed potential mechanisms underly-
ing these associations.2, 5 The mechanism that has been most advocated is bacteraemia followed by 
vascular contamination by periodontal pathogens.2, 6 On the other hand, there have also been many 
studies that failed to demonstrate such associations between periodontal infection and atheroscle-
rosis, particularly after adjusting for confounding variables.2 Furthermore, evidence that periodontal 
interventions or systemic antibiotic treatment result in improved cardiovascular outcomes is currently 
lacking.2, 7 Therefore, the proposed independent association between periodontal disease and athero-
sclerosis may still be considered as controversial.    
This controversy is further underscored by the nature of the measures that have been used for 
periodontal infection (i.e. exposure) and atherosclerotic disease (i.e. outcome) in previous studies. 
The measures for periodontal infection were mostly subjective or based on clinical findings, usually in 
studies with limited sample size.2 However, circulating immunoglobulin G (IgG) and immunoglobulin A 
(IgA) levels against periodontal pathogens may be more accurate measures of periodontal infection 
and its severity.8, 9 Furthermore, they may be used in large epidemiological studies. Major periodontal 
pathogens include Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Tannerella for-
sythia and Prevotella intermedia.2 The outcome measures that have been used in previous studies 
mostly consisted of clinical diagnosis of coronary heart disease (such as history of myocardial infarc-
tion), which is a clinical manifestation of the underlying atherosclerosis, but may not be an accurately 
measure of the extent of atherosclerosis. Conversely, intravascular ultrasound (IVUS) imaging of the 
coronary arteries allows for accurate measurement of coronary plaque burden, as well as measure-
ment of remodeling of coronary lesions.10-12 Additionally, IVUS virtual histology (IVUS-VH) (i.e. analysis 
of IVUS radiofrequency backscatter), allows for tissue characterization and for identification of virtual 
histology-derived thin-cap fibroatheroma (VH-TCFA) lesions, which have previously been shown to 
be predictive for future coronary events.10-15
This study aims to investigate whether there are positive associations between plasma IgG 
and IgA-class immunoglobulin levels against four major periodontal pathogens (i.e. P.gingivalis, 
A.actinomycetemcomitans, T.forsythia and P.intermedia) and the extent of coronary atherosclerosis, 
coronary plaque vulnerability and coronary remodeling as measured by IVUS, as well as 1-year car-
diovascular outcome. 
METHODS
Study population
The design of The European Collaborative Project on Inflammation and Vascular Wall Remodeling in 
Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study has been described in detail 
elsewhere.12, 16 In brief, 581 patients who underwent diagnostic coronary angiography or percutaneous 
coronary intervention (PCI) for acute coronary syndrome (ACS) (n=318) or stable coronary artery 
disease (n=263) have been included between 2008 and 2011 in the Erasmus MC, Rotterdam, the 
Netherlands. The ATHEROREMO-IVUS study was approved by the medical ethics committee of the 
Erasmus MC. The study was performed in accordance with the criteria described in the declaration of 
Helsinki. Written informed consent was obtained from all included patients. This study is registered in 
ClinicalTrials.gov, number NCT01789411.
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Antibodies against periodontal pathogens
Blood samples were drawn from the arterial sheath prior to the coronary angiography procedure. 
The blood samples were further processed in the clinical laboratory of the Erasmus MC, and stored 
at a temperature of -80oC within 2 hours after blood collection. Subsequently, EDTA-plasma samples 
(n=575) were transported under controlled conditions (at a temperature of -80oC) to the Labora-
tory for Vascular Translational Science, INSERM UMRS 1148 , Paris, France, where levels of IgG and IgA 
against A.actinomycetemcomitans, P.intermedia, P.gingivalis and T.forsythia were measured. In 6 patients, 
EDTA samples were not available for measurement of antibodies against the periodontal pathogens. 
Determination of  antibodies against the periodontal bacteria were performed by enzyme-linked 
immuno sorbent assay (ELISA).  One strain of P.intermedia, one strain of T.forsythia, a mixture of six 
A.actinomycetemcomitans strains and two P.gingivalis strains were used as antigens. The strains were: 
P.intermedia CIP 104480, T.forsythia CIP 105220, A.actinomycetemcomitans ATCC 29523, ATCC 
43718, ATCC 33384, IDH 781, IDH 1705 and C59 (representing serotypes a, b, c, d, e and one nonse-
rotypeable strain respectively) and P.gingivalis CIP 103683, OMGS 434 (representing serotypes a and c). 
The bacteria were cultivated in medium 20 (composition available on line at www.crbip.pasteur.fr) for 
the CIP strains and according to the multiserotype ELISA protocol published by Pussinen et al.9 Briefly, 
the suspensions of fixed bacteria (0.5% formalin-PBS) were centrifuged (5500g for 15 minutes at 4oC) 
and washed 3 times in PBS. The pellets were resuspended in 0.05 M bicarbonate buffer to obtain an 
optical density of 0.15 at 580 nm. For serotype mixture, equal volumes of the six A. actinomycetem-
comitans or two P.gingivalis strains were mixed and used to coat the 96-well plates. The bacteria were 
dispended in the plates and were incubated at 37oC for 4 hours and overnight at 4oC. The excess 
bacteria were removed by washing in 0.05% Tween 20 in PBS and the unspecific binding was blocked 
by 5% bovine serum albumin in PBS at room temperature for 30 minutes. Two dilutions of each serum 
were used in each assay. The dilutions used were 1:1500 and 1: 3000 for A.actinomycetemcomitans 
and P.intermedia, 1:100 and 1:200 for P.gingivalis, 1:400 and 1:800 for T.forsythia. After washing, 100 μl 
of peroxidase-labelled goat anti-human IgG or IgA (dilution 1:30,000 in 1% BSA-PBS) were added to 
each well and incubated for 1 hour at room temperature. After washing, o-phenylenediamine dihy-
drochloride  (SigmaFast™OPD) was used as substrate for peroxidase and the reaction was stopped 
with 0.5N H2SO4 before reading at 492 nm. On each plate, two dilutions of a high and a low control 
serum in duplicate were added to monitor for the inter-assay variations. The results are expressed in 
mean optical absorbances. 
Coronary intravascular ultrasound imaging
Following the standard coronary angiography procedure, IVUS imaging of the most proximal part of 
a non-culprit coronary artery was performed. Selection of the non-culprit vessel was predefined in 
the study protocol. The order of preference for selection of the non-culprit vessel was: 1. left anterior 
descending (LAD) artery; 2. right coronary artery (RCA); 3. left circumflex (LCX) artery. All IVUS data 
were acquired with the Volcano s5/s5i Imaging System (Volcano Corp., San Diego, CA, USA) using a 
Volcano Eagle Eye Gold IVUS catheter (20 MHz). An automatic pullback system was used with a stan-
dard pull back speed of 0.5 mm per second. The baseline IVUS images were sent to an independent 
core laboratory (Cardialysis BV, Rotterdam, the Netherlands) for offline analysis. The core laboratory 
personnel were blinded for baseline patient characteristics, data on anti-periodontal pathogens anti-
bodies and clinical outcomes. The IVUS virtual histology analyses were performed using pcVH 2.1 and 
qVH (Volcano Corp., San Diego, CA, USA) software. 
The extent, phenotype and remodeling of the coronary atherosclerosis were assessed. The external 
elastic membrane and luminal borders were contoured for each frame (median interslice distance, 
0.40 mm). Plaque burden was defined as plaque and media cross-sectional area divided by external 
elastic membrane cross-sectional area (Figure 1A). A coronary lesion was defined as a segment with 
a plaque burden of more than 40% in at least 3 consecutive frames. Using IVUS-VH, the composition 
of the atherosclerotic lesions was characterized into 4 different tissue types: fibrous, fibro-fatty, dense 
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calcium and necrotic core.14 IVUS-VH derived thin-cap fibroatheroma (VH-TCFA) lesion was defined as 
a lesion with presence of >10% confluent necrotic core in direct contact with the lumen in at least three 
consecutive frames (Figure 1B).10-13, 15 Remodeling of the plaque lesion was assessed by means of the 
remodeling index, expressed as the external elastic membrane cross-sectional area at the site of minimal 
luminal area divided by the reference external elastic membrane cross-sectional area. The reference site 
was selected <10 mm proximal to the lesion. Positive remodeling (arterial expansion) was defined as a 
remodeling index of >1.05 (Figure 1C). Negative remodeling (arterial shrinkage) was defined as a remod-
eling index of <0.95. 
Figure 1. Methodology for intravascular ultrasound measurements
A: Plaque burden is defined as plaque and media cross-sectional area (green) divided by 
external elastic membrane cross-sectional area (contoured in blue). B: Thin-cap fibroatheroma 
lesion, defined as a lesion with presence of >10% confluent necrotic core (red) in direct 
contact with the lumen. C: A lesion was defined as a segment with a plaque burden of more 
than 40% in at least 3 consecutive frames. Remodeling index was calculated by dividing the 
external elastic membrane cross-sectional area at the site of minimal luminal area (MLA) by 
the reference external elastic membrane cross-sectional area. Positive remodeling was defined 
as a remodeling index of >1.05.
Frame with largest 
plaque burden
MLA plaque
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Clinical endpoints
Clinical follow-up started at inclusion and lasted 1 year. Post-discharge survival status was obtained 
from municipal civil registries. Post-discharge rehospitalizations were prospectively assessed during 
follow-up. Questionnaires focusing on the occurrence of major adverse cardiac events (MACE) were 
sent to all living patients. Subsequently, hospital discharge letters were obtained and treating physicians 
and institutions were contacted for additional information whenever necessary. 
The primary clinical endpoint was MACE, defined as all-cause mortality, ACS or unplanned coro-
nary revascularization. ACS was defined as the clinical diagnosis of ST segment elevation myocardial 
infarction (STEMI), non-STEMI or unstable angina pectoris in accordance with the guidelines of the 
European Society of Cardiology.17 Unplanned coronary revascularization was defined as unplanned 
repeat PCI (either culprit or non-culprit coronary artery) or coronary artery bypass grafting (CABG). 
The endpoints were adjudicated by a clinical event committee that had no knowledge of the anti-
periodontal pathogen antibodies and IVUS data.  
Statistical analysis
The distributions of the continuous variables, including IgG and IgA levels against periodontal patho-
gens and the IVUS parameters, were tested for normality. Normally distributed continuous variables 
are presented as mean ± standard deviation (SD). Non-normally distributed continuous variables are 
presented as median and interquartile range (IQR). IgG and IgA levels were not normally distributed 
and were therefore ln-transformed when analyzed as continuous variable. IgG and IgA levels were also 
analyzed when categorized into tertiles. Categorical variables are presented as numbers and percent-
ages. 
We examined associations of concentration of IgG and IgA against individual periodontal pathogens, as 
well as of the sum of all IgG and all IgA levels, with (1) plaque burden in the imaged coronary segment 
(a measure of the extent of coronary atherosclerosis), (2) VH-TCFA morphology of the coronary 
lesions (a measure of coronary plaque vulnerability), (3) positive lesion remodeling and (4) incident 
MACE during the follow-up period. Linear regression analyses were performed to evaluate the as-
sociations with plaque burden. The results are presented as β with 95% confidence interval (95% CI) 
per standard deviation increase in ln-transformed IgG or IgA level. Generalized estimating equation 
analyses were performed to evaluate the associations with VH-TCFA and positive lesion remodeling. 
This method accounts for the presence of multiple lesions within one individual patient. The results 
are presented as odds ratio (OR) with 95% CI. Cumulative event rates of MACE were estimated ac-
cording to the Kaplan-Meier method. Cox proportional hazards regression analyses were performed 
to evaluate the associations with MACE. Patients lost to follow-up were considered at risk until the 
date of last contact, at which time-point they were censored. The results are presented as hazard ratios 
(HR) with 95% confidence interval (95% CI). 
In multivariable analyses, the variables age, gender, diabetes mellitus and smoking status (current smok-
ing vs. never/past smoking) were considered as potential confounders and were entered into the full 
model. These variables were chosen because they were considered the most important confounders 
based on etiologic consideration and previous literature. Additionally, stratified analyses by smoking 
status and diabetes were performed to assess effect modification. All data were analyzed with SPSS 
software (SPSS 20.0, IBM corp., Armonk, NY, USA). All statistical tests were two-tailed and p-values 
<0.05 were considered statistically significant.
RESULTS
Baseline characteristics
Mean age of the patients was 61.5 ± 11.3 years and 76% were men (Table 1). Coronary angiography 
was performed for various indications: 46% of patients had stable coronary artery disease, 26% of the 
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 n = 575 patients 
  
Clinical characteristics  
Age, years  61.5 ± 11.3 
Men, n (%) 435 (75.7) 
Diabetes Mellitus, n (%) 99 (17.2) 
Hypertension. n (%) 299 (52.0) 
Hypercholesterolemia, n (%) 319 (55.5) 
Smoking, n (%)  165 (28.7) 
Positive family history, n (%) 298 (51.8) 
Previous MI, n (%) 183 (31.8) 
Previous PCI, n (%) 186 (32.3) 
Previous CABG, n (%) 18 (3.1) 
Previous stroke, n (%) 25 (4.3) 
History of peripheral artery disease, n (%) 36 (6.3) 
History of renal insufficiency, n (%) 32 (5.6) 
History of heart failure, n(%) 19 (3.3) 
  
Plasma immunoglobulin levels  
IgG against P. gingivalis, OD 0.61 [0.52-0.72] 
IgG against A. actinomycetemcomitans, OD 0.13 [0.08-0.19]  
IgG against T. forsythia, OD 1.00 [0.77-1.22]  
IgG against P. intermedia, OD 0.31 [0.18-0.55] 
IgA against P. gingivalis, OD 0.28 [0.17-0.47] 
IgA against A. actinomycetemcomitans, OD 0.16 [0.11-0.23] 
IgA against T. forsythia, OD 0.36 [0.19-0.60] 
IgA against P. intermedia, OD 0.10 [0.06-0.15] 
  
Procedural characteristics  
Indication for angiography  
   Acute MI, n (%) 163 (28.3) 
   Unstable angina, n (%) 150 (26.1) 
   Stable angina, n (%) 262 (45.6) 
Coronary artery disease*  
   No significant stenosis, n (%) 43 (7.5) 
   1-vessel disease, n (%) 306 (53.2) 
   2-vessel disease, n (%) 165 (28.7) 
   3-vessel disease, n (%) 61 (10.6) 
PCI performed, n (%) 505 (87.8) 
  
IVUS characteristics  
Imaged coronary artery  
   Left anterior descending, n (%) 206 (35.8) 
   Left circumflex, n (%) 193 (33.6) 
   Right coronary artery, n (%) 176 (30.6) 
Median imaged segment length, mm 44.3 [33.9-55.4] 
Mean plaque burden, % 38.2 ± 11.5 
  
* A significant stenosis was defined as a stenosis "50% of vessel diameter by visual assessment on the 
coronary angiogram.  
Table 1. Baseline patient characteristics
patients had unstable angina pectoris and 28% of the patients had an acute myocardial infarction. ACS 
patients had slightly lower IgG-class antibody levels against A. actinomycetemcomitans compared to 
patients with stable coronary artery disease (Supplemental table 1). Antibody levels were similar in 
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patients with and without multivessel disease (Supplemental table 1). The median length of the imaged 
coronary segment was 44.3 [33.9-55.4] mm. Mean plaque burden in the imaged coronary segment 
was 38.2 ± 11.5 percent. In the imaged coronary segments, a total of 723 coronary lesions have identi-
fied in 505 (87%) patients, including 271 VH-TCFA lesions in 240 (42%) patients.
Antibodies to periodontal pathogens and extent and vulnerability of coronary plaque 
For reasons of conciseness, multivariable estimates are displayed in the tables. All univariable estimates 
are displayed in the online supplement. In the total study population, plasma levels of IgG and IgA 
against P. gingivalis, A. actinomycetemcomitans, T. forsythia and P. intermedia were not associated with 
plaque burden in the imaged coronary segment (Table 2 and supplemental table 2). Plasma levels of 
IgG and IgA against P. gingivalis, A. actinomycetemcomitans, T. forsythia and P. intermedia were not as-
sociated with VH-TCFA lesion morphology either (Table 3 and supplemental table 3). 
Table 2. Association between periodontal pathogens and coronary plaque burden 
    
  Adjusted !* 
(95% CI) 
 
P 
    
IgG against  tertile 1  reference  
P.gingivalis tertile 2 vs. 1 -0.70 (-2.99 ; 1.60) 0.55 
 tertile 3 vs. 1 1.21 (-1.07 ; -3.49) 0.30 
 Linear association  0.62 
IgG against  tertile 1 reference  
A.actinomycetemcomitans tertile 2 vs. 1 1.04 (-1.27 ; 3.36) 0.38 
 tertile 3 vs. 1 -1.06 (-3.28 ; 1.16) 0.35 
 Linear association  0.70 
IgG against  tertile 1  reference  
T.forsythia tertile 2 vs. 1 0.01 (-2.22 ; 2.24) 0.99 
 tertile 3 vs. 1 -0.04 (-2.35 ; 2.27) 0.97 
 Linear association  0.89 
IgG against  tertile 1  reference  
P.intermedia tertile 2 vs. 1 -2.33 (-4.61 ; -0.04) 0.046 
 tertile 3 vs. 1 -0.22 (-2.49 ; 2.05) 0.85 
 Linear association  0.69 
    
IgA against  tertile 1  reference  
P.gingivalis tertile 2 vs. 1 -0.53 (-2.71 ; 1.66) 0.64 
 tertile 3 vs. 1 -1.31 (-3.61 ; 0.99) 0.26 
 Linear association  0.58 
IgA against  tertile 1  reference  
A.actinomycetemcomitans tertile 2 vs. 1 1.28 (-1.01 ; 3.58) 0.27 
 tertile 3 vs. 1 -0.22 (-2.47 ; 2.02) 0.85 
 Linear association  0.29 
IgA against  tertile 1  reference  
T.forsythia tertile 2 vs. 1 -1.24 (-3.53 ; 1.06) 0.29 
 tertile 3 vs. 1 -1.68 (-3.87 ; 0.51) 0.13 
 Linear association  0.27 
IgA against  tertile 1  reference  
P.intermedia tertile 2 vs. 1 -1.90 (-4.17 ; 0.38) 0.10 
 tertile 3 vs. 1 -0.79 (-2.98 ; 1.40) 0.48 
 Linear association  0.56 
    
* β indicates the increase in plaque burden per standard deviation increase in ln-transformed 
immunoglobulin level. Adjusted for age, gender, smoking and diabetes. 
Table 2. Association between periodontal pathogens and coronary plaque burden
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Table 3. Association between periodontal pathogens and thin-cap fibroatheroma morphology
Table 3. Association between periodontal pathogens and thin-cap fibroatheroma morphology 
    
  Adjusted OR*  
(95% CI) 
 
P 
    
IgG against  tertile 1  reference  
P.gingivalis tertile 2 vs. 1 0.99 (0.67-1.45) 0.94 
 tertile 3 vs. 1 1.01 (0.68-1.49) 0.98 
 Linear association  0.91 
IgG against  tertile 1 reference  
A.actinomycetemcomitans tertile 2 vs. 1 1.20 (0.82-1.76) 0.36 
 tertile 3 vs. 1 0.85 (0.57-1.27) 0.43 
 Linear association  0.52 
IgG against  tertile 1  reference  
T.forsythia tertile 2 vs. 1 1.01 (0.69-1.49) 0.95 
 tertile 3 vs. 1 1.05 (0.71-1.56) 0.81 
 Linear association  0.96 
IgG against  tertile 1  reference  
P.intermedia tertile 2 vs. 1 0.88 (0.60-1.30) 0.52 
 tertile 3 vs. 1 0.95 (0.65-1.39) 0.80 
 Linear association  0.45 
    
IgA against  tertile 1  reference  
P.gingivalis tertile 2 vs. 1 0.81 (0.56-1.18) 0.28 
 tertile 3 vs. 1 0.84 (0.57-1.25) 0.40 
 Linear association  0.97 
IgA against  tertile 1  reference  
A.actinomycetemcomitans tertile 2 vs. 1 1.12 (0.77-1.64) 0.55 
 tertile 3 vs. 1 0.78 (0.53-1.16) 0.22 
 Linear association  0.32 
IgA against  tertile 1  reference  
T.forsythia tertile 2 vs. 1 0.91 (0.63-1.32) 0.62 
 tertile 3 vs. 1 0.94 (0.64-1.40) 0.78 
 Linear association  0.80 
IgA against  tertile 1  reference  
P.intermedia tertile 2 vs. 1 1.10 (0.75-1.61) 0.64 
 tertile 3 vs. 1 1.16 (0.79-1.71) 0.44 
 Linear association  0.92 
    
* Adjusted for age, gender, smoking and diabetes. 
Antibodies to periodontal pathogens and lesion remodeling
IgA-class antibody levels against A. actinomycetemcomitans were inversely associated with the extent 
of positive lesion remodeling (p for linear association 0.013) and directly with the extent of negative 
lesion remodeling (p for linear association 0.034). Similar associations with positive lesion remodeling 
were also seen with the highest tertiles of T. forsythia (p=0.012) and P. intermedia (p=0.012) IgA levels 
(Table 4, Figure 2, Supplemental table 4 and supplemental table 5).  
Antibodies to periodontal pathogens and cardiovascular outcome
Vital status at 1-year follow-up could be acquired for 573 (99.7%) patients. Response rate of the 
questionnaires that were sent to all living patients was 92.7%. After 1 year of follow-up, 56 patients 
had experienced a MACE. The cumulative Kaplan-Meier incidences of the 30-day, 6-month and 1-year 
MACE were 0.9%, 5.6%, and 9.8%, respectively. High plasma concentrations of IgG and IgA against P. 
gingivalis, A. actinomycetemcomitans, T. forsythia and P. intermedia were not associated with the occur-
rence of MACE during 1 year of follow-up (Table 5 and supplemental table 6).   
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Table 4. Association between periodontal pathogens and positive lesion remodeling
Table 4. Association between periodontal pathogens and positive lesion remodeling 
    
  Adjusted OR*  
(95% CI) 
 
P 
    
IgG against  tertile 1  reference  
P.gingivalis tertile 2 vs. 1 1.20 (0.75-1.92) 0.46 
 tertile 3 vs. 1 1.07 (0.66-1.75) 0.79 
 Linear association  0.36 
IgG against  tertile 1 reference  
A.actinomycetemcomitans tertile 2 vs. 1 0.71 (0.45-1.14) 0.71 
 tertile 3 vs. 1 0.74 (0.47-1.19) 0.22 
 Linear association  0.18 
IgG against  tertile 1  reference  
T.forsythia tertile 2 vs. 1 1.17 (0.74-1.83) 0.50 
 tertile 3 vs. 1 0.75 (0.46-1.25) 0.27 
 Linear association  0.63 
IgG against  tertile 1  reference  
P.intermedia tertile 2 vs. 1 0.81 (0.51-1.28) 0.37 
 tertile 3 vs. 1 0.73 (0.46-1.15) 0.18 
 Linear association  0.14 
    
IgA against  tertile 1  reference  
P.gingivalis tertile 2 vs. 1 0.72 (0.45-1.13) 0.15 
 tertile 3 vs. 1 0.71 (0.44-1.14) 0.15 
 Linear association  0.42 
IgA against  tertile 1  reference  
A.actinomycetemcomitans tertile 2 vs. 1 0.63 (0.39-1.00) 0.048 
 tertile 3 vs. 1 0.55 (0.35-0.88) 0.012 
 Linear association  0.013 
IgA against  tertile 1  reference  
T.forsythia tertile 2 vs. 1 1.08 (0.69-1.67) 0.74 
 tertile 3 vs. 1 0.53 (0.32-0.87) 0.012 
 Linear association  0.19 
IgA against  tertile 1  reference  
P.intermedia tertile 2 vs. 1 1.05 (0.66-1.66) 0.85 
 tertile 3 vs. 1 0.64 (0.40-1.02) 0.061 
 Linear association  0.20 
    
* Adjusted for age, gender, smoking and diabetes. 
Figure 2 Association between level of immunoglobulin A against periodontal pathogens and 
positively remodeled lesions
Aa = Aggregatibacter actinomycetemcomitans; IgA = immunoglobulin A; Pi = Prevotella inter-
media; Pg = Porphyromonas gingivalis; Tf = Tannerella forsythia.
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Table 5. Association between periodontal pathogens and 1-year major adverse cardiac events
Table 5. Association between periodontal pathogens and 1-year major adverse cardiac events 
    
  Adjusted HR*  
(95% CI) 
 
P 
    
IgG against  tertile 1  reference  
P.gingivalis tertile 2 vs. 1 0.85 (0.43-1.68) 0.63 
 tertile 3 vs. 1 1.03 (0.55-1.92) 0.94 
 Linear association  0.95 
IgG against  tertile 1 reference  
A.actinomycetemcomitans tertile 2 vs. 1 1.31 (0.69-2.49) 0.41 
 tertile 3 vs. 1 0.91 (0.46-1.79) 0.91 
 Linear association  1.00 
IgG against  tertile 1  reference  
T.forsythia tertile 2 vs. 1 0.51 (0.26-1.00) 0.048 
 tertile 3 vs. 1 0.68 (0.36-1.27) 0.23 
 Linear association  0.96 
IgG against  tertile 1  reference  
P.intermedia tertile 2 vs. 1 1.67 (0.90-3.08) 0.10 
 tertile 3 vs. 1 0.63 (0.29-1.36) 0.24 
 Linear association  0.91 
    
IgA against  tertile 1  reference  
P.gingivalis tertile 2 vs. 1 0.92 (0.48-1.77) 0.81 
 tertile 3 vs. 1 0.87 (0.46-1.67) 0.68 
 Linear association  0.67 
IgA against  tertile 1  reference  
A.actinomycetemcomitans tertile 2 vs. 1 1.78 (0.92-3.46) 0.087 
 tertile 3 vs. 1 1.19 (0.58-2.41) 0.64 
 Linear association  0.65 
IgA against  tertile 1  reference  
T.forsythia tertile 2 vs. 1 0.81 (0.41-1.60) 0.55 
 tertile 3 vs. 1 1.13 (0.59-2.14) 0.72 
 Linear association  0.91 
IgA against  tertile 1  reference  
P.intermedia tertile 2 vs. 1 1.20 (0.62-2.34) 0.59 
 tertile 3 vs. 1 1.18 (0.61-2.28) 0.63 
 Linear association  0.97 
    
* Adjusted for age, gender, smoking and diabetes. 
 
 
Sum of IgG and IgA levels
The sum of IgG levels and the sum of IgA levels were neither associated with coronary plaque bur-
den (p=0.86 and p=0.30 respectively), nor with VH-TCFA lesion morphology (p=0.60 and p=0.97 
respectively), nor with MACE (p=0.15 and p=0.67 respectively). The sum of IgA levels was inversely 
associated with the extent of positive lesion remodeling (highest versus lowest tertile OR 0.50, 95% 
CI 0.31-0.82, p=0.006), while the sum of IgG levels was not (p=0.68).
Analyses stratified by diabetes and smoking status
In patients with diabetes, the highest IgG tertile against P. gingivalis was associated with coronary 
plaque burden (p=0.020) while the corresponding IgA antibody levels tended to associate with MACE 
(p=0.16) (Figure 3). Although statistical significance mostly disappeared because of lower power in the 
subgroups, the estimates of the remaining associations that were found in the total study population 
remained materially the same after stratification on diabetes. The same applied to the estimates found 
in smokers and non-smokers.
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Figure 3 Associations of Porphyromonas gingivalis with extent of coronary atherosclerosis and 
with cardiovascular outcome in patients with diabetes
IgA = immunoglobulin A; IgG = immunoglobulin G; MACE = major adverse cardiac event; 
Pg = Porphyromonas gingivalis
DISCUSSION
This study investigated the associations between antibodies to major periodontal pathogens and coronary 
atherosclerosis on IVUS-VH. We found that IgG and IgA against P.gingivalis, A.actinomycetemcomitans, 
T.forsythia and P.intermedia were not associated with coronary plaque burden or VH-TCFA lesion 
morphology in the overall study population. High levels of IgA against A.actinomycetemcomitans, 
T.forsythia and P.intermedia, however, were associated with lower extent of positive lesion remodel-
ing. The serologic markers of periodontal infection were not predictive for 1-year MACE. In stratified 
analyses, antibodies against P.gingivalis tended to be associated with the extent of coronary atheroscle-
rosis and with incident MACE during 1 year follow-up in patients with diabetes.
The major strengths of this study include the objective measurements of the exposure (i.e. periodon-
tal infection as assessed by antibodies), the precise measurement of the extent of coronary athero-
sclerosis, as well as the assessment of the composition of coronary atherosclerosis (atherosclerotic 
plaque morphology and lesion remodeling). The validated multiserotype ELISAs that have been used 
for the measurement of P.gingivalis and A. actinomycetemcomitans antibodies have a good sensitivity 
(71%) and specificity (90%) for clinically and radiographically diagnosed periodontitis, and allowed us 
to measure the infection by these periodontal pathogens.18 IVUS enables for accurate measurements 
of various coronary plaque characteristics, including plaque burden, plaque morphology and lesion 
remodeling.12, 16 To our best knowledge, this is the first study on periodontal disease that used IVUS to 
measure the extent of coronary atherosclerosis, and the associations between periodontal infection 
and plaque morphology and lesion remodeling have so far not been investigated at all. 
Many observational studies have investigated the association between periodontal disease and car-
diovascular disease; the latter mostly defined as extent of atherosclerosis or occurrence of clinical 
cardiovascular events.2 However, in these studies, periodontal disease has been broadly defined by 
a variety of measures, including self-reported assessment of tooth loss or periodontal status, and 
clinically or radiographically assessed gingival inflammation or pathological periodontal pockets. Few 
studies have assessed the periodontal infection by measuring IgG and IgA antibody levels against sev-
eral bacteria.19-26 A study by Colhoun et al. found an association between IgG against P.gingivalis and 
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A.actinomycetemcomitans and coronary artery calcification as measured by computed tomography 
in diabetic subjects, although this association did not appear to be independent of baseline character-
istics.20 In line with this finding, our study showed an association between IgG against P.gingivalis and 
the extent of coronary atherosclerosis on IVUS in diabetic patients with established coronary artery 
disease. Cross-sectional and case-control studies by Pussinen et al., Beck et al, and Spahr et al. have 
reported positive associations between antibody levels against various periodontal pathogens and the 
presence of coronary heart disease within large population-based cohorts.19, 23-26 Furthermore, two 
prospective studies have investigated the association between serum antibody titers and risk of incident 
MACE during follow-up. Lund Haheim et al. measured IgG  to P.gingivalis, A.actinomycetemcomitans, 
T.forsythia, and Treponema denticola, and found that no single bacterium but rather combinations 
were related to increasing risk for incident myocardial infarction.21 Pussinen et al, measured IgG and 
IgA to P.gingivalis and A.actinomycetemcomitans, and found that IgA against P. gingivalis was associated 
with increased risk for occurrence of myocardial infarction during 10 years of follow-up.24 The latter is 
in line with our finding that IgA against P.gingivalis is associated with 1-year MACE in diabetic patients 
with coronary artery disease. The lack of further associations with extent of coronary atherosclerosis 
and with MACE in our full cohort may be explained by the fact that ours was a cohort of patients 
with known coronary artery disease, and associations may be different compared to population-based 
cohorts or case-control studies, which contain healthy control subjects.   
In the current study, we did not find an association between antibody levels against periodontal patho-
gens and VH-TCFA lesion morphology, which suggests that periodontal infection and its inflammatory 
reaction is not associated with coronary plaque vulnerability. However, we did find that IgA against 
A.actinomycetemcomitans, T.forsythia and P.intermedia (but not P.gingivalis) were inversely associated 
with extent of positive lesion remodeling. Modest positive lesion remodeling may be considered as a 
physiological, and thus favourable, response to progression of atherosclerotic plaque, also known as the 
Glagov adaptive phenomenon.27 In this light, infection with A.actinomycetemcomitans, T.forsythia and 
P.intermedia may be considered as being associated with a lower adaptive capacity to atherosclerotic 
burden. 
Some limitations of this study need to be acknowledged. Firstly, clinical periodontal examination was 
not performed in our study. Although measurement of antibodies provides good sensitivity and speci-
ficity for clinically and radiographically diagnosed periodontitis, data on actual presence of periodontitis 
or history of periodontal destruction is lacking. Furthermore, IgG and IgA levels reflect both past and 
recent exposure to the periodontal pathogens.28 In the current study, we could not investigate the 
effects of the active phase of periodontitis, which can only be determined by clinical measurements of 
changes in attachment level, on coronary atherosclerosis.8 The ideal analysis includes both the clinical 
diagnosis of periodontitis and the antibodies against periodontal pathogens. 
Secondly, a single non-culprit coronary vessel was imaged in this study. This approach was chosen 
based on the hypothesis that the phenotype of a non-culprit artery segment represents the patient’s 
systemic atherosclerotic disease burden.16 Although this hypothesis may be debated, it is highly sup-
ported by our previous finding that IVUS in only one non-culprit vessel has strong prognostic value.12 
Finally, the spatial resolution of IVUS-VH (150μm) is insufficient to exactly replicate histopathologic 
definitions of a thin fibrous cap (<65μm).29 Therefore, IVUS-VH tends to over-estimate the number 
of histopathological TCFA lesions. Nevertheless, the presence of VH-TCFA lesions has been shown to 
have prognostic information.10-12 
In conclusion, in the current study, plasma levels of IgG and IgA against four major periodontal patho-
gens were neither associated with the extent of coronary atherosclerosis, nor with coronary plaque 
vulnerability, as measured with IVUS-VH in a population of patients with established coronary artery 
disease. IgA against A.actinomycetemcomitans, T.forsythia and P.Intermedia were inversely associated 
with extent of positive coronary remodeling. IgG and IgA against the four major periodontal pathogens 
that we tested were not predictive for cardiovascular outcome at 1 year. Only in the subgroup of pa-
tients with diabetes, antibodies against P.gingivalis tended to be associated with the extent of coronary 
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atherosclerosis and with incident MACE during 1-year follow-up. Altogether, the results of the current 
study do not add evidence for the hypothesis that  systemic exposure to periodontal pathogens, as as-
sessed by antibodies against periodontal pathogens, plays a substantial role in coronary artery disease. 
Further studies in diabetic patients are needed to clarify the potential role of periodontal pathogens 
in coronary atherogenesis and associated cardiovascular events.
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GENERAL DISCUSSION AND SUMMARY
The main objective of this thesis was to improve characterisation and prognostication of patients un-
dergoing percutaneous coronary intervention (PCI). We will discuss our main findings and their impact 
on clinical practice and give some directions for further research.
PART 1
Since the introduction of reperfusion therapy a significant improvement in outcome has been ob-
served in patients presenting with acute ST-elevation myocardial infarction (STEMI). Meta-analyses 
of randomised clinical trials showed that so-called primary PCI (PPCI) results in lower mortality than 
fibrinolytic therapy in these patients. However, various reports indicate that outcome after PPCI de-
pends on clinical parameters such as infarct size, presence of cardiogenic shock, and treatment delay, as 
well as on patient-related risk factors. Age, gender, heart rate and blood pressure are relevant factors in 
this respect. Furthermore, several studies indicate the importance of logistic aspects, such as operator 
and site experience, and the ability to provide state-of-the-art treatment during off hours. 
Ambiguity remains whether gender affects outcome the Erasmus MC.1-9 Therefore, we analysed al-
most 12,000 consecutive patients who underwent PCI in and found that women undergoing PCI for 
STEMI had higher mortality than men. Importantly, the excess mortality in women appeared in the 
first month after PCI and could only partially be explained by differences in baseline characteristics. 
No gender differences were observed in outcome in patients undergoing PCI for non-ST-elevation 
acute coronary syndrome (NSTE-ACS) or stable angina pectoris. Our findings are in agreement with a 
recent meta-analysis of over 700,000 patients, which showed that women tend to have higher mortal-
ity post-PCI at both short and intermediate term follow-up.10 These observations demonstrated that 
research is warranted to study the presentation and treatment of coronary artery disease (CAD) in 
relation to gender. Ideally, this will eventually result in better-fitted diagnostic and treatment strategies 
for both genders, and consequently the disappearance of gender disparities in patient outcomes.
Smoking is a well-known risk factor for the development and progression of CAD11-15, and its rela-
tion with increased morbidity and mortality from cardiovascular causes has long been established.16, 
17 However, the effect of smoking cessation in terms of prolonged life-years is unknown. In order to 
quantify the effect of smoking cessation, we performed a follow-up of 1980-1985 cohort of PCI (bal-
loon angioplasty only) patients treated in the Erasmus MC. Based on this 30-year follow-up period, we 
estimated that (at least) 2.1 life-years were gained by patients who stopped smoking as compared to 
continuing smokers. Despite the introduction of national health campaigns in the 1980s, 27% of the 
general population in the Netherlands still smokes. 18 In patients with established CAD, this figure is 
as high as 15%, 19 sadly making smoking cessation still a current topic. We believe, our results should 
encourage physicians to keep convincing their patients to stop smoking. 
Several studies report that treatment during off-hours is related with poorer outcomes after PPCI 
than treatment during on-hours, although ambiguity exists. 20-26 27-30 In a cohort of more then 4,000 
consecutive STEMI patients treated with PPCI in the Erasmus MC we found no outcome differences 
between those treated during off- and on-hours. Absence of outcome differences was consistently 
found in clinically relevant subgroups, including the elderly and patients with multi-vessel disease. These 
findings, which are based on a systematic monitoring of treatment outcomes, do not give rise to 
change our practice. Instead, these results may encourage other centres to expand their service.
Another important issue that has been addressed in this thesis refers to the identification of categories 
of MI patients who may benefit most from a PPCI, and thus have lowest numbers needed to treat 
(NNTs) to prevent a death. Based on an analysis of 22 randomized trials, we concluded that PPCI 
is consistently associated with a strong relative reduction in 30 day mortality, irrespective of patient 
baseline risk, and should therefore be considered as the first choice reperfusion strategy whenever 
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feasible. In contrast, the absolute risk reduction was strongly related to estimated risk at baseline: the 
NNT to prevent one death by PPCI versus fibrinolysis was 516 in the lowest quartile (i.e. low risk 
based on baseline characteristics) of estimated risk compared to only 17 in the highest quartile (i.e. 
high risk based on baseline characteristics). If access to PCI is longer than 2 hours, however fibrinolysis 
remains a legitimate option in low risk patients, because of the small absolute risk reduction by PPCI 
in this particular cohort. 
Age is an important determinant of adverse outcome, however, elderly patient are often withhold 
PPCI. Clinicians tend to make decisions influenced by the presence of comorbid conditions and/or 
frailty of elderly patients rather than on the guidelines. Unfortunately, there is little clinical evidence, as 
most elderly patients are excluded from trial-participation due to the favour of clinical trialists to enrol 
patients at low risk of potential side effects 31. Therefore another analysis based on the individual data 
of the above mentioned 22 randomized control trials (RCT’s) was performed, which revealed that the 
reduction in clinical endpoints by PPCI was not influenced by age, and therefore strengthening the fact 
that age per se should not be considered an exclusion criterion for the application of PPCI.
To improve the generalizability of RCT results, the ‘real world’ or ‘all-comers’ (AC) design is becoming 
increasingly popular in cardiology. This design can potentially overcome the exclusion of patients with 
a perceived high risk of potential side effects. We studied the participants of two large AC trials that 
were enrolled in the Erasmus MC, and compared their characteristics with non-enrolled patients. It 
appeared that still half of the eligible patients who belonged to the target population were not in-
cluded in the AC trial AC trial participants were significantly younger than non-participants and had 
better survival The observed differences in 30-day and 1-year mortality between participants and non-
participants became smaller in those who survived the first 48 hours. These results reveal that the AC 
design does not fully represent daily ‘real world’ clinical practice. We speculate that the perception of 
clinical trialists still plays an important role in the selection of trial participants. It is to be expected that 
this is hard to overcome in future studies, although it is remains worth attempting. 
PART 2.
CAD is a complex disease, and after decades of cardiovascular research the mechanisms linking plaque 
composition and morphology, vascular inflammation, coagulability and patient outcome are still not 
fully understood. The European Collaborative Project on Inflammation and Vascular Wall Remodeling 
in Atherosclerosis - Intravascular Ultrasound (AtheroRemo-IVUS) was designed as an exploratory 
(non-pivotal) clinical study to investigate the associations between genetic profile, circulating biomark-
ers, and coronary atherosclerosis phenotype and vulnerability as determined by IVUS virtual histology 
or NIRS. Furthermore, the prognostic implications of (the combination) of established and novel bio-
markers and plaque phenotypes were assessed. The AtheroRemo had an AC design, which included 
patients with an ACS and stable angina pectoris.
CAD has a strong genetic component with epidemiological studies suggesting 50% of susceptibility 
is heritable32. Genome wide association studies, in which hundreds of thousands of single-nucleotide 
polymorphisms (SNPs) are tested for association with a disease, have proved successful in identifying 
genetic associations with complex traits. 33 Atherosclerosis genotyping programs have so far been of 
limited importance. In AtheroRemo a total of twelve SNPs in or in the proximity of eight genes were 
associated with indicators of vulnerable plaque. Two of these genes, GNA12 and SESN3 were also 
related to clinical outcome. We consider these findings hypothesis generating, and further validation of 
these SNPs in other (larger) cohorts of CAD patients is warranted.
Ex vivo as well as in vivo studies using IVUS in patients with myocardial infarction have demonstrated 
the presence of thin caped fibroatheroma’s (TCFAs) in other than the culprit lesion or even culprit 
artery.34 In AtheroRemo, we demonstrated that the presence of IVUS-derived TCFA lesions in a non-
culprit coronary artery was predictive of the occurrence of major adverse cardiac events within 1 year, 
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including death and ACS. TCFA lesions with a large plaque burden carry higher risk than small TCFA 
lesions. Thus, IVUS imaging of only part of the coronary system seems sufficient for prognostication. 
Near-infrared spectroscopy (NIRS) is a catheter based imaging modality with high potential to identify 
lipid-core containing coronary plaques (LCP) in CAD patients.  This intra-coronary imaging technique 
utilizes the variation in reflection of the emitted near-infrared light to detect LCP, which is visualized 
as a (block) chemogram and qualified by a lipid-core burden index (LCBI) score. 35, 36 In AtheroRemo, 
LCBI was associated with clinical features that represent high cardiovascular risk. Furhtermore, NIRS 
had prognostic value, since patients with an LCBI equal or above the median had a 4-fold risk of ad-
verse cardiovascular events during 1-year follow-up. 37 These early results are promising, but further 
research is warranted to evaluate the longer-term outcomes. Currently, the Lipid Rich Plaque (LRP) 
study is being conducted, aiming to further explore the relation between NIRS findings and adverse 
cardiac events in a large series of European and American patients. 
Finally, in AtheroRemo we sought to study the relation between a broad range of novel circulating bio-
markers and coronary atherosclerosis phenotype and vulnerability. We studied circulating cytokines38, 
acute phase proteins,39 chemokines40, antibodies to periodontal pathogens, and plasma concentrations 
of molecular lipid species. Although statistically significant relations with plaque composition and clinical 
outcomes were found for various markers, including TNF-α38, RANTES40, and several molecular lipids 
species41, we consider these finding hypothesis generating. We continue expanding our line of research 
to replicate our observations, and to study the relevance of the biomarker and imaging findings for 
clinical outcomes during longer-term follow-up.
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ALGEMENE DISCUSSIE EN SAMENVATTING
De belangrijkste doelstelling van dit proefschrift was om middels innovaties de karakterisering en de 
prognose te verbeteren van patiënten die een percutane coronaire interventie ondergaan. In dit proef-
schrift bespreken we onze bevindingen en ( de mogelijke) impact op de klinische praktijk en geven 
enkele voorstellen voor richtingen waarin verder onderzoek kan plaatsvinden.
DEEL 1
Sinds de introductie van reperfusietherapie  is een aanzienlijke verbetering in mortaliteit en morbiditeit 
waargenomen bij patiënten die zich presenteren met een acuut ST-elevatie myocardinfarct (STEMI). 
Meta-analyses van gerandomiseerde klinische studies hebben aangetoond dat primaire PCI (PPCI) 
resulteert in lagere mortaliteit dan fibrinolytische therapie bij deze patiënten. Echter, uit diverse onder-
zoeken blijkt dat uitkomst na PPCI ook afhankelijk is van klinische parameters zoals infarct grootte, 
aanwezigheid van cardiogene shock en vertraging in behandeling, alsmede patiënt-gerelateerde risico-
factoren zoals leeftijd, geslacht, hartslag en bloeddruk. Bovendien, hebben een aantal studies het belang 
aangetoond van de logistieke aspecten, zoals de ervaring van de interventie-cardioloog, het ziekenhuis 
en de mogelijkheid om state-of-the-art behandeling buiten kantooruren te bieden.
Momenteel bestaat nog onduidelijkheid of het geslacht van de patiënt die een PCI ondergaat van 
invloed is op uitkomst. 1-9 Om deze vraag te beantwoorden hebben we dit bij ongeveer 12.000 op-
eenvolgende patiënten die een PCI ondergingen voor verscheidende indicaties geanalyseerd en con-
cludeerden dat vrouwen die een PCI ondergingen voor STEMI een hoger sterftecijfer hadden dan 
mannen. Wel is het belangrijk te melden dat de oversterfte bij vrouwen alleen optrad tijdens  de 
eerste maand na PCI en slechts ten dele kon worden verklaard door verschillen in patiëntkenmerken. 
Bij patiënten die een PCI ondergingen voor niet-ST-elevatie acuut coronair syndroom (NSTE-ACS) of 
stabiele angina pectoris werden geen geslacht verschillen in uitkomst waargenomen. Deze bevindingen 
zijn in overeenstemming met een recente meta-analyse van meer dan 700.000 patiënten, waaruit blijkt 
dat vrouwen een hogere sterfte post-PCI hebben op zowel korte als middellange termijn follow-up.10 
Deze observaties laten zien dat meer onderzoek noodzakelijk is naar de presentatie en behandeling 
van coronaire hartziekte (CHZ)  bij vrouwen. Idealiter zal dit uiteindelijk resulteren in betere diagnos-
tische en therapeutische strategieën en verdwijnen daarmee de verschillen in uitkomst tussen mannen 
en vrouwen.
Een bekende risicofactor voor de ontwikkeling en progressie van CHZ is roken11-15, waarvan het 
verband met een verhoogde morbiditeit en mortaliteit door cardiovasculaire oorzaken reeds lang 
bekend is.16, 17 Ook het positieve effect van stoppen met roken op de lange termijn is bekend, echter 
is dit effect nog niet gekwantificeerd. Om dit effect van stoppen met roken te kunnen kwantificeren 
hebben we gekeken naar de lange termijn follow-up van patiënten uit een PCI cohort (alleen ballon-
dilatatie) uit de jaren 1980-1985, behandeld in het Erasmus MC. Op basis van een follow-up periode 
van 30 jaar, schatten we dat patiënten die stopten met roken (ten minste) 2,1 jaar langer leefden in 
vergelijking met ‘doorrokers’.  In Nederland rookt  27% van de bevolking nog steeds, ondanks de in-
voer van diverse nationale campagnes om het stoppen met roken te bevorderen in de jaren tachtig. 18 
Bij patiënten met vastgestelde CHZ, is dit cijfer nog steeds 15%, 19 wat stoppen met roken helaas nog 
steeds een actueel onderwerp maakt. Wij hopen dat met onze resultaten artsen een middel in handen 
hebben om patiënten te kunnen overtuigen te stoppen met roken.
Verschillende studies melden dat behandeling buiten kantooruren is gerelateerd aan slechtere resul-
taten na PPCI dan behandeling tijdens kantooruren, hoewel onduidelijkheid bestaat. 20-30 We hebben in 
een cohort van meer dan 4000 opeenvolgende STEMI patiënten behandeld met PPCI in het Erasmus 
MC gekeken of er verschil in uitkomst was na PPCI tijdens kantooruren versus buiten kantooruren en 
vonden geen verschil. Gelijke uitkomsten werden eveneens gevonden in klinisch relevante subgroepen, 
212 | General discussion and summary - Algemene discussie en samenvatting
waaronder ouderen en patiënten met meerdere aangedane kransslagvaten. Deze bevindingen, die 
zijn gebaseerd op een systematische monitoring van de resultaten van de behandeling, gaven geen 
aanleiding om onze praktijk te veranderen. In plaats daarvan, kunnen deze resultaten mogelijk andere 
centra stimuleren om hun dienstverlening uit te breiden.
Een andere belangrijke kwestie die in dit proefschrift aanbod komt, is de identificatie van de catego-
rieën van patiënten met MI die het meest van een PPCI kunnen profiteren. We hebben 22 geran-
domiseerde studies geanalyseerd en vonden dat PPCI consequent geassocieerd was met een sterke 
relatieve reductie van mortaliteit op 30 dagen, ongeacht het risicoprofiel van patiënt. Reden om 
reperfusiestrategie als behandeling van eerste keuze te beschouwen. Daarentegen was de absolute ri-
sicoreductie sterk gerelateerd aan het geschatte risico op baseline: het aantal patiënten dat behandeld 
moest worden om één sterfgeval te voorkomen door PPCI versus fibrinolyse was 516 in het laagste 
kwartiel (d.w.z. een laag risico op basis van de uitgangskenmerken) in vergelijking met slechts 17 in 
de hoogste kwartiel (d.w.z. met een hoog risico op basis van de uitgangskenmerken). Indien een PCI 
centrum op meer dan 2 uur afstand is, blijft vanwege de lage absolute risicoreductie van PPCI in dit 
cohort, fibrinolyse een legitieme optie bij laag risico patiënten, 
De oudere patiënt wordt vaak PPCI onthouden, dit komt omdat artsen de neiging hebben om bes-
lissingen te maken gebaseerd op basis van co-morbiditeit en/of broosheid van de oudere patiënt in 
plaats van op de richtlijnen. Helaas is er weinig wetenschappelijke bewijs over de behandeling van de 
oudere patiënt, omdat de meeste oudere patiënten vanwege de eerder genoemde co-morbiditeit / 
broosheid zijn uitgesloten van deelname aan wetenschappelijk onderzoek. Wetenschappers hebben 
een voorkeur voor de categorie patiënten die het laagste risico lopen op mogelijke bijwerkingen/ 
slechte uitkomst31. Daarom hebben we de individuele gegevens van de bovengenoemde 22 geran-
domiseerde studies opnieuw geanalyseerd, hieruit bleek dat de reductie in klinische eindpunten door 
behandeling met PPCI onafhankelijk is van de leeftijd. Dit laat zien dat leeftijd op zich geen reden is om 
af te zien van PPCI in de oudere patiënt.
Het ‘dagelijkse klinische praktijk’ of ‘all-comers’ (AC) design om de generaliseerbaarheid van geran-
domiseerde studies te vergroten, wordt steeds populairder binnen de cardiologie. Dit design heeft als 
doel zowel patiënten met een met een hoog als laag risico op mogelijke bijwerkingen in wetenschap-
pelijk onderzoek te includeren. Om te evalueren in hoeverre het AC design hierin slaagt hebben we 
de patiëntkenmerken van deelnemers aan twee grote AC studies in het Erasmus MC vergeleken 
met niet- deelnemers. Ondanks de ruime inclusiecriteria, bleek dat nog steeds maar de helft van alle 
mogelijke deelnemers, deelnam aan het wetenschappelijk onderzoek. AC deelnemers waren significant 
jonger dan niet-deelnemers en hadden een betere overleving.  De waargenomen verschillen in de 
30-dagen en 1-jaars mortaliteit tussen de deelnemers en niet-deelnemers werden kleiner in zij die de 
eerste 48 uur overleefden. Deze resultaten tonen aan dat de AC-ontwerp niet geheel representatief 
is voor de dagelijkse klinische praktijk. We denken dat de perceptie van de klinische onderzoekers nog 
steeds een belangrijke rol speelt bij de selectie van de deelnemers aan het wetenschappelijk onder-
zoek. Dit probleem is moeilijk op te lossen, hoewel het, het proberen waard blijft.
DEEL 2.
CHZ is een complexe ziekte, en na decennia van cardiovasculair onderzoek zijn de mechanismen 
die plaque samenstelling, plaque morfologie, vasculaire ontsteking, coagulatie en uitkomst met elkaar 
verbinden nog steeds niet volledig begrepen. Het Europese samenwerkingsproject over Inflammation 
and Vascular Wall
Remodeling in Atherosclerosis - Intravascular Ultrasound (AtheroRemo-IVUS) is ontworpen als een 
verkennende klinische studie naar de associatie tussen genetische profiel, circulerende biomarkers, en 
plaquemorfologie als bepaald door IVUS virtuele histologie en/of NIRS. Bovendien zullen de prognos-
tische implicaties (de combinatie) van bekende en nieuwe biomarkers en plaque fenotypes worden 
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bekeken. De AtheroRemo had een AC ontwerp, zowel patiënten met een ACS als stabiele angina 
pectoris werden geïncludeerd. 
Epidemiologische studies suggereren dat 50% van de gevoeligheid voor CHZ genetisch bepaald is 
32. Genome wide assosciation studies, waarin honderdduizenden single-nucleotide polymorfismen 
(SNP’s) worden getest op associatie met een ziekte, zijn succesvol in het identificeren van genetische 
associaties met complexe aandoeningen. 33 Programma’s met atherosclerose genotypering hebben 
tot op heden geen belangrijke doorbraak laten zien. In de AtheroRemo studie werden in totaal twaalf 
SNPs in of in de nabijheid van acht genen geassocieerd met indicatoren van een kwetsbare plaque. 
Eerder onderzoek heeft laten zien dat twee van deze genen, GNA12 en SESN3 ook geassocieerd zijn 
met klinische uitkomst. We beschouwen onze bevindingen als hypothese genererend en zijn van men-
ing dat verdere validatie van deze SNPs in andere (grotere) cohorten van CHZ patiënten noodzakelijk 
is.
Zowel ‘ex vivo’ alsook ‘in vivo’ studies waarbij met behulp van IVUS de kenmerken van atheroscle-
rotische plaques bij patiënten met een hartinfarct geëvalueerd werden hebben de aanwezigheid van 
thin capped fibroatheroma’s (TCFAs; deze plaques hebben de hoogste kans op ruptuur) aangetoond 
in coronairen die niet de primaire oorzaak van het infarct waren.34 In AtheroRemo hebben we laten 
zien dat de aanwezigheid TCFA laesies (met behulp van IVUS) in deze zogenaamde non-culprit krans-
slagaders voorspellend waren voor het optreden van cardiale incidenten binnen 1 jaar, met inbegrip 
van de dood en (recidief) ACS. TCFA laesies met een hoge plaque burden (de hoeveelheid plaque) 
brengen een groter risico met zich mee dan met een lagere plaque burden. Hieruit concludeerden 
we dat ook wanneer slechts een deel van de kransslagvaten in beeld wordt gebracht, IVUS voldoende 
prognostische waarde lijkt te hebben.
Near-infrarood spectroscopie (NIRS) is een beeldvormende modaliteit op een katheter met een hoge 
potentieel om lipide-rijke coronaire plaques (LCP) bij CHZ-patiënten te identificeren. Deze intra-
coronaire beeldvormende techniek maakt gebruik van de variatie in het reflecteren van uitgezonden 
near-infrarood licht om LCP te detecteren. Dit gereflecteerde near-infrarood licht wordt gevisualiseerd 
als een (blok) chemogram en gekwalificeerd door een lipid core burden index (LCBI) score. 35, 36 In 
AtheroRemo, werd een associatie aangetoond tussen LCBI en relevante (hoog cardiovasculair risico) 
klinische kenmerken. Ook bleek NIRS een prognostische waarde te hebben, aangezien patiënten met 
LCBI gelijk aan of boven de mediaan een 4 keer zo groot risico hadden op cardiovasculaire incidenten 
geobserveerd tijdens een 1 jaar durende follow-up. 37 Deze eerste resultaten zijn veelbelovend, maar 
verder onderzoek is geboden. Momenteel wordt het Lipid Rich Plaque (LRP) onderzoek uitgevoerd, 
met als doel de relatie tussen NIRS bevindingen en cardiale incidenten bij een groot aantal Europese 
en Amerikaanse patiënten nader te bestuderen.
Concluderend, in AtheroRemo zochten we naar de relatie tussen een breed scala van nieuwe circul-
erende biomarkers en de kwetsbaarheid/fenotype van plaques in de coronairen. We bekeken cytok-
ines38, acute fase eiwitten, 39 chemokines40, antilichamen tegen parodontale pathogenen en plasma con-
centraties van moleculaire lipide soorten.41 Hoewel we statistisch significante relaties vonden tussen 
diverse markers, plaque samenstelling en uitkomst, beschouwen we deze resultaat vooral hypothese 
genererend. We blijven ons lijn van onderzoek uitbreiden met als doel onze waarnemingen te rep-
liceren en het effect van onze bevindingen (biomarker en beeldvorming) op uitkomst te bestuderen 
gedurende de langere-termijn follow-up.
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Non-fatal endpoints and the combined endpoint
Repeat PCI was seen more often in trial-participants (18.1% versus 30.7% (KM estimate), p < 0.001); uHR 
1.81, 95%CI 1.65–2.00). Similar results were obtained after multivariate adjustment for potential 
confounders of the relation between trial participation and the incidence of rePCI (aHR 1.91, 95%CI 
1.73–2.10), Table 2, and Fig. 2A. Results were comparable at short-term and long-term follow-up ( Fig. 3) 
and in the different indication groups ( Table 2).Trial-participants underwent re-PCI in an earlier phase as 
compared to non-participants (median 114 (IQR: 35 – 195 days) versus 55 days (IQR: 10 – 148 days), p 
< .001 respectively).
We did not find any clinically relevant difference in the incidence of CABG and non-fatal MI between trial 
participants and non-participants. Results were similar at short-term and long-term follow-up (Fig. 3), and 
similar in the patients treated for different indications (Table 2). The cumulative incidence curves were 
superimposed for these endpoints (Fig. 2C and D). Trial participation had no contribution in multivari-
able Cox PH models that related patient characteristics with CABG and non-fatal MI. Adjusted HRs of 
trial participation were non-significant and close to 1 for CABG and non-fatal MI at all three investigated 
follow-up moments (Fig. 3).
The composite endpoint of all-cause mortality, repeat PCI, CABG or MI was observed more often in trial-
participants as compared to non-participants (aHR.1.36 95% CI 1.25 – 1.47), Table 2, and Fig. 2B.
DISCUSSION
Clinical trials are important to evaluate the efficacy and safety of CAD treatment; however, due to strict in- 
and exclusion criteria their generalizability is often limited. We studied the effect of trial participation in all 
consecutive patients undergoing PCI within the last decade at our PCI centre. As expected, we observed 
important differences in baseline characteristics between trial-participants and non-participants. Mortality 
was higher in non-participants than in trial-participants, even in those who survived the first month. There 
was no difference in occurrence of non-fatal MI between both groups. Interestingly, trial-participants had 
an almost 2-fold higher incidence of repeat PCI. As a result, the composite of mortality, repeat revascu-
larization, and non-fatal MI was (in contrast to mortality) higher in trail-participants. These results show 
that trial-participation does not fully represent “real world” clinical practice and indicate that the external 
validity of trial results is limited.
The better survival of trial participants may be related to the increased likelihood (strict inclusion and 
exclusion criteria) of excluding high risk patients from trials. For example, patients presenting with STEMI 
(high risk patients) were less likely to be enrolled in clinical trials: 37% of the non-participants had a STEMI 
versus 29% of the trial participants. Another explanation, as we demonstrated previously in a subset of 
these patients, is that critically-ill patients are not able to provide informed consent, whereas physicians 
tend to avoid including a patient with high risk of adverse effects 4. Secondly, in patients who survived the 
first month, excluding acute treatment effects, we also observed a higher mortality in the non-participants. 
This may be due to the fact that trial participants, in the years following the index-procedure, are subjected 
to strict adherence to the carefully developed protocol and extra visits to the outpatient clinic. Third, as 
indicated by others, trial-participants may have had better education and be of higher socioeconomic 
status, which may contribute to better overall treatment adherence 12. Fourth, it can also be hypothesized 
that due to the informed consent procedure and more frequent contacts (phone and outpatient clinic) 
trial-participants are better informed and motivated to adhere to the initiated treatment and life-style 
changes, resulting in improved clinical outcome 13.
Within this study we observed a significant difference in subsequent PCI procedures between trial par-
ticipants and non-participants, whereas CABG and non-fatal MI did not differ between the two groups. 
Univariate as well as multivariate analysis revealed that almost twice as many trial-participants underwent 
repeat PCI within 1 year after the initial PCI. Importantly, in the vast majority of trial-participants a follow-
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